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ABSTRACT 
Cerebral white matter hyperintensities (WMH) on MRI are an indicator of cerebral 
small vessel disease, a major risk factor for vascular dementia and stroke. DNA methylation 
may contribute to the molecular underpinnings of WMH, which are highly heritable. We 
performed a meta-analysis of 11 epigenome-wide association studies in 6,019 middle-aged to 
elderly subjects, who were free of dementia and stroke and were of African (AA) or 
European (EA) descent. In each study, association between WMH volume and each CpG was 
tested within ancestry using a linear mixed model, adjusted for age, sex, total intracranial 
volume, white blood cell count, technical covariates, BMI, smoking and blood pressure (BP). 
To detect differentially methylated regions (DMRs), we also calculated region-based p-
values accounting for spatial correlations among CpGs. No individual CpG reached 
epigenome-wide significance, but suggestive novel associations were identified with 
cg17577122 (CLDN5, P=2.39E-7), cg24202936 (LOC441601, P=3.78E-7), cg03116124 
(TRIM67, P=6.55E-7), cg04245766 (BMP4, P=3.78E-7) and cg06809326 (CCDC144NL, 
P=6.14E-7). Gene enrichment analyses implicated pathways involved in regulation of cell 
 
 
development and differentiation, especially of endothelial cells. We identified 11 DMRs 
(PSidak<0.05) and two were mapped to BP-related genes (HIVEP3, TCEA2). The most 
significant DMRs were mapped to PRMT1, a protein arginine methyltransferase involved in 
glioblastomagenesis (P=7.9E-12), and mapped to CCDC144NL-AS1, an antisense transcript 
of CCDC144NL (P=1.6E-11). Genes mapping to DMRs were enriched in biological 
processes related to lipoprotein metabolism and transport. Bi-directional Mendelian 
randomization analysis showed that DNA methylation level at cg06809326 influenced WMH 
burden (OR [95% CI] = 1.7[1.2-2.5], P=0.001) but not the reverse (P=0.89). Additionally, 
increased methylation at cg06809326 was associated with lower expression of CCDC144NL 
(P=3.3E-2), and two-step Mendelian randomization analysis supported its mediating role in 
the association of cg06809326 and WMH burden. CCDC144NL is known to be associated 
with diabetic retinopathy and the coiled coil proteins in general promotes integrin-dependent 
cell adhesion. Integrin-related pathway was further supported by integrative genetic analyses. 
In conclusion, we identified novel epigenetic loci associated with WMH burden, and further 
supported the role of cg06809326 in the WMH etiology implicating integrin-mediated 
pathology.
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BACKGROUND 
Literature Review 
Cerebral Small Vessel Disease: Definition and classifications 
Small vessel disease is a general term for various abnormalities related to small blood 
vessels often referred to in the cardiovascular system.1 Blood vessels play a crucial role in the 
cardiovascular system, and any abnormalities can lead to severe sequelae. Small vessel 
disease in the heart involves coronary arterioles and the sub-endocardial plexus of 
microvessels.2 Abnormalities developed in the heart vessels can lead to acute or stable 
coronary syndromes, as well as heart failure in the long term.3,4 Cerebral small vessel disease 
is an umbrella term for a group of abnormalities of the small arteries, arterioles, venules, and 
capillaries in the brain.5 Most often, cerebral small vessel disease studies paid attentions to 
the arterial part.6 A single occlusion of these vessels may result in lacunar stroke syndrome. 
The main focus of this dissertation is on cerebral small vessel disease (CSVD). 
Blood vessels are widely and densely dispersed in the brain. These perforating vessels 
play a crucial role of carrying essential amount of oxygen and nutrients, thus maintaining 
optimal functioning of the brain’s metabolically active nuclei and complex white matter 
networks.7 The brain greatly depends on the circulatory system in that it receives up to 20% 
of cardiac output and consumes up to 20% of the total body’s oxygen, though it only 
constitutes ~2% of total body mass.8 Arterial blood is supplied to the brain by two major sets 
of vessels: carotid and vertebral arteries.9 Large arteries - anterior cerebral artery (ACA) and 
middle cerebral artery (MCA) - which supply blood to most parts of the cerebral hemispheres 
arise from carotid arteries; while posterior cerebral arteries (PCA) are formed from vertebral 
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arteries. The two major circulation arteries divide into smaller branch vessels to reach out to 
every corner of the brain. Small vessels in the brain originate from two sources: superficial 
and deep.10–13 Superficial small vessels, stemming from the subarachnoid circulation, pass 
the cortical layers and meet the deep originated small vessels which have passed the deep 
grey matter in the deepest areas of the subcortical white matter.  
Since abnormalities of brain vessels can be characterized clinically differently by 
size, they are conveniently called either as a “large” with a diameter larger than 0.5 to 1.0 
millimeter or a “small” vessel with a diameter less than 0.5 millimeter. In CSVD, “small” 
vessels generally means those with a diameter less than 0.2 millimeter.14 Clinical trials 
performed to develop the ischemic stroke classification system, also named as the TOAST 
(Trial of Org 10172 in Acute Stroke Treatment), claimed that stroke caused from large artery 
atherosclerosis should be differentiated from that caused from small-vessel occlusion.15 
Additionally, two other widely used classification systems distinguish these two origins of 
ischemic stroke.16,17 
Small vessel disease is the most common pathological neurological process;18 its 
consequence can be pathologically discerned either as hemorrhagic or ischemic.5 A disease 
with ischemic origin occurs when blood flow is blocked by a blood clot; while that with 
hemorrhagic origin happens when a weakened blood vessel wall bursts and bleeds into the 
lesion. Ischemic small vessel disease accounts for a third of acute cerebral ischemic events.19 
In terms of stroke, a recent study on behalf of the American Heart Association reported that 
87% of all stroke is ischemic.20 Hemorrhagic stroke accounts for a relatively small portion of 
all strokes, but the consequence is more acute and devastating.21 Ischemic stroke subtypes 
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can be further divided into large artery atherosclerotic stroke (LAS), cardioembolic stroke 
(CES), stroke due to small vessel disease (SVS), stroke of other known etiologies, and stroke 
of undetermined etiologies according to the TOAST criteria. Small vessel disease can explain 
about a quarter of ischemic strokes.22–24 
Small vessel disease systematically affects multiple organs and areas of the body and 
can be classified based on its etiopathogenesis. There has been proposed six subtypes of 
small vessel disease; the most prevalent forms are type 1: arteriolosclerosis and type 2: 
sporadic and hereditary cerebral amyloid angiopathy.5 A group of inherited CSVDs such as 
CADASIL (cerebral autosomal dominant arteriopathy with subcortical ischemic strokes and 
leukoencephalopathy) and Fabry’s disease have been recently reported,25 and these forms are 
crucial to understand the pathogenesis of sporadic CSVDs.  
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White matter hyperintensity (WMH) 
White matter lesions are confluent areas on brain magnetic resonance image (MRI) 
that are bilaterally and symmetrically sited in the periventricular and deep white matter of the 
cerebral hemispheres, the basal ganglia which is deep grey matter, the pons, and occasionally 
in the other parts of the brainstem and cerebellar white matter.5,26 It appears hyperintense on 
T2-weighted and fluid-attenuated inversion recovery (FLAIR) images (Figure 127) or 
appears with decreased signal on T1-weighted MR imaging.5,26 It is unclear whether 
differential locations of white matters indicate different disease stages or distinct 
mechanisms, but white matter tends to be numerously distributed in the cerebral hemispheres 
first and then to appear in the brainstem. 
 
The confluent areas in the brain first drew scientific attention more than 30 years ago 
with the term leukoaraiosis.28 At the time that the term “leukoaraiosis” was introduced, most 
Figure 1 Signs of cerebral small vessel disease Adapted from Inzitari 
et al, BMJ. 2009 Jul 6;339:b2477. doi: 10.1136/bmj.b2477 
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studies measured the lesion with computed tomography (CT) imaging, while the most 
updated white matter lesion studies do so with MRI. The lesions are developed by chronic 
hypoperfusion of the white matter and disruption of the blood-brain barrier which cause 
chronic leakage of plasma into the white matter. Pathological studies on the lesions included 
myelin pallor, tissue rarefaction associated with loss of myelin and axons, and mild 
gliosis.13,29 A further study with consideration of the lesion’s location and risk factors found 
that leukoaraiosis is likely to be another expression of CSVD.30 As MRI has become widely 
available in various clinical settings, the data on white matter lesions becomes tremendously 
abundant and white matter lesions are now generally considered a consequence of CSVD. 
WMH is widely used as a surrogate of CSVD.31–33 Symptomatic presentations can be 
used as markers of CSVD since it is difficult to visualize small vessels in vivo.34 As 
mentioned above, CSVD affects the brain vessels which include the perforating cerebral 
arterioles, capillaries, and venules resulting in brain damage in the cerebral white and deep 
grey matter.5 On conventional brain MRI taken at 1.5 or 3T, CSVDs manifest in several 
forms such as lacunar infarcts or hemorrhages, lacunes,35 WMH (mostly clinically silent),36 
visible perivascular spaces,37 and microbleeds38. As one of the key markers of CSVD, WMH 
is more common in lacunar stroke, which is a clinical manifestation of CSVD, than other 
subtypes of stroke.36 Additionally, WMH is correlated with other CSVD correlates i.e. 
lacunes,39 perivascular spaces,37 microbleeds38 and brain atrophy.40 With the advance of 
imaging techniques, large population studies and clinical trials use white matter lesion traits 
as a surrogate marker of CSVD in that WMH can be measured quantitatively via non-
invasively means.32 Epidemiologic studies employ several different endpoints of white 
6 
 
matter. Frequently used terms are white matter hyperintensities (WMH), white matter 
lesions, white matter progression, and white matter changes. WMH is a term for white matter 
lesions appearing hyperintense on brain MRI. This dissertation will focus on WMH, which is 
the most commonly studied marker of CSVD, to provide an additional body of evidence to 
the current knowledge in CSVD with comparability to other studies.  
 
Epidemiology of WMH 
As WMH is highly prevalent in the aging population and associated with age-related 
neurological changes;41,42 it has been hypothesized that WMH is a neuroimaging correlate of 
age-associated disabilities.43 Even though white matter lesions may develop in young 
age,44,45 prevalence increases with age in a “dose-response relationship”. WMH becomes 
universal in the older ranging from 11-21% in adults aged around 64 to 94% at age 82.32,35,46–
50 Furthermore, white matter lesions are associated with many geriatric disabilities which 
include cognitive disorders, gait and mood disturbances, and urinary problems.51  
Risk factors for WMH are a similar set to those for vascular diseases;52 hypertension 
plays a crucial role in WMH.53,54 Large population-based studies have shown that advancing 
age, female gender, higher blood pressure or hypertension, African American ethnicity, 
smoking, alcohol use, lower education attainment, low income, silent infarct, diabetes, and 
lower forced expiratory volume in 1 second (FEV1) are associated with WMH as a marker of 
CSVD.55 Hypertension is considered as the most important modifiable risk factor for CSVD 
and, particularly, WMH and lesions.48,49,56–63 Some of those studies have also shown that 
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duration of hypertension is associated with WMH.60,61 In this perspective, the 
pharmacological treatment standard of CSVD has been designed to manage blood pressure.64 
Despite that the pathophysiology of WMH is little known and that various 
pathologies can lead to WMH,33,65 it is likely to have ischemic or degenerative origin that 
damages the small vessels of the brain, leading to chronic cerebral hypoperfusion and myelin 
rarefaction.66 Large-scale brain imaging studies have shown that WMH is associated with 
incident stroke, vascular cognitive impairment, dementia, Alzheimer’s disease or death.42,67 
Specifically, the association of cognitive decline with WMH has been reported for more than 
20 years.31,32,68 A meta-analysis of 23 cross-sectional and 14 longitudinal studies reported 
that presence of WMH was associated with concurrent cognitive deficits in every test 
domain, and the effect was constant over time.69 Studies in older subjects without 
neurological diseases reported mixed results on individual domains, but WMH is considered 
to be particularly correlated with decline in information-processing speed and executive 
function.70 
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Physiological characteristics of cerebral small vessels 
As mentioned earlier, blood flow to the brain is crucial. A few minutes interruption of 
blood flow can cause severe brain damage and even the slightest insufficient blood flow can 
lead to chronic brain injury.71 The brain exhibits unique functional properties to ensure this 
crucial blood flow.72 First, since the brain has little means to store energy, the brain works to 
regulate vessels to sustain an adequate supply of blood in cerebral blood flow (CBF) under a 
variety of conditions. CBF is primarily determined by mechanisms including perfusion 
pressure, autoregulatory mechanisms, and vascular reactivity to the partial pressure of arterial 
CO2.73 Second, the brain has an auto-regulation mechanism to maintain the constant 
transmural pressure against variations in arterial pressure during daily activity. Myogenic 
reactivity is known to play a major role in auto-regulation, and there are other candidate 
mechanisms to be studied.73,74 Third, the brain has a unique anatomical structure called the 
blood-brain-barrier (BBB), which is an important mechanism to regulate the entry and exit of 
blood composites including ions, nutrients, macro molecules and energy metabolites.75 
Specifically, BBB protects the brain from physiological fluctuation in plasma composites, 
and from harmful agents circulating in the blood supply.76 In essence, the homeostasis in the 
brain is precisely controlled by an elaborate system of unique physiological structures and 
mechanisms. 
Physiological studies found that the unique feature of the cerebral vasculature, BBB 
does not function independently, but as a module called the neurovascular unit (NVU),75 
which enables tight regulation of blood flow to the brain. The NVU consists of endothelial 
cells and smooth muscle cells, and are surrounded by a basement membrane, the perivascular 
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(Virchow-Robin) space, pia mater, and astrocyte endfeet.77 Pial arteries running on the brain 
surface in the subarachnoid space branch out into the smaller, penetrating arteries. Likewise, 
penetrating arteries further branch out into parenchymal arteriole and further into capillaries. 
As shown in Figure 2,77 pial arteries and penetrating arteries are covered by smooth muscle 
cells and are separated from brain tissues by parenchymal basement membrane. Branching 
out into parenchymal arterioles, both parenchymal basement membrane and pia matter 
disappears; further branching out into the capillaries, eventually smooth muscle cells 
disappear. Without smooth muscle cells and pia mater, capillaries gain pericytes between 
endothelial cells and astrocytes; thus, neurons and astrocytes are in direct contact with them. 
 
Figure 2 Blood-brain Barrier (BBB) and the neurovascular unit (NVU) Adapted from Yu 
Yamazaki et al. 2017 
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Mechanisms underlying CSVD: Current understanding 
Animal models are useful to simulate ischemic changes in the brain; however, due to 
the lack of pathological understanding the optimal animal models in CSVD or WMH have 
not yet been developed. Hypertension, as an important risk factor in CSVD, has been 
thoroughly studied in rodents and other model animals. Studies confirmed deleterious effects 
of hypertension on the cerebral vascular structure and functions; those changes are thought to 
be associated with cerebral blood flow (CBF) reduction, impaired vasodilation and 
vasodilator reserve, and shifts in the autoregulatory curve.78,79 The studies suggested several 
underlying mechanisms, and the effect of angiotensin II mediated by oxidant-dependent and 
immune-dependent mechanisms also seems to play a crucial role in the pathology.78,79 
Angiotensin II mechanism is often a therapeutic target in hypertension and other 
cardiovascular disease treatments. Although animal models showed the effect of 
hypertension on vasculature, the causal relationship with brain lesions is lacking.72 Also, a 
common animal model known as “sporadic small vessel disease model” typically induces 
malignant severe hypertension which is beyond the range of autoregulation;72,80 thus, the 
sporadic model cannot show the specific influence of modest blood pressure variability. A 
recent animal study for dementia implemented a device called an ameroid constrictor that 
precisely replicates chronic cerebral hypoperfusion by gradually narrowing cerebral 
vessels.81 A study with a novel animal model using this device showed the role of reduced 
CBF in white matter damage.82 
Modern concepts in CSVD etiopathology originate in the post-mortem work of C. 
Miller Fisher during 1955-1973, which took clinicopathological-vascular examinations in 20 
11 
 
patients with lacunes, lacunar infarcts, and perforating arterioles.83–87 Lacunar ischemic 
stroke is a type of stroke attributable to a recent small infarct in the white matter, basal 
ganglia, pons, or brainstem. Lacunar stroke patients provided a clue about the CSVD 
etiology, as a clinically overt stage of CSVD. Historically, it was believed that symptomatic 
lacunar infarcts are due to atherosclerosis or embolism in larger arterioles and the silent ones 
are due to lipohyalinosis or fibrinoid necrosis in the smaller arterioles.87  
More recently, three possible etiologies for lacunar ischemic stroke are suggested:26,88 
atheroma, embolism, and intrinsic small vessel disease. Atherosclerosis in the middle 
cerebral artery (MCA), a type of parent artery, has been suspected as a common cause of 
lacunar stroke in Fisher’s studies, but stenosis does not seem to address lacunar strokes. In 
the Wafarin Aspirin Symptomatic Intracranial Disease (WASID) trial in subjects with stroke 
history and current stenosis, only 11% (38/347) of randomized subjects had lacunar stroke as 
an index.89 Also, intracranial stenosis is rare in the Caucasian population at less than a 1 to 
2 % prevalence, but still a quarter of ischemic stroke is lacunar in the population.90 To 
address this discrepancy it was hypothesized that there are two distinct subtypes of lacunar 
stroke: those due to proximal perforating arteriolar atheroma and the others due to 
lipohyalinosis/arterioloscerosis.91 However, it is unclear how to differentiate them reliably.  
The next possible mechanism is embolism, but it also does not appear to be a common 
cause of CSVD. Although embolism can cause an acute lacunar infarct, cohort studies and 
meta-analyses showed that only 10-15% of lacunar infarcts and few WMH are explained by 
embolism.92–94 Also, a systematic review of experimental studies that induced stroke in 
animals concluded that emboli mostly caused cortical, but not small subcortical, lesions.95 
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One of the studies reported that only less than 6% of emboli injected into the carotid arteries 
entered the perforating arterioles.96 Thus, lacunar stroke is less likely to be associated with 
overt emboli compared to non-lacunar stroke,92,93 and, thusly, the stenosis is unlikely to cause 
the infarct93 or WMH94.  
In his post-mortem studies Fisher claimed blood pressure is the cause of pathologies in 
CSVD i.e. arteriolosclerosis, lipohyalinosis or fibrinoid necrosis; however, the relationship 
between blood pressure and CSVD or WMH is not clearly understood yet. In a study of 70 
brain autopsies, many CSVD patients did not have classic vascular risk factors including 
hypertension.97 Blood pressure is still considered as an important risk factor for 
WMH,57,60,61,63,98 but the relationship between blood pressure and WMH is complex. It is still 
unclear whether systolic63 or diastolic62,99 BP is important in WMH; it is not consistent if BP 
does predict WMH progression57 or not100. 
The emerging hypothesis in CSVD pathology is that the loss of normal endothelial 
function in the blood-brain barrier (BBB) causes pathological changes in the brain. BBB 
consists of endothelial cells tightly anchored to each other. The failure of the cerebral 
arteriolar and capillary endothelium could explain the arteriolar wall infiltration and 
thickening via perivascular tissue changes (e.g. damaged arteriolar smooth muscle and fibrin 
deposition known as lipohyalinosis and fibrinoid necrosis).101 These changes were referred to 
as “microvascular pathology” in Fisher’s original paper.102 Cumulative microvascular 
pathology in perivascular tissue can lead to rarefaction and demyelination, which are 
pathologically observed in WMH carriers.29 More severe consequences of endothelium 
failure include vessel lumen dilation and narrowing and stiffened vessels with loss of normal 
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autoregulation; as scientists long suspected for CSVD etiology.103,104 As the mechanism 
involving endothelium dysfunction has been hypothesized relatively recently, our 
understanding of the role of cerebrovascular endothelium in CSVD pathology is lacking.105  
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Previous Genetic Studies of CSVD and WMH 
Even though a myriad of studies put intensive efforts to decipher molecular 
mechanisms underlying CSVD, the precise mechanism is not fully understood. Poor 
understanding of biological mechanisms behind the disease continues to impede the 
development of effective and precise treatments for CSVD. Studying microvessels in the 
brain has been a struggle due to the limited accessibility to them, the difficulties of in-vivo-
visualization, and the lack of adequate animal models.106 However, genetic studies have been 
expanding our understanding of CSVD mechanisms; monogenic forms of CSVD were 
discovered and results from large-scale studies are promising to decode the genetic basis of 
sporadic CSVDs. From the current understanding it is hypothesized that CSVDs are likely to 
result from various pathogeneses such as atheroma (decreased blood flow), emboli 
(blockage-causing piece of material inside a blood vessel), inflammation with BBB 
disruption, cell degeneration, and myelin breakdown. Genetic studies are designed both to 
investigate whether or not WMH is developed by these mechanisms and to identify genetic 
markers for prevention or intervention purposes.  
Animal model 
Transgenic mouse models have been numerously employed to study mechanisms of 
known causal genes in monogenic CSVDs such as CADASIL. Vascular protein deposits 
(granular osmiophilic material) containing the Notch3 extracellular domain have been 
identified in transgenic mouse models expressing a pathogenic mutant,107–111 but not in 
knockout mice.112–114 Through these animal studies NOTCH3 is now strongly claimed to 
have a gain-of-toxic-function rather than a loss-of-function mechanism.114,115 Proteomic 
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profiles of HTRA1 gene knockout mouse was shown to overlap with the protein profiles of 
CADASIL patients.114 Unlike monogenic CSVD, animal studies in common and complex 
form of CSVD are lacking. Since large-scale epidemiologic studies have recently identified 
genetic variants associated with common and complex form of CSVDs presented as WMH, 
brain infarcts, and other clinical manifestations; it is necessary to confirm the mechanistic 
function of those genes in transgenic animal studies. A recent study using CRISPR/Cas9 
models examined the role of a SNP (rs9349379) located in PHACTR1 gene on five vascular 
diseases including hypertension.116 This suggests a potential utility of the modern gene-
editing technology with WMH and CSVD causal variants. 
Compared to non-cases a family history of stroke is more likely to be found in stroke 
patients, and a positive family history of stroke is strongly associated with CSVDs [odds 
ratio of 1.93 to 2.76].117,118 Specifically for WMH, twin studies showed that correlations of 
WMH volume in pairs are greater in monozygotic twins than dizygotic twins, and the 
heritability estimate of 71% adjusted for age and head size was very high.119 High heritability 
in WMH volume was also estimated in family-based studies ranging from 52 to 78%.120–122 
The Framingham Heart Study suggested that the heritability estimate may depend on gender 
and age.120 However, heritability estimates based on common genetic variants, known as 
narrow-sense heritability, is generally lower; the estimate in small vessel-related stroke and 
deep intracerebral hemorrhage ranged from 15 to 30%,123,124 and was only 6.4 % for WMH 
specifically.125 This discrepancy between the estimates can be explained by other genomic 
variants or mechanisms not included in GWASs (i.e. rare variants, DNA methylation, gene 
expression, gene-gene interaction, and gene-environment interaction).  
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Genetic studies have identified nine genes for mendelian forms of CSVD including 
NOTCH3, COL4A1, COL4A2, TREX1, HTRA1, FOXC1, PITX2, CECR1, and CTSA.126 
NOTCH3, known to be associated with CADASIL,127–130 encodes the NOTCH3 
transmembrane receptor involved in arterial differentiation and vascular smooth muscle cell 
remodeling.131 HTRA1 (high temperature requirement protein A1) is involved in TGF-β 
signaling, playing an important role in vessel development and maintenance.132 Also, HTRA1 
is associated with cerebral autosomal recessive arteriopathy with subcortical infarcts and 
leukoencephalopathy (CARASIL).25,133 Studies also identified that some genes cause specific 
CSVD in a monogenic manner; basement membrane abnormality related to COL4A1 and 
COL4A2, which are associated with COL4-related angiopathies,134,135 changes in endothelial 
and pericyte proliferation as well as impairment of BBB integrity were found to be associated 
with FOXC1/PITX2 in animal models,136–138 and CECR1 is associated with ADA2 deficiency 
leading to early-onset strokes and inflammations.139,140 Additionally, TREX1 is associated 
with retinal vasculopathy with cerebral leukodystrophy and systemic manifestations (RVCL-
S) and the gene plays a role in basement membrane defects in capillaries.141,142 Recently, 
investigators found a novel association of CTSA with a subtype named cathepsin A-related 
arteriopathy with strokes and leukoencephalopathy (CARASAL). CTSA encodes cathepsin A 
which is involved in the inactivation of neuropeptides and regulation of a lysosomal pathway 
of protein degradation and pathological change leads to fibrous thickening of the small 
vessels.143,144 Mutations in NOTCH3, COL4A1 and COL4A2 are thought to explain a large 
portion of familial CSVDs, and penetrance of these genes are high so that individuals with 
even a single mutation are at almost 100% risk of the disease.126 Even though monogenic 
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CSVDs are considered genetically heterogeneous and rare, the shared clinical and 
radiological features between monogenic and sporadic CSVD implies that the genetic 
underpinning of monogenic CSVDs provides important information to understand the 
genetics of the common and prevalent forms of CSVD.106 
Knowing the presence of genetic components in WMH, scientific efforts to map the 
trait-associated locus were made with linkage studies. Linkage studies test a genetic locus 
transmitted with the disease in larger regions (tens of centiMorgans). The co-transmission of 
two close-enough genetic loci is called “linkage disequilibrium (LD)” and the degree of LD 
is assessed with a logarithm of the odds (LOD) score, the odds of co-transmission compared 
to expected independent inheritance. Linkage studies of WMH identified the locus at 4 cM 
on chromosome 4 in healthy elderly white subjects.145,146 Also suggestive LOD scores have 
been reported at 95cM on chromosome 17 (LOD=1.78)145, at 118 cM on chromosome 11 
(LOD=2.21), and at 13 cM on chromosome 21 (LOD=1.75) in white subjects, and at 36 cM 
on chromosome 22 (LOD=2.02) as well as at 58 cM on chromosome 21 (LOD=1.99) in 
black subjects.147 Additionally, bivariate linkage analysis suggested that 1q24, 1q42, 10q22-
q26 and 15q26 loci are in LD both in WMH volumes and BP measurements, indicating 
pleiotropic effects in the regions.148 
Moreover, candidate gene studies investigated dozens of biologically plausible genes in 
the association with WMH. A recent systematic review described46 candidate gene studies 
having investigated the association between WMH and 19 genes which are mostly involved 
in lipid metabolism, control of vascular tone, or blood pressure regulation.149 The study also 
performed a meta-analysis for four genes (APOE, ACE, MTHFR, and AGT), and none of 
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them were significantly associated with the WMH grade.149 However, the AGT gene has been 
repeatedly implicated in WMH linkage studies and the most studied SNP in the gene,147,148 
M235T has been reported in a genome-wide association study150 suggesting that M235T is 
likely to be in LD with functional causal variants for WMH.151  
The advance of genotyping and computational technologies enabled finer mapping of 
causal loci associated with WMH. In addition to the linkage findings, genome-wide 
association studies (GWAS) explored which single nucleotide polymorphism (SNP) is 
associated with WMH (Table 1). The Cohorts for Heart and Aging Research in Genomic 
Epidemiology (CHARGE) consortium has published GWAS associations of WMH in 
disease-free populations. These studies excluded subjects with stroke history due to WMH 
being prevalent in stroke patients and thus discounting the cases of WMH formed as a stroke 
comorbidity. The first large-scale association study by CHARGE identified SNPs in six 
genes (TRIM65, TRIM47, WBP2, MRPL38, FBF1, and ACOX1) at 17q25;150 a follow-up 
study with a larger number of subjects in a multiethnic population additionally mapped 
SH3PXD2A at 10q24, HAAO at 2p21, PMF1-BGLAP at 1q22, and EFEMP1 at 2p16.152 
Under the hypothesis of shared genetics among stroke and stroke-free populations, a meta-
analysis of the latter CHARGE GWAS and a GWAS in 3,670 ischemic stroke patients was 
performed for the previously reported 15 SNPs.153 This candidate-gene meta-analysis 
identified four significant loci, NBEAL1 at 2q33, EVL at 14q32, C1QL1 at 17q21, and 
COL4A2 at 13q34.153 The most recent and largest meta-analysis of GWASs, including 2,797 
stroke subjects and 8,429 stroke-free individuals from UK Biobank, identified a novel locus 
in PLEKHG1 at 6q25 and confirmed two previously reported loci i.e. 17q25 and 2p16.125 The 
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novel gene PLEKHG1 was also suggestively significant in a GWAS of stroke-free population 
(P value=7.9x10-7).125 There was also an effort to identify rare variants associated with 
WMH. Jian et al. performed an exome-wide association analysis including up to 250,000 
exonic variants in 20,719 individuals.154 In this analysis the known loci 17q25 and 2q33 were 
confirmed and a novel gene in the locus (MRPL38) was identified at the genome-wide 
significance level. Most recently, a meta-analysis of two of the exclusively largest GWASs 
from CHARGE and UK Biobank confirmed previous findings and additionally identified ten 
novel loci for WMH. This study is currently under review for publication, and the identified 
genome-wide significant loci were informed during personal communications with the 
authors. 
Functions of some genome-wide significant SNPs can be plausibly explained in 
relation to the CSVD pathology. HAAO at 2p21 encodes 3-hydroxyanthranilate 3,4-
dioxygenase, which catalyzes the synthesis of quinolinic acid (QUIN). QUIN has been 
identified in studies of Alzheimer’s disease and Huntington’s disease. PMF1-BGLAP at 1q22 
encodes polyamine-modulated factor 1, a nuclear protein regulated by polyamines. This 
protein is required in chromosome alignment and segregation during mitosis. Genes 
including NEURL (neuralized E3 ubiquitin protein ligase 1), TRIM47 (tripartite motif 
containing 47), SH3PXD2A (tyrosine kinase substrate with five SH3 domains), EEMP1 
(endothelial cell membrane glycoprotein fibulin-3) and NBEAL1 (neurobeachin like 1) were 
implicated in white matter-related malignant brain tumors involving glial cells.152 COL4A2, 
aforementioned in relation to the monogenic form of CSVD, encodes one of the six subunits 
of type IV collagen, the major structural components of the basement membrane. Variants in 
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this gene were reported to be associated with intracerebral hemorrhage and ischemic small-
vessel stroke.155,156 Lastly, PLEKHG1 encodes pleckstrin homology and RhoGEF domain 
containing G1 which is one of the Rho guanine nucleotide exchange factors (Rho-GEFs). 
Rho-GEFs are involved in cyclic stretch-induced cell reorientation in the vascular 
endothelium.157  
Table 1 Genome-wide significant loci associated with WMH 
Locus Gene Population Analysis Method Ref 
1q22 PMF1, BGLAP Pooled GWAS 152 
1q24 200cM Hispanic Bivariate Linkagea  148 
1q31.3 DENND1B EA GWAS PC 
1q42s 272cM Hispanic Bivariate Linkagea 148 
2p16 EFEMP1 Pooled, EA GWAS 125,152 
2p21 HAAO EA GWAS 152 
2q32.1 AC007319.1 EA GWAS PC 
2q33 
NBEAL1 Pooled, EA GWAS 152–154 
WDR12 Pooled, EA GWAS 154 
CARF Pooled, EA GWAS 154 
4p 4cM EA Linkage 145,146 
5q23.2 CTC-441N14.4 EA GWAS PC 
6q25.1 PLEKHG1 EA GWAS 125 
7q22.1 ZAN EA GWAS PC 
10q24-26s 15cM Hispanic Bivariate Linkagea 148 
10q24 
PDCD11 EA GWAS 152 
NEURL Pooled, EA GWAS 152 
SH3PXD2A Pooled, EA GWAS 152 
PDCD11 Pooled GWAS 152 
11s 118cM EA Linkage 147 
13q34 COL4A2 EA GWAS PC 
14q32.2 EVL, DEGS2 EA GWAS PC 
15q22.31 MTFMT, SLC51B EA GWAS PC 
15q26s 94cM Hispanic Bivariate Linkagea 148 
16q12.1 RP11-437L7.1 EA GWAS PC 
16q24.2 C16orf95 EA GWAS PC 
17s 95CM EA Linkage 145 
17p11.2 EPN2 EA GWAS PC 
17q21.31 DCAKD, NMT1 EA GWAS PC 
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17q25 
UNC13D Pooled, EA GWAS 152 
TRIM65 Pooled, EA GWAS 125,150,152,154 
TRIM47 EA GWAS 150,152 
WBP2 EA GWAS 150 
FBF1 Pooled, EA GWAS 152,154 
ACOX1 Pooled GWAS 152,154 
MRPL38 EA GWAS 154 
19q13.32 APOE EA GWAS PC 
21s 13cM, 58cM AA, EA Linkage 147 
22s 36cM AA Linkage 147 
a Bivariate analysis of WMH and blood pressure measures (pulse pressure and 
arterial blood pressure). s Linkage result with suggestive LOD score. EA: Subjects of 
European ancestry, AA: Subjects of African ancestry. PC: based on personal 
communication 
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Epigenetic studies and integrative analysis 
 In genetic epidemiology “missing heritability” has been a mystery to unravel. 
Although GWASs found a myriad of common variants associated with complex diseases, a 
large portion of heritability is not completely accounted for yet. This unexplained portion of 
heritability (“missing heritability”) can be due to overestimated heritability or underestimated 
SNP effects in GWASs. In the post-genome era, several additional explanations are 
suggested to fill this gap. Rare alleles with bigger effects are being studied actively as the 
first alternative explanation. Tagger SNPs in GWASs do not cover rare alleles enough plus 
the ability to impute those is limited;158 exome-wide association studies covering rare alleles 
(i.e. minor allele frequency <0.01 or 0.05) may find extra genetic variants. Some rare variants 
may have greater effects than common variants which may indicate a single-gene disorder.159 
Secondly, it is shown that genetic interactions or epistasis account for a significant portion of 
missing heritability. Estimation of heritability requires an assumption that there is no genetic 
interactions or epistasis in the heritability estimation; thus, existence of epistasis can lead to 
over-estimation. This overestimated gap is referred as “phantom heritability”. Thirdly, 
epigenetics is another explanatory factor for the missing heritability. The genome is wrapped 
around units of histones, which are collectively called chromatin. Chromatin can be modified 
through DNA methylation, modifications of histone proteins, or post-transcriptional silencing 
mediated by micro-RNAs (miRNAs).160,161 Epigenetic changes are mostly transient, but some 
epigenetic changes can be inherited in the short term.162 Epigenetics is dynamically 
influenced by the environmental factors such as smoking, stress, and nutrients161,163 and 
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regulates gene expression; thus being likely to contribute to phenotypic variance and explain 
some extent of missing heritability. 
Epigenetics receives considerable interest among many aspects of genomics as it 
involves the regulatory process of translating encoded DNA into proteins. Since epigenetic 
phenomenon is reversible, it provides information on the complex dynamics between genes 
and environment. DNA methylation has been most studied of the several epigenetic changes 
since it is more feasible to measure in an epidemiological setting.164 DNA methylation is an 
epigenetic phenomenon that cytosine in the genome is attached with a methyl group onto its 
C5 position by DNA methyltransferases (DNMTs). It is well shown in cancer cells that 
changes including chromosomal instability, activation of oncogenes, silencing of tumor 
suppressor genes and inactivation of DNA repair systems are not caused only by genetic but 
also by epigenetic abnormalities such as genome-wide hypomethylation and regional 
hypermethylation of CpG islands.165–169 The role of epigenetics has also been studied in the 
epidemiologic settings and studies have identified DNA methylation sites associated with 
complex diseases such as cardiovascular diseases and stroke.170–173 In the search for DNA 
methylation sites involved in disease etiology, the analytic strategy in GWAS is used in 
epigenetic studies. A genome-wide investigation of associations between DNA methylation 
levels and a complex trait is now coined as an epigenome-wide association study 
(EWAS).174–176 
As our understanding broadens with data at different molecular levels (i.e. genome, 
epigenome, and transcriptome), an integrative analysis of the multi-omics data became 
important. Although GWAS approaches identified genetic loci related to WMH burden, the 
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precise mechanistic pathway involving molecular events (e.g. DNA methylation, regulation 
of gene transcription, translation, post-translation modification, etc.) is not fully addressed. 
Integrative genomics has been introduced to combine genomics and emerging functional 
omics (i.e. epigenomics, transcriptomics, proteomics, and metabolomics) and derive a 
meaningful causal etiological pathway utilizing multi-omics data. An integrative approach 
has been successful in many complex traits including immunology,177 oncology,178,179 
cardiovascular diseases,180 and some neurological diseases such as narcolepsy,181 
Alzheimer’s disease,182 schizophrenia,183 and autism184.  
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Public Health Significance 
The use of WMH burden as an endpoint may improve CSVD prevention, thusly 
facilitating general brain health. Since brain imaging is non-invasive and became accessible, 
prevention strategies based on WMH burden is widely applicable to the public. Large-scale 
brain imaging studies have shown that WMH is associated with public health burdens of 
extreme significance such as incident stroke, vascular cognitive impairment, dementia, 
Alzheimer’s disease, and death.42,67 Early detection of relevant brain diseases is more feasible 
with utilizing WMH burden as the accessible endpoint rather than diagnosing based on 
symptoms. For instance, using MRI-defined infarcts, silent ischemic stroke was found to be 
significantly more prevalent than symptomatic events.185 Furthermore, genetic epidemiology 
may enable us to earlier identify individuals at higher risk of WMH burden125,150,152 and 
prevent brain diseases before the damage accumulates and the changes become irreversible.  
Understanding WMH etiology can help to establish an effective and safe CSVD 
treatment strategy. Precision medicine, the medical care designed to optimize efficiency or 
therapeutic benefit, can be achieved first by subtyping CSVD.186 Although the 
pathophysiology is not fully addressed (and various pathologies can lead to WMH),33,65 
WMH is likely to have an ischemic or degenerative origin that damages the small vessels of 
the brain, leading to chronic cerebral hypoperfusion and myelin rarefaction.66 Due to the 
limited understanding of the etiology, current practice of ischemic vascular disease 
prevention is barely limited to management of modifiable risk factors such as high blood 
pressure and compositions of lipids;187moreover, these treatments have not shown agreed 
upon and consistent effectiveness for CSVD. The current treatments of CSVDs are listed as 
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thrombolysis, antihypertensive, statins and antiplatelets. Observational studies - the 
Rotterdam Scan Study and the Epidemiology of Vascular Ageing study - showed that 
effective hypertension treatment was associated with lower risk of CSVD manifested as 
WMH,60,61 while it has shown inconsistent effects in randomized controlled trials.188–190 
Likewise, lipid-lowering treatments also did not show optimal effectiveness in preventing 
WMH;191,192 even worse, safety issues were elevated with these medications. Excessive 
blood pressure decrease may even induce cognitive decline in older patients with extensive 
WMH as shown in the Secondary Prevention of Small Subcortical Strokes trial.193A recent 
large statin study in a stroke-free population showed that statin use can even increase the risk 
of ischemic stroke.194 Also, antiplatelet therapy should be avoided due to the excessive risk 
of intracerebral hemorrhage in CSVDs.195 Furthermore, treatments for strokes are not 
effective in CSVDs. The gold-standard treatment of acute ischemic stroke, tissue 
plasminogen activator (t-PA) showed an increased risk of hemorrhage in patients with 
WMH.196–199 Failure of traditional treatment options leads us to the conclusion that CSVD is 
etiologically dynamic and heterogeneous; therefore, the treatment strategy needs to be 
designed based on its etiology and progression. Subtyping WMH etiology and developing a 
precision medicine strategy based on epigenetics can be the new way to achieve the second 
prevention of CSVD.  
The main goal of this dissertation is to identify the role of DNA methylation in WMH 
burden in the reasonable hope that it may provide a key to understanding the CSVD etiology 
in relation to aging. As life expectancy increases, disabilities in the older population are even 
more subject to public health interest. One of the important risk factors in many neurological 
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diseases is advancing age, since many neurological changes develop as an individual ages.200 
Senescence, the condition or process of deterioration with age, is composed of many 
neurological changes53 - including cerebral white matter development.201 WMH is very 
prevalent in the aging population; 95% of older adults aged 60-90 have these signs on brain 
MRI. Age-related changes in WM are also associated with increased risk of stroke and stroke 
mortality.202 DNA methylation is known to be affected by aging,201,203 and it is suggested as a 
biomarker for cognitive dysfunction and brain aging.204 Epigenetics is a composite factor of 
genetic composition nurtured by environmental exposures such as aging, making it a useful 
tool to study age-related genetics in CSVD. 
To summarize, results of this dissertation might bring a few positive impacts to public 
health. First, the use of WMH burden as the endpoint would facilitate CSVD prevention. 
Since WMH burden can be measured using MRI techniques, it is accessible, non-invasive, 
quantitative, and a representative marker of CSVD. Therefore, a prevention strategy based on 
WMH burden is more widely applicable to the public. Second, the discovery of epigenetic 
risk factors in addition to genetic risk factors may improve personalized medicine for CSVD. 
CSVD is a complex disease leading to heterogeneous medical conditions; understanding the 
genetic architecture behind WMH burden will help us classify individuals by their potential 
risk genotypes. Furthermore, we can develop a more effective treatment strategy that is 
customized for distinct etiological pathways associated with each genotype. Thirdly, because 
epigenetic factors are influenced by both genetic and environmental exposures, the 
identification of CSVD-associated epigenetic changes may provide an avenue to intervene on 
“modifiable” environmental risk factors to prevent CSVD. 
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Specific Aims and Hypotheses 
Emerging evidence suggests that a complex disorder can be understood better with 
epigenetics. WMH on magnetic resonance imaging (MRI) are a subclinical marker of 
vascular brain injury, therefore a clinical biomarker of CSVD.43 Twin and family studies 
have shown that WMH is highly heritable with an estimated heritability ranging from 52 to 
78%120–122. However, the underlying genetic architecture is still unresolved in that all 
identified risk loci explain only a small portion of the heritability (6.4%).125,150,152–154 To fill 
this gap, research has drawn attention to new aspects of genomic variation. In this 
dissertation, we aim to investigate one aspect called “epigenetics” in association with WMH 
burden. Epigenetics receives increasing attention since it is involved in the regulatory process 
of gene expression. Also, epigenetics reflects the complex interactions of gene and 
environment, and thus, it is expected to provide novel findings and explain an additional 
layer of genetic architecture in WMH, which is previously unrealized. 
The objective of this dissertation is to identify novel genes associated with WMH 
burden, implicate through variation in DNA methylation - the most commonly studied 
epigenetic phenomenon. First, we will complete an epigenome-wide association study 
(EWAS) of WMH, where DNA methylation sites associated with WMH will be identified. 
Second, we will examine the causal direction between the identified DNA methylation and 
WMH using genetic instruments in order both to confirm if the epigenetic association is 
under genetic control and to establish directionality of the EWAS associations. Lastly, we 
will incorporate multi-omics information (i.e. genetic, epigenetic and transcriptional 
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information) to aid in interpretation, and characterize functional relationships that will help 
infer etiology of WMH.  
Below are the study questions in more scientific forms. 
Aim 1: To identify DNA methylation (DNAm) loci associated with WMH burden 
(Epigenome-wide association study) 
Q1. Are there DNAm loci associated with WMH burden? 
Q2. Are the associated DNAm loci implicated in biological pathways or etiology of 
relevant diseases or traits? 
Aim 2: To identify the causal pathway in DNAm-WMH associations using genetic 
instruments 
Q1. Are there single nucleotide polymorphisms (SNPs) that influence DNA methylation 
levels at loci associated with WMH? 
 Q2. How is the causal direction between DNAm and WMH burden? 
 Q3. Is gene expression associated with the WMH-associated DNAm? 
Aim 3: To investigate the role of DNAm in WMH etiology using multi-dimensional (genetic, 
epigenetic and transcriptional) data 
Q1. Are there etiological pathways identifiable by the integrated multi-dimensional 
WMH burden associations? 
Q2. Does any gene play a mediator role in the association between DNA methylation and 
WMH burden?  
Q3. Do the genetic associations of multi-dimensions (i.e. DNAm, gene expression and 
WMH burden) co-localize at the known WMH loci?
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METHODS 
Aim 1: Meta-analysis of epigenome-wide association studies (EWASs) of WMH burden 
 The overall study design is shown in Figure 3. In this aim (Aim 1), we performed a 
meta-analysis of EWASs in WMH burden. Accounting for spatial correlation among 
DNAms, P values were collated to identify a group of DNAms associated with WMH 
burden. Results were interpreted in the context of biological functions using two strategies 
based on: 1) the genes mapped to the identified DNAm and 2) the shared epigenetics. 
 
Figure 3 The schema of overall study designs 
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Study subjects 
We included ten population- or family-based cohort studies - Alzheimer’s Disease 
Neuroimaging Initiative (ADNI), Atherosclerosis Risk in Communities (ARIC) study, 
Biobanking and BioMolecular Resources Research Infrastructure (BBMRI), Coronary Artery 
Risk Development in Young Adults (CARDIA), Cardiovascular Health Study (CHS), 
Framingham Heart Study (FHS) Offspring Cohort, Genetic Epidemiology Network of 
Arteriopathy (GENOA), Lothian Birth Cohort 1936 (LBC1936), Rotterdam Study III (RS3) 
and The Study of Health in Pomerania TREND (SHIP-TREND). Eligible subjects were 
middle-age to elderly, free of stroke or dementia, and of African or European ancestry (AA 
or EA). Description of participating cohorts and study-specific methods are described in the 
Supplemental Material. Descriptive statistics in participating cohorts are presented in the 
Table S1.  
Protection of human subjects  
All participating studies had received institutional review board approval for its 
informed consent process, clinical examinations (brain imaging, anthropometric measures, 
blood pressure measures, etc.), methylation sample collection and its use, and data access and 
distribution. Approvals were granted to individual studies and the study-specific ethic 
statements are presented in Appendix A. Supplemental Material. Subjects who provided 
written informed consent for study participation, MRI scanning, and use of methylation data 
were entered in this study. Study protocol for this dissertation was also reviewed by the 
University of Texas Health Science Center Committee for the Protection of Human Subjects, 
the approval letter is attached in Appendix A. Supplemental Material. 
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White matter hyperintensity (WMH) measurements 
WMH on brain MRI in this study indicates the high-intensity areas within cerebral 
white matter on T2-weighted images. MRI was taken in the same or the closest subsequent 
visit to the visit where DNA methylation sample was taken. Diagnosis of clinical dementia or 
stroke for eligibility were made at MRI scans. MRI was scanned and interpreted according to 
the standardized method in each study, with demographic or clinical information of subjects 
blinded. Participating studies obtained T2-weighted scans using either spin-echo pulse 
sequences or fluid-attenuated inversion recovery (FLAIR) sequences from all subjects. MRI 
scan of WMH is measured either on a quantitative volume (mL) or qualitative scale (grade). 
Since WMH distribution is typically right-skewed, WMH burden is quantified as the log-
transformation of a validated WMH value +1. Addition of 1 is to make the WMH burden be 
always a positive value for convenience in later analyses. MRI procedures and WMH 
quantification in each study are detailed in Appendix A. Supplemental Material. 
DNA methylation profiling 
DNA methylation levels have been measured in whole blood samples with the 
Illumina Infinium Human450 Methylation BeadChip in most participating cohorts. The 
GENOA study measured methylation levels at 26,449 probes with the Illumina Infinium 
HumanMethylation 27 BeadChip, which are covered by the Illumina Human450 Methylation 
BeadChip. ADNI, CARDIA and SHIP-TREND measured methylation with the Illumina 
MethylationEPIC BeadChip with a denser coverage of probes (~850K). Each study 
independently performed the quality control (QC) for DNA methylation data, complying the 
agreed minimum QC guideline; methylation probes with detection P value < 0.01 were 
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selected, and then probes having more than 5% of samples with a detection P value of >0.01 
were excluded; a sample was removed if the total proportion of probes with a detection P 
value <0.01 is less than 95%. DNA methylation values were then standardized using an intra-
array normalization method. Beta values from the output were used as a dependent variable 
in an individual EWAS. The details of DNA methylation measurements are described in 
Supplemental Material. 
Cohort-level epigenome-wide association analyses 
Individual CpG probes were tested for the association with the WMH burden in two 
linear mixed effect regression models i.e. a reduced- and a full-adjustment model according 
to the following formulae. In two models, the untransformed methylation beta value for CpG 
sites is the dependent variable and WMH burden is the independent variable of interest. In a 
reduced-adjustment model, age, sex, study site if applicable, total cranial volume (cm3), 
white blood cell proportion (%), technical covariates (i.e. plate, chip-position, row, and 
column) and race-specific genetic principal components of ancestry (PCs) were included as 
covariates. In a full-adjustment model, smoking status (pack-year), body mass index (BMI, 
kg/m2), systolic blood pressure and diastolic blood pressure (SBP and DBP, mmHg) were 
added as covariates. White blood cell proportion was estimated with the Houseman 
method.205 In both models, technical covariates were treated as random effects and the 
remaining covariates were treated as fixed effects. Family structure was also adjusted 
according to cohort-specific strategies. In ARIC, EWASs were performed separately by 
ancestry. Multi-ethnic studies with a small number of subjects in each ancestry, namely 
CARDIA and CHS, performed the EWAS in a pooled population. Additionally, subgroup 
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analyses in hypertensive and normotensive groups were conducted to investigate distinct 
etiology depending on the existence of the most important risk factor, hypertension. 
Hypertension was defined if either systolic or diastolic blood pressure is greater than 140 
mmHg or 90 mmHg, respectively, or if a subject was taking any anti-hypertensive 
medication at the time of MRI measurement. 
Epigenome-wide meta-analysis 
The meta-analysis combined EWAS results based on sample-size weighted z-score-
based fixed-effect method in METAL.206 This study primarily aims to identify novel DNA 
methylation loci for WMH burden rather than estimate accurate effect sizes of methylation 
probes. For this reason, a fixed-effect model-based meta-analysis was chosen to maximize 
statistical power in this study.207 EWASs were first combined altogether for a pooled 
analysis, then race-specific EWASs were meta-analyzed within each ancestry. Subgroup 
meta-analyses were also performed within either hypertensive or normotensive groups, in a 
pooled population and in each ancestry. An association was considered as significant if the P 
value is below 0.05 either of Q value (Benjamini-Hochberg false discovery rate208) or of 
Bonferroni threshold corrected for the number of methylation probes (approximately 1.0E-7). 
The less stringent threshold was also set as 1.0E-06 to detect putative associations. Probes on 
sex chromosomes and cross-reactive probes reported by Chen et al.209 were removed from 
the meta-analyses post hoc. 
Differentially methylated region analysis 
We performed a differentially methylated region (DMR) analysis to identify a group 
of DNA methylation sites that collaboratively influence WMH burden. Two specific 
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methods, Comb-P210 and DMRcate211 compute a region-based P value using summary 
statistics of individual DNA methylation sites accounting for their spatial correlations. 
Comb-P computes correlations at varying distance lags and uses them to compute correlated 
P values at each CpG site. DMRcate collapses contiguous significant CpGs that are within a 
certain number of nucleotides from each other. Multiple testing error was corrected with a 
one-step Sidak method.212 We considered a DMR as valid if it was identified by both Comb-
P and DMRCate. 
Biological functions associated with EWAS findings 
To explore population structures and inter-relationships in DNAm, Spearman 
correlations among 11 EWAS probes (“target probes”) were calculated in 906 EA and 639 
AA subjects in the ARIC study. DNAm may regulate functional DNA elements in specific 
tissues. The RegulomeDB213 annotates DNA features and regulatory elements such as 
transcription factor binding sites, position-weight matrix for transcription factors (TF) 
binding (PWM), DNase footprinting, DNase sensitivity, chromatin states, eQTLs, 
differentially methylated regions, manually curated regions and validated functional SNPs to 
genomic positions of interest. We scored genomic positions of target probes according to the 
RegulomeDB’s criteria ranging from 5 (minimal binding evidence) to 1 (likely to affect 
binding and linked to expression of a gene target). Probes at the locations with significant 
DNA features or regulatory functions (score 1 or 2) were discussed. Furthermore, we 
investigated tissue- and cell type-specific regulation by our target probes using the 
experimentally derived database, the Functional element Overlap analysis of ReGions from 
EWAS (eFORGE ver. 2.0).214,215 Probes were pruned to be at least 1 kb apart then tested for 
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overlap with DNase I hypersensitive sites against 1,000 annotation-matched background 
probe sets from the 850K array, ENCODE, and Roadmap Epigenomics data. Hypergeometric 
P values were generated from counts of overlaps between a TF and all target probes, and 
counts of overlaps between a TF and all probes.214,215 Multiple-testing corrected Q values 
were calculated using the Benjamini-Yekutieli method.216 TF binding sites were considered 
“significantly enriched” where Q value<0.05. 
 To explore the shared genetics between WMH burden and its comorbidities, genes 
mapped to significant DNAm probes and DMRs were searched within publicly available 
GWAS results of relevant traits i.e. blood-pressure, dementia, Alzheimer’s disease (AD), 
stroke and white matter abnormalities.217 The search terms for each trait are as below.  
Relevant trait Search term 
Blood Pressure (BP) BP, Systolic BP, Systolic BP change 
measurement, Diastolic BP, Diastolic BP 
change measurement, hypertension, mean 
arterial pressure, pulse pressure measurement 
Dementia dementia, vascular dementia, lewy-body 
dementia measurement and lewy-body dementia 
Stroke stroke, ischemic stroke, cardioembolic stroke, 
small vessel stroke and small artery occlusion in 
brain 
Alzheimer’s disease (AD) AD and late-onset AD 
 
In addition, genes mapped to significant probes and DMRs were tested for gene-
enrichment. We investigated tissue-specific expression patterns of the genes and biological 
pathways that the genes are enriched in via GENE2FUNC analysis using the Functional 
Mapping and Annotation of Genome-Wide Association Studies (FUMA)218 platform. Gene 
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enrichment was evaluated with a hypergeometric test against the gene sets obtained from two 
large databases, namely MsigDB219 and WikiPathways220.. 
Shared epigenetics with cognitive ability (CA)  
Cognitive decline is one comorbidity of CSVD, in particular of WMH.31,32,68,221 To 
investigate the shared epigenetics between WMH burden and CA, we compared our WMH 
burden EWAS with our recent EWAS of seven cognitive ability tests:222 animal naming 
(Semantic Verbal Fluency abbreviated as “Animal”), letter fluency (Phonemic Verbal 
Fluency abbreviated as “Verbal Fluency”), executive function (Trail Making Test Part B 
abbreviated as “Trails”), verbal declarative memory (Wechsler Logical Memory abbreviated 
as “Logical Memory”), processing speed (Wechsler Digit Symbol Test/Symbol digit 
Modalities Test/Letter Digit Substitution Test abbreviated as “Digit Symbol”), vocabulary 
(Boston Naming Test or National Adult Reading Test abbreviated as “Vocabulary”) and 
global cognitive function (Mini-Mental State Examination abbreviated as “MMSE”). Also, a 
DMR analysis was performed using summary statistics and regions identified in both WMH 
burden and CA. In the CA EWAS, the reduced- and full-adjustment models included similar 
sets of covariates as in our WMH EWAS; thus, comparisons were made in both models. 
Furthermore, we performed a multivariate association test to identify pleiotropic 
DNA methylation which influences both WMH burden and CA. DNA methylation probes 
associated with both traits were tested against the null hypothesis H0: βWMH = βCA = 0. The 
test uses Z-scores for each trait and estimates multivariate test statistics accounting for the 
trait correlation. This method is implemented in the ‘metaUSAT’ software.223 The trait 
correlation matrix R, 2 × 2 correlation matrix of two traits, is estimated using Z-scores of the 
38 
 
null SNPs which are not associated with any trait (PCA and PWMH > 1E-5). P values were 
Bonferroni-adjusted with the number of DNA methylation probes included in each analysis. 
 
Aim 2: Genetic control and transcriptional impact of WMH epigenetics 
To achieve interventions based on WMH burden epigenetics, it is crucial to 
understand the causal relationship with genetics and transcriptome. This aim is designed to 
investigate 1) genetic control behind the target probes and 2) the probes’ biological functions 
(represented by gene expression). A recent study showed that DNAm is heritable and 50% of 
CpG sites had evidence of a significant genetic component.224 To examine genetic control 
behind the WMH epigenetics, we estimated heritability of WMH-associated probes (“the 
target probes”), and performed a methylation quantitative locus (mQTL) analysis. Based on 
the mQTL associations, we also tested the causal direction between each target probe and 
WMH burden. Secondly, we investigated gene expressions associated with the target probes 
to imply biological functions in action. 
Heritability of WMH-associated DNAms  
  For the target probes, the narrow sense heritability (h2meth) was estimated in the FHS  
Offspring Cohort subjects (N= 2,377). The narrow sense heritability is defined as the 
proportion of the total phenotypic variance of a DNA methylation level explained by the 
additive polygenic variance: h2meth = σ2A/ σ2meth, where σ2A denotes the additive polygenic 
genetic variance and σ2meth denotes the total methylation variance at the probe. Age, sex, 
blood cell counts, principal components and technical covariates were included for 
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adjustment in the reduced model. BMI and smoking status were additionally corrected in the 
full model.  
Identification of methylation quantitative loci (mQTLs) 
DNAm levels at the target probes may be influenced by nearby (cis-effect) or distant 
(trans-effect) DNA sequence. Methylation QTL analysis was performed for the target probes 
in EA (n=984) and AA (n=2,225) individuals from ARIC. Our target CpGs are from WMH 
EWAS (Aim 1). Inverse-normal transformed methylation beta values were regressed for age, 
sex, and significant population structure factors (up to the first 10 genetic principal 
components (PCs) and the first 10 methylation PCs in each ancestry). A genome-wide 
association study was then performed on 1000 Genomes Phase I imputed SNPs 
(GRCh37/hg19). SNPs with low imputation quality (r2<0.3) and with low minor allele 
frequency (MAF<0.05) were excluded from analyses. Association from mQTL analysis was 
regarded as genome-wide significant if the P value is below 5E-8. Since cis-effects tend to be 
significantly larger than trans-effects225, our primary mQTL for later analyses was limited to 
cis-effect mQTLs. The cis-significance was set to 0.05 divided by the number of mQTLs in 
the region (CpG±1Mb). We validated significant mQTL associations with mQTL 
associations in the FHS mQTL study of 4,170 EA subjects226. 
Bi-directional Mendelian Randomization (MR) analysis 
To determine if the DNAm level is a causal factor for WMH burden (Forward MR) or a 
secondary outcome of WMH burden (Backward MR), we performed a bidirectional two-
sample MR analysis.227 Two sample MR analysis requires summary statistics including the 
effect size (β) and its standard error for exposure and outcome traits from independent 
40 
 
samples. For DNAm associations, we used our mQTL analysis result, and for WMH 
associations, a previous GWAS in UK biobank (UKBB) participants (n=11,226) was used.125 
Summary statistics were downloaded from the GWAS catalog website (Accession ID: 
GCST007305) accessed on 01/09/2019. Forward MR analysis tested if any of the target 
probes influences WMH. Instrumental variables (IVs) for forward MR analysis are cis-effect 
mQTLs identified in ARIC EA participants. To meet the fundamental assumption of 
independence in MR analysis, IVs were pruned at r2<0.2. For target probes having at least 
three IVs, we performed a multi-instrument MR analysis. The backward MR analysis was 
used to test if target probes are influenced by WMH. Twenty three sentinel SNPs were 
reported by previous GWASs (including the recent meta-analysis under review) and an 
exome-wide association study.125,152,154 The SNP rs12120143 was excluded from analysis 
due to low frequency in the UKBB GWAS (minor allele frequency (MAF) =0.02). Sentinel 
SNPs that did not exist in the UKBB GWAS were replaced with a SNP in high linkage 
disequilibrium (LD) in the HapMap European population - rs7894407 replaced with 
rs2176448 (r2=0.94), rs17576323 with rs13417165, rs17148926 with rs11957829 and 
rss3215395 with rs3891038 (r2=1.0). 
For each target probe in both MR directions, causation was tested based on the inverse-
variance weighted (IVW) effects across all IV-DNAm and IV-WMH estimates in the R 
package TwoSampleMR.228 Causation with P value <0.05 was considered significant. To 
validate the MR result, built-in tests for pleiotropy, heterogeneity and directionality were also 
performed. For existence of pleiotropy (MR egger intercept test P value <0.05), Egger 
regression estimates was assessed instead of the IVW method.  
41 
 
Gene expression associated with WMH epigenetics 
Gene expression associated with target probes was investigated to functionally 
annotate target probes. First, we tested associations between a DNAm level at each probe and 
an expression level at the nearest gene in 1,966 EA subjects from FHS. The DNAm β score 
at each target probe was regressed on the expression level adjusting for age, sex, population 
and family structure, blood cell counts and technical covariates. Technical covariates and 
family structure were modeled as random effects. Secondly, to explore the genome-wide 
effects of target probes, transcriptome-wide association studies (TWASs) were performed in 
the FHS (n=1,966) and RS (n=728) subjects. In this analysis, we included the expression 
level as a dependent variable and the DNAm level as an independent variable with the same 
set of covariates. In RS, mRNA expression levels were dependent variables. Estimates from 
two studies were combined for each gene using the sample-sized based meta-analysis method 
in METAL. We corrected the associations for multiple-testing burden based on the 
Bonferroni method. As a secondary threshold, Q value using the FDR method was 
calculated, and associations with Q <0.05 were considered significant. 
 
Aim 3: Integrative genetic analyses of WMH burden 
In the last aim, we used multi-dimensional data to get holistic evidence to support 
WMH burden etiology. Firstly, we performed gene-based pathway analyses on WMH 
association studies at genome-wide, epigenome-wide and transcriptome-wide levels and 
merged them to identify the common biological function shared by multiple layers. Second, 
we tested co-localization of quantitative trait loci (QTLs) associated with multi-dimensional 
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traits (i.e. DNAm, gene expression and WMH burden) at the WMH loci to show how the 
genetics influences WMH burden involving different molecular levels. Lastly, causation 
from DNAm to WMH mediated by gene expression was tested using two-step MR analysis.  
Two-step Mendelian randomization  
 To confirm if the functionally annotated gene expression mediates the relationship 
between the target probe and WMH burden, a two-step Mendelian randomization (2SMR) 
analysis was performed.229 In the first step, we tested the directional relationship from “the 
exposure” target probes to “the mediator” gene expression. The ARIC mQTL associations 
for target probes were selected as IVs after pruning to be independent (r2<0.2). For the IVs, 
we confirmed associations with gene expression in the FHS whole blood eQTL data 
(n=5,257) and in the GTEx ver.7 brain eQTL data. For brain tissues, cortex, frontal cortex, 
anterior cingulate cortex, and caudate basal ganglia were selected. The second step was to 
establish the causation from the implicated genes to “the outcome” WMH. For the genes 
confirmed significant in the first step, eQTLs were taken as IVs and pruned to be 
independent (r2<0.2). Then we evaluated associations with WMH in the UKBB GWAS.125 
Gene expression validated in both steps with P value < 0.05 was considered as a mediator in 
the directional relationship of the target DNAm and WMH burden.  
Identification of biological pathways with multi-dimensional data 
 Based on hierarchical gene-based permutation, we performed marker set enrichment 
analyses (MSEAs) on genetic, epigenetic and transcriptional associations of WMH in the R 
package Mergeomics.230,231 For the genetic association, we meta-analyzed two WMH 
GWASs (CHARGE152 and UK Biobank125) based on the sample-size weighted z-score based 
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fixed-effect. Marker were then pruned to be independent (r2<0.5) based on HapMap3 LD 
information. For epigenetic and transcriptional associations, we used our EWAS result and a 
recent TWAS of WMH, 232 respectively. Markers were primarily mapped to the nearest 
genes. For epigenetic markers, cis-acting genes reported in the MesaEpiGenomics study233 
were additionally annotated. We tested marker-level enrichment with permutation size 
20,000 based on biological pathways from pre-defined public databases: KEGG, 
REACTOME, Biocarta and the Gene Ontology (GO) knowledgebase.234,235 Then, enriched 
results from individual studies were meta-analyzed using the Meta MSEA function in the 
package. Pathways with a permutation-based P value smaller than 0.05 were considered 
significant. 
Co-localization of multi-dimensional QTLs 
The P value based Bayesian co-localization test was conducted using QTLs 
associated with multi-dimensions – genotype associated with WMH (QTL), with DNAm 
(mQTL) and with gene expression (eQTL) - at the WMH loci using the R package 
“coloc”.236 In this analysis, “the WMH locus” indicates the cytoband where a previously 
reported sentinel variant is located. We have selected QTLs ± 500 kb of 23 sentinel SNPs 
from WMH GWASs including the recent meta-analysis, 11 sentinel DNAm probes from our 
EWAS and 13 genes from WMH TWAS.125,152,153,232 For QTL, we used the UKBB GWAS 
associations (n=11,226). For mQTL and eQTL, we identified associations at the target loci 
from publicly available data. In FHS, mQTLs and eQTLs were identified using whole blood 
samples from 4,170 and 5,257 EA subjects.226,237 To explore co-localization in brain tissues, 
we also used the GTEx Consortium data (version 7) in four brain tissues – cortex (n=175), 
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frontal cortex (n=143), caudate basal ganglia (n=174) and anterior cingulate cortex 
(n=129).238 Due to limited number of subjects in the GTEx brain eQTL data, we took the 
FHS whole blood as a primary endpoint.239 The GTEx version 7 data was obtained from the 
GTEx Portal on 12/19/19. Out of 13 TWAS loci, the ARL17A locus did not have mQTL 
associations, therefore it was excluded from the analysis. We evaluated the posterior 
probability of full co-localization (PPFC), that multiple traits (WMH, gene expression and 
DNAm) share a causal variant at each locus, given the data, using the R moloc package. Co-
localization was tested for a unique combination of DNAm probe and a gene with at least 5 
QTLs in common. We considered the WMH locus with a PPFC greater than 80% as a 
convincingly co-localized locus.  
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RESULTS 
Aim 1: Meta-analysis of epigenome-wide association studies (EWASs) of WMH 
burden 
Study sample characteristics 
The number of subjects in each participating study ranged from 194 to 1,545. Mean 
age ranged from 49.7 to 74.6 years, and proportion of female participants ranged from 40.5 
to 72.8%. Mean BMI was similar among studies ranging from 26.4 to 31.0 kg/m2. Smoking 
prevalence was the highest in the ADNI study (40.8%), but similarly low among other 
studies (from 5.6% to 20.7%). Prevalence of hypertension ranged from 21.6 to 85.4 %. Two 
(ARIC and GENOA) studies included subjects of African ancestry (AA) and seven other 
cohorts and ARIC included subjects of European ancestry (EA). CARDIA and CHS 
included subjects of multiple ancestries, but they contributed only to the trans-ethnic 
analyses due to small sample sizes. Median WMH burden (log transformed WMH grade or 
volume) ranged from 0.18 to 2.1 (Q1: 0.10 to 1.81; Q3: 0.41 to 2.56). Numbers of markers 
and subjects, and demographic descriptions in participating studies are presented in Table 
S1. 
Epigenome-wide association study (EWAS) model diagnostics 
The genomic inflation statistics (λs) were heterogeneous in studies ranging from 
0.71 to 1.33. Individual studies corrected the statistics according to their protocols where 
significant inflation exists. The lambdas in the trans-ethnic meta-analyses were 1.03 and 
1.01 for the reduced and full-adjustment model, respectively (Table 2 and Figure S2). In 
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all meta-analyses including race-specific and blood-pressure subgroup analyses, we did not 
observe significant inflation evidence, with the lambdas from 0.93 to 1.02. 
Table 2 Genomic inflation in meta-analyses 
 Pooled Hypertensive Normotensive 
Model All EA AA All EA AA All EA AA 
Reduced 1.03 1.00 0.97 1.02 0.99 0.97 1.01 1.01 0.95 
Full 1.01 0.99 0.99 1.01 0.97 0.98 0.99 0.99 0.93 
 
Meta-analysis of EWASs  
We included 6,019 (EA: 4,452 and AA: 995) and 5,589 (EA: 4,023, AA: 994) 
subjects in reduced- and full-adjustment models, respectively. There was no genome-wide 
significant methylation probe either at Bonferroni corrected P value threshold (P value 
<1.12 X 10-7) or a Benjamini-Hochberg false discovery rate (Q <0.05). However, with 
suggestive significance (P value <1.0 X 10-6), three probes, cg24202936 mapped to septin 7 
pseudogene (LOC441601; P value=3.78x10-7), cg06809326 mapped to coiled-coil domain 
containing 144 A N-terminal pseudogene (CCDC144NL; P value=6.14x10-7) and 
cg03116124 mapped to tripartite motif containing 67 gene (TRIM67;P value=9.32x10-7) 
were identified in a reduced model. Adjusting for BMI and smoking, we identified 
cg17577122 mapped to claudin 5 gene (CLDN5; P value=2.39x10-7) in addition to 
cg24202936 (P value=5.20x10-7) and cg03116124 (P value=6.55x10-7). In a race-specific 
analysis, a suggestive association at cg04245766 mapped to bone morphogenetic protein 4 
gene (BMP4; P value=3.78E-7) was identified from the full-adjustment analysis in EA 
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subjects. Top associations from trans-ethnic analyses are shown in Table 3 and Manhattan 
plots of epigenome-wide associations are presented in Figure S1.  
Table 3 Top associations from a meta-analysis 
Probe Gene 
Regulatory 
feature 
Chr Position Z score P value Q value Weight 
Reduced 
 cg24202936 LOC441601 Body 11 50257256 5.08 3.78E-7 0.122 5,663 
 cg06809326 CCDC144NL TSS200 17 20799526 4.99 6.14E-7 0.122 5,663 
 cg03116124 TRIM67  1 231293208 -4.91 9.32E-7 0.122 5,433 
Full 
 cg17577122 CLDN5 1st Exon; Body 22 19511967 5.12 2.39E-7 0.106 5,234 
 cg24202936 LOC441601 Body 11 50257256 5.02 5.20E-7 0.106 5,234 
 cg03116124 TRIM67  1 231293208 -4.97 6.55E-7 0.106 5,004 
 
Stratified meta-analyses by hypertensive status 
At the genome-wide significance level, no probe was further identified in the 
stratified analysis (Table 4). However, different sets of putative associations were 
identified in hypertensive and normotensive groups. In hypertensive subjects, cg25317585 
mapped to FGF14 (fibroblast growth factor 14) showed robust significance in both 
reduced- and a full-adjustment models (P value= 2.05E-7 and 2.76E-7). In normotensive 
subjects, two probes, namely cg06450373 mapped to CDH18 (cadherin 18) (P 
value=3.36E-7) and cg18950108 mapped to DPCR1 (diffuse panbronchiolitis critical region 
protein 1) (P value=4.22E-7) were identified as suggestive associations from the reduced 
model. We also performed race-specific stratified analyses. In hypertensive AA subjects, a 
putative association at cg02741985 mapped to coiled-coil domain containing 57 gene 
(CCDC57) was identified (P value=3.93E-7) from the reduced-model. More suggestive 
associations were found in normotensive EA subjects; cg07675682 at the SLC26A11 (solute 
48 
 
carrier family 26 member 11) locus (P value =6.30E-7) and cg10051414 at the MAFF 
(MAF bZIP transcription factor F) locus (P value =9.37E-7) in the full model. So far, from 
the pooled and stratified analyses, we identified 11 probes in the association with WMH 
burden. To evaluate whether the effects of those 11 probes differ by hypertensive status, we 
showed the association statistics in hypertensive and normotensive groups (Table S2).  
Table 4 Top associations from a stratified meta-analysis  
Probe Gene Regulatory 
feature 
Chr Position Z score P value Q value Weight 
Hypertensive subgroup 
 Reduced  
  cg25317585 FGF14 Body;1st exon 13 102568886 5.19 2.05E-07 0.098 3,006 
  cg19059707   12 64080622 -4.47 7.66E-06 0.594 1,377 
  cg16790423 HSPA1L 5'UTR 6 31781328 -4.45 8.61E-06 0.594 1,377 
 Full 
  cg25317585 FGF14 Body;1st exon 13 102568886 5.14 2.76E-07 0.121 2,858 
  cg27501293 SFTPD 3'UTR 10 81697500 -4.86 1.16E-06 0.187 2,858 
  cg08106319 ZFAND3 Body 6 37849427 -4.61 4.05E-06 0.470 2421 
Normotensive subgroup 
 Reduced 
  cg06450373 CDH18 Body 5 19766434 -5.10 3.36E-07 0.101 2,437 
  cg18950108 DPCR1; 
MUCL3 
Body 6 30920171 -5.06 4.22E-07 0.101 2,599 
  cg20443254 ASCL4 1st Exon 12 108169020 4.37 1.23E-05 0.797 2,599 
 Full 
  cg25313122   7 6121416 4.81 1.53E-06 0.371 1,926 
  cg12176783 TCEA2 TSS200;5'UTR 20 62694000 -4.69 2.74E-06 0.384 2,321 
  cg06450373 CDH18 Body 5 19766434 -4.62 3.78E-06 0.384 2,186 
 
Differentially methylated regions (DMRs) 
 Fourteen DMRs were identified from the reduced model (Šidák P value <0.05) and 
regions near PRMT1, CCDC144NL-AS1, IFITM10, VARS2, SLC12A4, SLC45A4, KITLG 
and ZNF311 loci were overlapped with intron or exon of genes (Table 5). Five regions near 
PRMT1, ZNF311, SLC45A4, LCP1 and KAT6B were also identified from the full-
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adjustment model as well as six additional regions; DMRs at the PRMT1, ZNF311, 
HIVEP3, SLC45A4 and TCEA2 loci were within intron or exon of genes. In a DMR 
analysis of EA population, 13 and 15 DMRs were identified from the reduced- and the full-
adjustment models, respectively (Table S3). Among DMRs identified from the pooled 
analysis, the PRMT1, CCDC144NL-AS1 and LCP1 loci in the reduced model and the 
PRMT1, ALLC, ZNF311 and LCP1 loci in the full model were replicated in the EA 
population. DMRs at the PRMT1, KDM2B, ATP13A4; ATP13A4-AS1, SPIRE2, 
SH3PXD2A, LCP1, RHPN1 and LOC101930114 loci were identified regardless of 
adjustment models in EA. In the AA population, 15 and 17 DMRs were identified in the 
reduced- and the full-adjustment model, respectively, and none of pooled analysis results 
were replicated. Nine loci (MIR596, LOC100294145, LAMB2, C3orf56, FAM120B, 
WASH3P, EDARADD, EBF3, and TM9SF2) overlapped in both models. None of the DMRs 
overlapped between two races. 
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Table 5 DMR analysis result 
DMR analysis in hypertensive subgroup 
In the hypertensive subgroup, five DMRs were identified from the reduced model 
and seven from the full model, and OSR2 and ATP13A4; ATP13A4-AS1 loci were identified 
Chr start end #probe PComb-P PDMRCate Gene Distance from 
Gene 
Reduced-adjustment Model 
19 50191341 50191882 6/8 7.97E-12 3.25E-11 PRMT1 0 
17 20799407 20799769 10/13 1.63E-11 5.57E-14 CCDC144NL
-AS1 
0 
11 1769288 1769645 8/10 5.92E-07 2.12E-06 IFITM10 0 
6 30882707 30883203 6/13 4.31E-05 1.11E-06 VARS2 0 
6 28973317 28973497 9/17 1.86E-04 9.61E-06 ZNF311 0 
11 130185383 130185670 3/3 1.23E-03 7.96E-04 ZBTB44 -776 
7 157092681 157092982 2/2 1.35E-03 2.64E-03 UBE3C 30,615 
8 142233381 142233705 5/5 1.35E-03 3.50E-03 SLC45A4 0 
12 88974242 88974665 8/11 3.88E-03 1.13E-02 KITLG 0 
13 46757317 46757415 3/3 4.52E-03 5.25E-03 LCP1 -858 
16 67997857 67998164 4/5 8.70E-03 2.03E-02 SLC12A4 0 
10 76573395 76573506 2/4 1.31E-02 4.87E-04 KAT6B -12,664 
22 50984367 50984597 3/3 2.37E-02 2.74E-02 KLHDC7B -1,864 
2 233284401 233284661 2/3 2.81E-02 5.05E-03 ALPPL2 8,977 
Full-adjustment Model 
19 50191341 50191683 5/8 1.54E-07 4.58E-07 PRMT1 0 
6 28973317 28973497 9/17 1.52E-04 2.59E-05 ZNF311 0 
1 42384389 42384564 3/10 2.79E-04 1.56E-05 HIVEP3 0 
8 142233426 142233642 3/7 5.72E-04 5.96E-06 SLC45A4 0 
10 76573395 76573506 2/5 1.87E-03 8.35E-05 KAT6B -12,664 
2 3704500 3704793 6/7 3.07E-03 1.55E-02 ALLC -992 
13 46757317 46757415 3/3 4.39E-03 4.97E-03 LCP1 -858 
20 62693942 62694005 6/9 8.72E-03 6.92E-03 TCEA2 0 
3 145879429 145879710 6/2 1.78E-02 4.44E-02 PLOD2 -147 
11 89956572 89956777 6/8 4.82E-02 1.42E-02 CHORDC1 -40 
6 31148369 31148666 14/16 4.57E-02 8.50E-03 PSORS1C3 -2,693 
PComb-P: combined p value after Sidak multiple testing adjustment, PDMRCate: minimum 
adjusted p-value from the CpGs constituting the significant region 
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in both (Table S4). In the EA specific analysis, nine and twelve associations were identified 
from the reduced and full models (Table S5). Irrespective of adjustment models, DMRs at 
the PON3, RGMA and ATP13A4; ATP13A4-AS1 loci were identified. Among DMRs 
identified in the pooled hypertensive population, DMRs at the ATP13A4/ATP13A4-AS1 and 
MIR4291 were replicated in the EA analyses. In the AA specific analysis, ten and eleven 
DMRs were identified from the reduced and full models (Table S5). Among them, DMRs 
at LDLRAD4, RABL6, SLC36A3, FAM222A, RASIP1 and MUC4 were found regardless of 
models. One of ten DMRs at the CCDC57 locus involved the cg02741985 probe, which 
was a suggestive signal from our meta-analysis in the AA hypertensive subgroup. The 
LDLRAD4 locus was one of the loci found in the hypertensive pooled analysis. None of the 
DMRs overlapped between two races.  
DMR analysis in normotensive subgroup 
In the pooled population, 13 and 16 DMRs were identified to be associated with 
WMH in the reduced- and the full-adjustment model, respectively (Table S6). Five regions 
at the CHORDC1, FBXO47, LINC01983, NFAM1 and TCEA2 loci were found in both 
models. Five (at the DRC7, FBXO47, KDM2B, NRBP1; KRTCAP3 and TCEA2 loci) and 
six (at the DRC7, FBXO47, LINC00702, NFAM1, TCEA2 and THBS1 loci) were replicated 
in the respective models in the EA population. In the EA population, 10 and 12 DMRs were 
found to be associated with WMH in two models, and five loci of CD248, DRC7, FBXO47, 
KHDC3L and TCEA2 were identified regardless of adjustment models (Table S7). Among 
the ten DMRs identified in the reduced model, a region at the CCDC144NL locus involved 
the cg06809326 probe which was identified in a meta-analysis of the pooled population. In 
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the AA population, a different set of DMRs were identified from both models (Table S7). 
DMRs at the DNHD1, F10, LAMB2, LOC151174; LOC643387, PAPD7, and VTRNA2-1 
loci showed significance irrespective of models. Only one DMR at the LINC01983 locus 
from the pooled analysis was replicated in AA. 
Functional genomics of target probes 
 Significant correlations (r>0.3 with p-value<0.05) among cg03116124, cg06450373, 
and cg18951018 were observed in both ancestries. Correlations among 11 EWAS probes 
(“target probes”) are presented in Figure S3. Genomic positions of 11 EWAS probes 
(“target probes”) were searched in the RegulomeDB. We identified that cg17577122, 
cg06809326 and cg10051414 are situated in the genomic position likely to affect protein 
bindings. In umbilical vein endothelial cells, RNA Polymerase II Subunit A (POLR2A) was 
found to be likely bound to the genomic positions of three probes: cg17577122 
(chr22:19511967), cg04245766 (chr14:54421051) and cg10051414 (chr22:38598733). 
Interestingly, the positions of cg06809326 (chr17:20799526), cg10051414 
(chr22:38598733) and cg25317585 (chr13:102568886) were likely to be bound by the 
CCCTC-binding transcriptional regulator protein (CTCF) in the brain microvascular 
endothelial cells. Proteins binding to target probes in brain tissues and endothelial cells are 
shown in Table S8. The eFORGE tested enrichment of transcription factor (TF) binding 
sites for 11 target probes based on common TF databases. DNase I hypersensitivity signals 
surrounding target probes are shown in Figure S4. We observed significant overlap with 
transcription factor binding sites at 5 target CpGs: cg06450373, cg06809326, cg17577122, 
cg24202936, and cg25317585 (Table S9).  
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Genetic sharing with blood pressure, stroke, dementia and white matter-related traits 
From the GWAS catalog, we identified 1,990 BP genes, 59 white matter trait genes, 
317 stroke genes, 67 dementia genes and 913 Alzheimer’s disease genes as of 03/06/2019. 
Among 11 genes identified with suggestive evidence from our EWAS, CDH18 was 
reported in the association with blood-pressure. From 159 genes annotated to significant 
DMRs, we found 15 BP-related genes (CETP, NRBP1, PRDM8, TM9SF2, WBP1L, 
UBE3C, TNXB, TCEA2, MCF2L, HIVEP3, PLEC, IRF6, GRAMD1B, RPTOR and 
LOC102546294), four stroke-related genes (SLC44A2, CETP, NRBP1 and SH3PXD2A) and 
one Alzheimer’s disease gene (IRF6).  
Genetic function enrichment in FUMA 
 We input four genes, CLDN5, CCDC144NL, TRIM67 and BMP4, mapped to WMH-
associated methylation probes for the GENE2FUNC program implemented in the FUMA 
platform. Three genes, BMP4, CLDN5 and TRIM67, were enriched in the regulation of cell 
development, especially the first two genes were enriched in the regulation of endothelial 
cell differentiation (Table 6). We also performed a DMR analysis in CA using summary 
statistics. Based on genes mapped to all DMRs we identified, we found enriched pathways 
related to lipoprotein metabolism and transport. Genes mapped to the probes found in the 
pooled and race-specific analyses, were significantly enriched with previous GWAS 
findings in HIV-1 control and squamous cell lung carcinoma. 
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Table 6 FUMA gene-enrichment results 
Gene Set Size P value PFDR genes 
Single 
Positive regulation of 
endothelial cell differentiation 24 2.68E-6 0.020 BMP4, CLDN5 
Regulation of endothelial cell 
differentiation 42 8.35E-6 0.031 BMP4, CLDN5 
Positive regulation of cell 
development 538 1.41E-5 0.035 TRIM67, BMP4, CLDN5 
Positive regulation of 
epithelial cell differentiation 65 2.02E-5 0.037 BMP4, CLDN5 
Outflow tract morphogenesis 77 2.84E-5 0.042 BMP4, CLDN5 
DMR – all genes 
High density lipoprotein 
particle remodeling 15 1.80E-5 0.040 APOC3, SCARB1, CETP 
Regulation of plasma 
lipoprotein particle levels 45 1.85E-5 0.040 APOC3, SCARB1, CETP 
Reverse cholesterol transport 17 2.68E-5 0.040 
APOC3, SCARB1, LMF1, 
RP11-161M6.2, CETP 
DMR – excluding stratified analyses 
HIV-1 control 22 4.35E-6 0.008 RNF39, VARS2, PSORS1C3 
Squamous cell lung carcinoma 132 4.15E-5 0.038 HIVEP3, PLOD2, ZNF311, 
VARS2 
 
Shared epigenetics with cognitive ability 
 In seven CA tests, 61 methylation probes were reported with putative associations 
(P value <10E-5).222 For 51 probes also included in our WMH EWAS, we confirmed the 
epigenetic associations in both CA and WMH EWASs at the Bonferroni significance 
threshold of 9.8E-4 (0.05/51). We identified three methylation probes significantly shared 
with both CA and WMH burden. In the reduced model, cg17417856 mapped to PRMT1 
(PWMH=2.40E-06 and PCA=1.82E-4 in Digital Symbol). In the full model, cg18676110 
mapped to RAF1 (PWMH=1.12E-06 and PCA=3.67E-4 in Vocabulary). In both models, 
cg05704155 mapped to PGD was identified for the MMSE test (PWMH=1.07E-06 and 
PCA=8.65E-4 in the reduced model; PWMH=1.07E-06 and PCA=4.11E-4 in the full model). A 
55 
 
multivariate joint analysis of two EWASs identified significant probes shared by both 
WMH burden and CA: 115 probes for Digit Symbol, 10 for MMSE, 12 for Verbal Fluency 
and 1 for Vocabulary. Weak associations in one trait were strengthened by the other trait 
based on the trait correlation (Table S10). In Table 7, we showed the significant shared 
epigenetic association which were significant for individual traits (PWMH and PCA < 1E-3). 
Two methylation probes, cg17417856 (PRMT1) and cg05704155 (PGD), that we identified 
in the comparisons were confirmed with the same CA domains. Especially, PGD was 
consistently identified regardless of statistical models. PGD encodes a 6-phosphogluconate 
dehydrogenase enzyme which has previously been reported to be involved in 
hyperglycemia-induced oxidative stress in the neonatal diabetic brain.240 
Table 7 Multivariate joint analysis of CA and WMH epigenetic associations 
Test CpG Gene ZWMH, PWMH ZCA, PCA Pjoint Qjoint 
Reduced model 
Verbal 
Fluency 
cg12582616 JARID2 -3.54, 3.96E-04 -4.15, 3.38E-05 4.66E-08 9.83E-03 
cg12025310 TMPRSS6 3.43, 6.00E-04 -4.05, 5.16E-05 1.36E-06 4.77E-02 
MMSE cg05951221  -3.61, 3.12E-04 4.84, 1.29E-06 1.45E-08 6.10E-03 
cg25923609  3.59, 3.32E-04 -4.46, 8.17E-06 8.71E-08 7.35E-03 
cg05704155 PGD 4.55, 5.26E-06 -3.33, 8.65E-04 1.39E-07 9.75E-03 
cg01127300  -3.97, 7.21E-05 3.74, 1.86E-04 3.93E-07 2.37E-02 
cg19859270 GPR15 -3.87, 1.09E-04 3.60, 3.18E-04 9.48E-07 4.44E-02 
Digit 
Symbol 
cg05951221  -3.61, 3.12E-04 5.75, 9,12E-09 4.55E-10 4.79E-05 
cg17417856 PRMT1; C19orf76 -4.72 ,2.40E-06 3.74 ,1.82E-04 3.77E-08 1.22E-03 
cg19859270 GPR15 -3.87 ,1.09E-04 4.26 ,2.00E-05 1.54E-07 3.41E-03 
cg04885881  -3.34 ,8.48E-04 4.25 ,2.17E-05 9.43E-07 9.02E-03 
cg01127300  -3.97 ,7.21E-05 3.42 ,6.33E-04 2.09E-06 1.40E-02 
cg04994217 C9orf170 -3.32 ,9.12E-04 3.64 ,2.69E-04 9.07E-06 3.38E-02 
Full model 
MMSE cg05704155 PGD 4.88, 1.07E-06 -3.53, 4.11E-04 1.42E-08 6.00E-03 
Test: A cognitive ability test domain, PWMH: P value estimated in the reduced-adjusted trans-
ethnic WMH burden EWAS, PCA: P value estimated in the reduced-adjusted trans-ethnic 
cognitive abilities EWAS, Pjoint and Qjoint : P value and local FDR-adjusted P value estimated in 
the joint analysis  
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In a reduced-adjusted DMR analysis for CA, we identified 130 DMRs associated 
with 7 CA tests: 9 for Animal naming, 35 for Digit Symbol, 14 for Logical Memory, 15 for 
MMSE, 15 for Trails, 26 for Verbal Fluency, and 16 for Vocabulary. In a fully-adjusted 
DMR analysis for CA, we identified 98 DMRs associated with 7 CA tests: 10 for Animal 
naming, 21 for Digit Symbol, 12 for Logical Memory, 15 for MMSE, 15 for Trails, 15 for 
Verbal Fluency, and 10 for Vocabulary. We identified a DMR within ALPP2 (2q37.1) 
shared by Digit Symbol test and WMH burden with reduced-adjustment (Sidak 
PWMH=0.028 and Sidak PCA=9.10E-11). In EA subjects, a DMR near SH3PXD2A was 
identified in both adjustment models (Sidak PWMH=0.028 and Sidak PCA=3.82E-4 in the 
reduced model; Sidak PWMH=0.028 and Sidak PCA=7.55E-4 in the full model).  
Aim 2: Genetic control and transcriptional impact of WMH epigenetics 
Heritability of the target probes 
 For 11 methylation probes which we identified from trans-ethnic, race-specific and 
stratified meta-analyses, heritability was estimated in two linear models. We found that a 
big proportion (48.2%) of DNAm variance at cg06450373 was explained by the additive 
genetic variance (Table 8). Moderate heritability was estimated for cg02741985 (36.3%) 
and cg06809326 (26.5%). Small, but significant heritability estimates were calculated for 
cg24202936 (15.5%), cg25317585 (12.0%) and cg17577122 (14.3%). For cg03116124, 
cg07675682, cg10051414 and cg18950108, we could not identify meaningful heritability 
estimates. Estimates additionally adjusted for BMI and smoking were not significantly 
different from the reduced model estimates.  
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Table 8 Heritability estimates of WMH-associated methylation probes 
 Reduced model Full model 
Probe ID h2 S.E. P value h2 S.E. P value 
cg02741985 0.363 0.071 2.95E-08* 0.367 0.071 2.06E-08* 
cg03116124  0.009 0.069 4.46E-01 0.006 0.069 4.67E-01 
cg06450373 0.482 0.075 1.92E-11* 0.480 0.075 2.35E-11* 
cg06809326 0.265 0.075 1.03E-04* 0.266 0.075 9.51E-05* 
cg07675682  0.000 - 5.00E-01 0.000 - 5.00E-01 
cg10051414  0.009 0.073 4.51E-01 0.007 0.073 4.64E-01 
cg18950108 0.000 - 5.00E-01 0.000 - 5.00E-01 
cg24202936  0.155 0.073 1.34E-02* 0.158 0.073 1.17E-02* 
cg25317585 0.120 0.072 4.31E-02* 0.116 0.072 5.07E-02 
cg17577122 0.143 0.078 2.80E-02* 0.150 0.078 2.27E-02* 
h2: the narrow-sense heritability in an additive genetic model. S.E.: standard error 
 
Methylation QTLs for target probes 
 To show genome-wide patterns of genetic control, we performed GWASs of 11 
target probes in ARIC study (984 EA and 2,225 AA subjects). Cg04245766 was only 
included in the analysis of AA subjects since the probe did not pass the QC criteria in the 
EA population. The genome-wide pattern of genetic control in target probes are shown in 
Manhattan plots (Figure S5). As shown in the plots, we observed the genetic influence in 
cis on cg02741985, cg06450373, cg06809326, cg07675682 and cg24202936 regardless of 
ancestry. Cg02741985 showed more amplified cis-genetic influence in AA subjects and 
cg03116124 appeared to have cis-influence only in AA subjects. Cis-mQTLs were defined 
in EA subjects for a Mendelian randomization analysis. In EA, numbers of markers within 
cis-regions of target probes were 5,902 for cg02741985, 5,207 for cg03116124, 5,118 for 
cg06450373, 3,070 for cg06809326, 6,538 for cg07675682, 4,346 for cg10051414, 4,475 
for cg17577122, 15,062 for cg18950108, 5,903 for cg24202936 and 5,317 for cg2531758. 
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The mQTL associations significant at Bonferroni threshold (0.05/number of markers in cis-
region) were identified for four target probes: 57 mQTLs for cg02741985, 74 for 
cg06450373, 162 for cg06809326 and 2,981 for cg24202936. We validated the same four 
probes with mQTLs in the FHS mQTL study,226 the same four target probes were also 
identified with significant mQTLs.  
Causal relationship from target probes to WMH burden 
 The forward MR analysis was performed for four target probes having mQTLs. We found a 
significant causal relationship from cg06809326 to WMH burden using three independent genetic 
proxies. The odds ratio (OR) was estimated as 1.78, indicating that a 1% increase in methylation 
level at cg06809326 is associated with a 78% increment in WMH burden unit. Three IVs for 
cg06809326 were rs116963987, rs73298018 and rs7501645. In the backward MR analysis, we 
confirmed that WMH burden does not significantly influence the methylation level at cg06809326. 
In addition, a more causal relationship that a standard deviation increase in WMH burden leads to 
14 % higher methylation level was observed at cg03116124 (P value=0.03). Pleiotropy tests for MR 
associations in both directions showed non-significant P values except for two backward MR 
analyses in cg03116124 and cg06450373. For the analyses with pleiotropy evidence, we took MR 
Egger-based estimates as the primary result instead of inverse variance-weighted estimates. Results 
from all MR analyses are presented in Table 9. 
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Table 9 Bi-directional MR analysis result 
Probe ID No.IV Beta (S.E.) OR[95%CI] PMR Ppleiotropy 
Forward 
cg02741985 2 -1.56E-2(0.428) 0.98[0.43,2.28] 0.97 NA 
cg06450373 2 3.89E-2(0.280) 1.04[0.60,1.81] 0.89 NA 
cg06809326 3 0.5751(0.178) 1.78[1.25,2.52] 1.21E-3* -0.80 
cg24202936  3 0.193(0.214) 1.21[0.80,1.85] 0.37 0.56 
Backward 
cg02741985 18 3.50E-3(1.65E-2) 1.00[0.97,1.04] 0.83 -0.57 
cg03116124 18 0.134(5.65E-2) 1.14[1.02,1.28] 3.07E-2* -1.80E-2* 
cg06450373 18 0.100(5.45E-2) 1.11[0.99,1.23] 0.08 -4.88E-2* 
cg06809326 18 -2.39E-3(2.36E-2) 1.00[0.95,1.04] 0.92 -0.53 
cg07675682 18 1.60E-3(1.77E-2) 1.00[0.97,1.04] 0.93 -0.19 
cg10051414 18 2.59E-5(4.38E-3) 1.00[0.99,1.01] 1.00 -0.72 
cg17577122 18 3.53E-3(2.81E-3) 1.00[1.00,1.01] 0.21 -0.43 
cg18950108 18 -4.84E-3(1.61E-2) 1.00[0.96,1.03] 0.76 -0.12 
cg24202936 18 -2.13E-2(1.92E-2) 0.98[0.94,1.02] 0.27 -0.25 
cg25317585 18 5.81E-4(1.25E-2) 1.00[0.98,1.03] 0.96 0.40 
No.IV: Number of instrumental variables included. OR: Odds ratio, PMR and Beta (S.E.): P 
value, effect size and its standard error for the causal direction, primarily based on the 
inverse variance-weighted method, or in existence of pleiotropy (Ppleiotropy <0.05) based on 
MR Egger method. Ppleiotropy: P value estimated from MR Egger intercept pleiotropy test 
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Gene expression associated with target probes  
Excluding missing cg04245766, the association between each of 10 target probes 
and its nearest gene was tested. As shown in Table 10, we found significant associations 
for relationships between cg03116124 and TRIM67 (P value=0.02) and between 
cg06809326 with CCDC144NL (P value=0.03). 
Table 10 Associations between target probes and the nearest genes 
CpG Gene Chr Start Stop Coefficient SE P-value 
cg03116124 TRIM67 1 231244657 231357304 2.0E-2 8.9.E-3 2.4.E-2* 
cg06809326 CCDC144NL 17 20739760 20844644 -9.7E-3 4.5.E-3 3.3.E-2* 
cg06450373 CDH18 5 19473080 19988319 -9.1E-3 9.6.E-3 0.35 
cg25317585 FGF14 13 102344869 103054799 -1.6E-3 1.9.E-3 0.40 
cg17577122 CLDN5 22 19510550 19515068 -6.1E-4 1.1.E-3 0.59 
cg24202936 LOC441601 11 50205720 50280104 -3.1E-3 6.6.E-3 0.65 
cg07675682 SLC26A11 17 78194232 78227297 1.7E-3 4.5.E-3 0.71 
cg02741985 CCDC57 17 
80081038 80191192 -1.1E-3 3.1.E-3 0.72 
80059350 80111346 8.8E-4 3.2.E-3 0.78 
cg18950108 DPCR1 6 30902400 30921998 -8.0E-4 2.3.E-3 0.72 
cg10051414 MAFF 22 38576894 38612509 -1.1E-4 9.3.E-4 0.91 
 
Next, we performed TWASs of ten target probes to examine both cis- and trans-
effects. In FHS (n=1,966), 17,873 transcripts were included, and a study-level Bonferroni 
threshold was set to 2.80E-6. No gene-DNAm probe association was identified at the 
transcriptome-wide significance level in FHS. In RS (n=728), TWASs were performed with 
21,238 mRNA transcripts, 1 gene (CHKB; choline kinase-like protein) for cg06809326, 7 
genes for cg02741985, 38 genes for cg03116124, 61 genes for cg06450373, 296 genes for 
cg18950108 and 4 genes for cg253147585 were identified as significant at the Bonferroni 
threshold of 2.35E-6. Among significant associations, three WMH-associated genes232 - 
FCRL6, TGFBR3 and IL4R – were found to be associated with our target probes 
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(cg03116124, cg06450373 and cg08950108) (Table 11). However, a meta-analysis did not 
find any significant association due to lack of significance in FHS. 
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Table 11 TWAS results in target probes for WMH-associated genes 
CpG Site Gene CHR 
FHS (n=1,966) RS (n=728) Meta-analysis WMH TWAS 
T Q value T Q value N Z-score P value HetP T Q value 
cg03116124 TGFBR3 1 0.56 0.858 -5.00 0.002 2,683 0 1.00 0.31 4.27 0.036
cg06450373 TGFBR3 1 -0.43 0.976 -5.89 2.16E-05 2,686 -0.99 0.32 0.41 4.27 0.036
cg18950108 TGFBR3 1 -0.22 0.997 -11.40 2.58E-06 2,691 0.24 0.81 0.41 4.27 0.036
cg18950108 FCRL6 1 -1.85 0.250 -7.38 2.58E-06 5.23 0.003
cg18950108 IL4R 16 0.97 0.997 4.72 0.002 2,691 1.53 0.13 0.52 -5.502.61E-04
CHR: chromosome. HetP: P-value for heterogeneity test (H1:ZFHS≠ZRS). FDR Q: false-discovery rate adjusted P-value 
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Aim 3: Integrative genetic analyses of WMH burden 
Gene expression as a mediator in DNAm-WMH causal relationship 
 Previously we confirmed that four of our target probes (i.e. cg02741985, 
cg06450373, cg06809326 and cg24202936) are under in cis genetic control. Also, we found 
that cg06809326 was associated with the nearest gene CCDC144NL. In the two-step 
Mendelian randomization analysis, we confirmed that CCDC144NL mediates the 
relationship between cg06809326 and WMH burden in caudate basal ganglia, but not in the 
other brain tissues or whole blood (Table 12). The selected instrumental variable for step 1, 
rs7501645 was in high linkage disequilibrium (LD) with the instrumental variable for step 
2, rs11653586 (r2=0.98). 
Table 12 Two-step MR analysis result 
Step 1 (CpG -> Gene) Step 2 (Gene->WMH burden) 
Beta±S.E. IV PIV Beta±S.E. IV PIV Tissue 
11.52±2.43 rs7501645 2.13E-6 0.05±0.03 rs11653586 4.80E-2 Caudate 
basal ganglia 
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Meta-analysis of enriched pathways from multi-dimensional associations 
Based on independent SNPs, we observed three significantly enriched gene 
ontologies: extracellular matrix constituent conferring elasticity, microfibril and camera-type 
eye development (Table 13). From epigenetic markers, copulation, insulin secretion involved 
in cellular response to glucose stimulus, positive regulation of heat generation, pre-synapse 
assembly and negative regulation of dopamine secretion were significantly enriched. Lastly, 
from transcriptional markers, we found two ontologies including adaptive immune response 
and co-receptor activity enriched. Pathway-based meta-analysis of the three MSEA outputs 
identified that multi-omics associations in WMH burden were enriched in extracellular 
matrix structural constituent, camera-type eye development, alphaV-beta3 integrin-IGF-1-
IGF1R complex, retinol dehydrogenase activity and phosphatidylinositol-4-phosphate 
binding.  
Table 13 Meta-analysis of marker set enrichment 
MODULE P FDR DESCR 
GWAS 
GO:0030023 2.38E-05 4.35E-02 Extracellular matrix constituent conferring elasticity 
GO:0001527 3.03E-05 4.58E-02 Microfibril 
GO:0043010 4.70E-05 4.89E-02 Camera-type eye development 
GO:0035583 4.98E-05 5.01E-02 Sequestering of TGF-beta in extracellular matrix 
GO:0006066 1.53E-04 9.15E-02 Alcohol metabolic process 
GO:0008090 2.04E-04 0.103 Retrograde axonal transport 
GO:0060346 2.31E-04 0.108 Bone trabecula formation 
GO:0004022 2.98E-04 0.118 Alcohol dehydrogenase (NAD) activity 
GO:0035276 3.14E-04 0.120 Ethanol binding 
rctm0368 3.28E-04 0.120 Elastic fiber formation 
EWAS 
GO:0007620 7.60E-06 0.026 Copulation 
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MODULE P FDR DESCR 
GO:0035773 7.86E-06 0.026 
Insulin secretion involved in cellular response to 
glucose stimulus 
GO:0031652 1.34E-05 0.036 Positive regulation of heat generation 
GO:0099054 1.76E-05 0.039 Presynapse assembly 
GO:0033602 3.48E-05 0.049 Negative regulation of dopamine secretion 
GO:0033685 3.89E-05 0.051 Negative regulation of luteinizing hormone secretion 
GO:0034260 4.33E-05 0.052 Negative regulation of GTPase activity 
rctm0313 4.64E-05 0.053 Degradation of GABA 
GO:0007269 4.66E-05 0.053 Neurotransmitter secretion 
GO:0009450 4.71E-05 0.053 Gamma-aminobutyric acid catabolic process 
TWAS 
GO:0002250 4.27E-06 0.022 Adaptive immune response 
GO:0015026 1.10E-05 0.037 Coreceptor activity 
M4085 3.00E-05 0.068 Primary immunodeficiency 
GO:0006955 3.07E-05 0.069 Immune response 
M6856 7.03E-05 0.134 Hematopoietic cell lineage 
GO:0009897 9.84E-05 0.148 External side of plasma membrane 
GO:0030020 1.02E-04 0.150 
Extracellular matrix structural constituent conferring 
tensile strength 
rctm0115 1.13E-04 0.152 
Antigen activates B cell receptor leading to 
generation of second messengers 
GO:0000145 1.28E-04 0.155 Exocyst 
GO:0070371 1.48E-04 0.157 ERK1 and ERK2 cascade 
Combined  
GO:0005201 4.23E-06 0.019 Extracellular matrix structural constituent 
GO:0043010 8.26E-06 0.021 Camera-type eye development 
GO:0035867 8.47E-06 0.022 AlphaV-beta3 integrin-IGF-1-IGF1R complex 
GO:0004745 9.52E-06 0.023 Retinol dehydrogenase activity 
GO:0070273 1.99E-05 0.039 Phosphatidylinositol-4-phosphate binding 
GO:0006955 4.03E-05 0.069 Immune response 
rctm1075 6.36E-05 0.096 SHC-related events triggered by IGF1R 
M6856 7.41E-05 0.101 Hematopoietic cell lineage 
GO:0019841 8.74E-05 0.108 Retinol binding 
GO:0032024 1.44E-04 0.163 Positive regulation of insulin secretion 
rctm0115 
1.77E-04
0.169 
Antigen activates B cell receptor leading to 
generation of second messengers 
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Genetic loci associated with DNAm, gene expression and WMH burden 
At the WMH loci identified previously - 23 GWAS, 11 EWAS and 13 TWAS loci- 
we tested co-localization for each combination of DNAm probe and gene expression. The 
numbers of combinations were 182,499 in whole blood and 472 (77 in the same cytoband) 
combinations were identified as significant (PPFC>0.8). Significant co-localization 
combinations were located for 4 GWAS loci including rs3215395 at 7q22.1, rs6587216 at 
17p11.2, rs8071429 at 17q21.31 and rs7214628 at 17q25.1. (Table 14) At 7q22.1, we 
observed multi-level QTLs co-localized at MAP11 (microtubule associated protein 11), 
MOSPD3 (motile sperm domain containing 3) and SLC12A9 (potassium-chloride transporter 
9). At 17p11.2, 10 probes were co-localized with CCDC144A (coiled-coil domain containing 
144A), 15 probes with FAM106A (family with sequence similarity 106 member A) and 6 
probes with GRAPL (growth factor receptor-bound protein 2-related adaptor protein). At 
17q21.3, KANSL1 (lysine acetyltransferase 8 regulatory nonspecific lethal complex subunit 
1) and PLEKHM1 (pleckstrin homology domain containing protein family member 1) were 
identified as co-localized. At 17q25.1, we identified EXOC7 (exocyst complex component 
7); ZACN (zinc activated ion channel), GALK1 (galactokinase 1); ITGB4 (integrin subunit 
beta 4), H3F3B;H3F3A;H3F3C (H3 histone family member 3B;3A;3C), TEN1(telomere 
length regulation protein TEN1 homolog);TEN1-CDK3 (cell division protein kinase 
3);ACOX1 (acyl-CoA oxidase 1), UNC13D (unc-13 homolog D) and WBP2 (WW domain 
binding protein 2) co-localized with WMH QTLs and mQTLs. Three genes with full co-
localization – UNC13D, ACOX1 and WBP2- were previously reported;150,152 however, other 
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reported genes including TRIM47, TRIM67, and FBF1 did not show the full co-localization. 
One of the EWAS loci, cg06809326 is also located at 17p11.2, and one of the TWAS loci, 
ARL17A is also located at 17q21.31. Significant co-localization at cg06809326 was not 
identified; however, 10 methylation probes were co-localized with CCDC144A, which is a 
paralog of the gene mapped to the probe, CCDC144NL. We did not conduct the analysis at 
ARL17A, since the cis region for this gene does not have any mQTLs.  
Table 14 MOLOC result in whole blood 
Gene CpG nsnp PPFC PPFC_SNP 
7q22.1     
MAP11 cg21406967 14 0.87 7:100285888 
MOSPD3 cg04742719 23 0.85 7:100359454 
SLC12A9 cg17194182 21 0.89 7:100300898 
17p11.2     
CCDC144A; CCDC144B; CCDC144C cg01534423 14 0.89 17:19165179 
cg15971010 6 0.89 17:19253613 
cg21495715 16 0.89 17:19165179 
cg13305951 14 0.87 17:19172196 
cg16674433 16 0.86 17:19172196 
cg04279801 17 0.85 17:19204863 
cg13832201 23 0.85 17:19196440 
cg27589594 25 0.85 17:19165179 
cg20538986 25 0.84 17:19194812 
cg11465639 29 0.84 17:19165179 
FAM106A;FAM106CP;FAM106B cg15971010 9 0.92 17:19253613 
cg21158317 17 0.91 17:19204863 
cg13305951 17 0.91 17:19224397 
cg21495715 17 0.91 17:19224397 
cg01627492 10 0.91 17:19165179 
cg16674433 17 0.9 17:19247075 
cg04279801 17 0.9 17:19239432 
cg01534423 17 0.89 17:19213335 
cg22671072 17 0.89 17:19194812 
cg27589594 17 0.89 17:19165179 
cg13832201 17 0.88 17:19196440 
cg14817867 17 0.87 17:19165179 
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Gene CpG nsnp PPFC PPFC_SNP 
cg18633784 17 0.85 17:19165179 
cg01735398 17 0.84 17:19165179 
cg12137220 17 0.81 17:19217261 
GRAPL;GRAP cg13305951 19 0.88 17:19196440 
cg01534423 20 0.88 17:19196440 
cg16674433 23 0.83 17:19196440 
GRAPL;LOC79999;LOC100132472 cg21495715 19 0.89 17:19224397 
cg13305951 18 0.89 17:19224397 
cg01534423 20 0.84 17:19224397 
17q21.31     
KANSL1 cg17123029 21 0.89 17:43153006 
cg14750215 46 0.85 17:43161353 
PLEKHM1;PLEKHM1P cg16826777 11 0.80 17:43376447 
17q25.1     
EXOC7;ZACN cg16649771 8 0.90 17:73926121 
cg02497559 10 0.90 17:73904155 
cg04225089 8 0.90 17:73896299 
cg19804488 16 0.87 17:73896299 
cg05611719 18 0.86 17:73904155 
cg10935138 19 0.83 17:73896299 
cg08125733 19 0.83 17:73896299 
GALK1;ITGB4  cg10138630 9 0.94 17:73881056 
cg09795027 11 0.89 17:73881056 
cg03700492 9 0.89 17:73850819 
cg18082885 36 0.87 17:73881056 
H3F3B;H3F3A;H3F3C cg00759043 12 0.86 17:73904155 
TEN1;TEN1-CDK3;ACOX1 cg18082885 6 0.94 17:73899533 
UNC13D cg26780705 14 0.97 17:73876473 
cg00759043 12 0.97 17:73931787 
cg23806715 19 0.94 17:73764500 
cg00943312 13 0.94 17:73874684 
cg19026231 23 0.92 17:73764500 
cg10295360 23 0.90 17:73874684 
cg20772300 38 0.84 17:73876473 
cg24166112 38 0.82 17:73874684 
WBP2 cg26780705 14 0.98 17:73876473 
cg11015353 6 0.97 17:73884948 
cg15177359 26 0.97 17:73839366 
cg00943312 13 0.96 17:73874684 
cg23806715 19 0.94 17:73796617 
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Gene CpG nsnp PPFC PPFC_SNP 
cg10295360 23 0.92 17:73874684 
cg24563967 55 0.92 17:73874684 
cg00759043 12 0.91 17:73931787 
cg19026231 23 0.91 17:73775825 
cg06407111 91 0.87 17:73874684 
cg04442638 65 0.87 17:73874684 
cg24166112 42 0.87 17:73874684 
cg14955151 75 0.86 17:73874684 
cg20772300 42 0.86 17:73874684 
cg09253696 77 0.86 17:73874684 
cg03700492 73 0.85 17:73874684 
cg04225089 91 0.83 17:73874684 
cg10644544 65 0.82 17:73874684 
cg18082885 90 0.81 17:73874770 
nsnp: number of SNPs included for co-localization test. PPABC_SNP: the SNP with the 
most evidence of colocalization 
 
Out of 234,336 gene-probe combinations in cortex, significant co-localization 
evidence was observed in 22, in 9 of 232358 combinations in frontal cortex, 12 of 230,792 in 
anterior cingulate cortex, and 9 of 234,905 in caudate basal ganglia. In cortex, co-
localizations at 7q22.1, 17q21.31 and 17q25.1 were observed, some of genes at 17q25.1 were 
replicated in other brain tissues – frontal and anterior cingulate cortex tissues and caudate 
basal ganglia tissue (Table 15). At 7q22.1, co-localization was identified for non-coding 
genes only. Many genes were co-localized at 17q25.1 including TRIM47 in all cortex tissues 
and FBF1 in all brain tissues. TRIM47 was not included in the whole blood analysis since 
eQTLs at the locus did not have any in cis associations with the gene. There were also tissue-
specific co-localizations. In only cortex tissue, we observed co-localization of QTLs, mQTLs 
for cg03706109 and eQTLs for DCAKD at 17q21.31. Co-localization at TEN1 was confirmed 
in frontal cortex, TRIM65 and CDK3 in anterior cingulate cortex, and WBP2 in caudate basal 
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ganglia. We confirmed the genes reported by previous GWASs with full-co-localization - 
DCAKD at 17q21.31, FBF1, TRIM47, TRIM65 and WBP2 at 17q25.1. Except for WBP2, 
these genes were not co-localized with whole blood eQTLs.  
Table 15 MOLOC result in brain tissues 
Symbol Tissue DNAm nsnp PPABC PPABC_SNP
7q22.1     
 
AC069294.1 Caudate basal ganglia cg04120578 66 0.91  7:100264893 
cg14016363 20 0.86  7:100359797 
cg00621899 53 0.86  7:100359797 
cg25923345 75 0.85  7:100264893 
cg25224090 71 0.84  7:100359797 
cg05392513 81 0.81  7:100359797 
cg22813798 148 0.81  7:100359797 
RP11-395B7.2 Cortex cg04120578 68 0.90  7:100264893 
cg25923345 79 0.82  7:100264893 
17q21.31 
     
DCAKD Cortex cg03706109 148 0.87  17:43128906 
17q25.1 
     
CDK3 Anterior cingulate cortex cg00943312 13 0.82  17:73874684 
FBF1 Anterior cingulate cortex cg00759043 12 0.82  17:73943942 
Caudate basal ganglia cg00759043 12 0.92  17:73909948 
Cortex cg00943312 13 0.93  17:73890363 
cg00759043 12 0.92  17:73931787 
cg26780705 19 0.92  17:73876473 
cg10295360 23 0.84  17:73874684 
cg24166112 57 0.81  17:73874684 
Frontal cortex cg00759043 12 0.91  17:73931787 
TEN1 Frontal cortex cg00943312 13 0.83  17:73874684 
TRIM47 Anterior cingulate cortex cg00943312 13 0.96  17:73874684 
cg26780705 19 0.96  17:73873656 
cg08125733 286 0.86  17:73850940 
cg10935138 278 0.85  17:73862646 
cg04442638 180 0.85  17:73874684 
cg09253696 217 0.85  17:73874684 
cg06407111 246 0.85  17:73874684 
cg04225089 279 0.83  17:73874684 
cg10295360 23 0.83  17:73874684 
Cortex cg26780705 19 0.97  17:73876473 
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cg00943312 13 0.94  17:73874684 
cg10295360 23 0.88  17:73876473 
cg20772300 57 0.84  17:73876473 
cg04442638 180 0.84  17:73874684 
cg06407111 246 0.83  17:73874684 
cg09253696 217 0.83  17:73874684 
cg24166112 57 0.83  17:73876473 
cg12714757 188 0.82  17:73876473 
cg04225089 279 0.82  17:73874684 
cg10935138 278 0.81  17:73862646 
cg14955151 136 0.81  17:73874684 
cg03700492 98 0.81  17:73876473 
cg10644544 79 0.80  17:73876473 
Frontal cortex cg26780705 19 0.96  17:73873656 
cg00943312 13 0.95  17:73873656 
cg04442638 180 0.87  17:73874684 
cg09253696 217 0.86  17:73874684 
cg06407111 246 0.86  17:73874684 
cg10295360 23 0.85  17:73874684 
cg04225089 279 0.83  17:73874684 
TRIM65 Anterior cingulate cortex cg00759043 12 0.84  17:73943942 
WBP2 Caudate basal ganglia cg26780705 19 0.89  17:73876473 
nsnp: number of SNPs included for co-localization test. PPABC_SNP: the SNP with the 
most evidence of colocalization 
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DISCUSSION 
Our study identified 11 methylation probes associated with WMH burden. These 
probes mapped to genes that may have an implication in CSVD etiology. CLDN5 (claudin 5) 
mapped to cg17577122 encodes integral membrane proteins that comprise tight junctions 
specifically in brain microvascular endothelial cells that regulate blood-brain barrier (BBB) 
permeability.241 Claudin-5 is the most enriched tight junction protein at BBB, and its 
dysfunction has been implicated in neurodegenerative and neuroinflammatory diseases.242 In 
a rat model of WM injury, a decrease in endothelial CLDN5 gene expression was observed in 
regions of BBB damage.243 The profile of claudins and tight junction-associated marvel 
proteins was studied in rats; up-regulation of Cldn5 after middle cerebral artery occlusion 
was paralleled with down-regulated Cldn-1, 3, and 12, and occludin in cerebral capillaries in 
pathological ischemia.244 Supporting this, CLDN5 was enriched in the regulation of 
endothelial cell differentiation with another EWAS gene, BMP4 (bone morphogenetic 
protein 4), in the FUMA gene enrichment analysis. Transforming growth factor beta 1 
(TGFB1) is dysregulated in the heredity form of CSVD, CARASIL. BMPs are the largest 
group of the TGFB superfamily, and a study using post mortem samples from SVD patients 
showed that BMP4 was highly expressed in white matter pericytes and suggested that 
ischemic white matter damage evolves in parallel with BMP4 upregulation in pericytes,245 
that inhibits maturation of oligodendrocytes and blocks the expression of myelin proteins.246 
Accounting for the spatial correlation among DNAm probes, we could enhance 
DNAm associations for WMH burden. Among genes mapped to the DMRs, we could 
implicate several genes to the WMH pathology. Protein arginine N-methylase 1 (PRMT1) 
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transfers methyl group to arginine residues on histones; methylation mediated by PRMT1 is 
promoted in genes involved in glioblastomagenesis.247 Generally, arginine methyltransferase 
enzymes (PRMT1, PRMT4, and PRMT5) regulate myeloid differentiation.132 Mice lacking 
PRMT1 were characterized with severe central nervous system defects, particularly defects in 
oligodendrocyte maturation processes.248 PRMT1 is a predominant type I protein arginine 
methyltransferase,249 which is mainly expressed in the endothelium and smooth muscle cells 
of the cardiovascular system.250 Under oxidative stress, type 1 PRMT enzymes enhanced by 
low-density lipoproteins methylate arginine competing against asymmetric dimethylarginine 
(ADMA); thus leading to increased level of ADMA that inhibits synthesizing nitric oxide 
resulting in endothelial dysfunction.251,252 DNAm at PRMT1 was also identified as the shared 
epigenetics between cognitive ability (processing speed in specific) and WMH burden. The 
link between DNAm at PRMT1 and cognition-related white matter changes needs to be 
further studied; however, the mechanism is likely to be related to ischemia in endothelial 
cells. Another DMR was mapped to the mast cell growth factor gene (KITLG, KIT ligand 
gene), encoding the ligand of the tyrosine-kinase receptor which is a pleiotropic factor in 
neural cell development. The gene is overexpressed by neurons to recruit neural stem cells to 
the cerebral injury site for angiogenic response.253  
WMH burden-associated DMRs and the probes shared with cognitive abilities 
suggested that immunity- or infection- related functions are closely related to the CSVD 
etiology. Innate and adaptive immune responses coincide with leukocyte adhesion to the 
blood-vessel wall; therefore, the influx of leukocytes through endothelial cells influences the 
immune reactions in the tissues.254,255 In this study, genes mapped to DMRs were enriched in 
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HIV-1 control (enrichment FDR-adjusted P value =0.008) and squamous cell lung 
carcinoma256 (FDR-adjusted P value=0.038) (Table 5). The arginine methyltransferase 
enzyme encoded by PRMT1 binds to the intracytoplasmtic domain of the type I interferon 
complex; reduced PRMT1 expression was found with the reduced antiproliferative effect of 
interferon-beta.257 More DMRs were mapped to genes in infection-related or immune 
system-related pathways. Zinc finger protein 311 (ZNF311) is known to be included in the 
herpes simplex virus 1 infection superpathway with many other zinc finger proteins.258 In 
addition, two genes, UBE3C and KITLG, involved in the class I MHC mediated antigen 
processing,259 lymphocyte cytosolic protein 1 (LCP1) associated with B-cell non-Hodgkin 
lymphoma,260 human immunodeficiency virus (HIV) type I enhancer binding protein 3 
(HIVEP3) and mitochondrial valyl-tRNA synthetase 2 (VARS2) implicated in vaccinia virus 
infection,261,262 procollagen-lysine 5-dioxygenase 2 (PLOD2) implicated in decreased HIV-1 
infection,276 psoriasis susceptibility 1 candidate 3 (PSORS1C3),263 and solute blood cell 
counts (SLC45A4) associated with blood cell counts (plateletcrit, leukocyte and reticulocyte 
counts) were mapped to DMRs.264,265 HIVEP3 has been also reported in blood pressure and 
eosinophil GWASs.265–268 
Cg06809326 mapped to CCDC144NL was identified in the trans-ethnic analysis 
when BMI, smoking status and blood pressure measures were not adjusted. Blood pressure is 
an important risk factor for WMH burden, and BMI and smoking are known to influence 
DNAm levels. To remove false positive signals, the risk factors should be corrected for in the 
models; however, the unadjusted association is still meaningful as a crude measure of 
DNAm-WMH burden relationship. And we confirmed that cg06809326 or CCDC144NL 
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have not been reported in the epigenetic association with BMI269, smoking270, or blood 
pressure271. A regional plot at cg06809326 shows that the epigenetic locus is likely to 
associate with WMH burden with multiple signals (Figure S5). Correlations among 
methylation probes in 1,597 ARIC subjects were shown below the plot, probes making the 
association signal at the locus were significantly correlated. The heritability estimate for 
cg06809326 was 26.5% and the genetic control indicated by mQTL associations was present 
in cis in both EA and AA subjects (Figure S6). The directionality from the DNAm level at 
cg06809326 to WMH burden was established by the bi-directional MR analysis. To further 
elaborate the cg06809326-linked etiology, we confirmed the direct association with the gene 
expression of CCDC144NL as well as the gene’s mediation in the relationship between the 
DNAm level at cg06809326 and WMH burden. However, a TWAS in FHS subjects did not 
report a significant association between CCDC144NL and WMH burden.232 The 
CCDC144NL gene (coiled-coil domain containing 144 family (CCDC144A) N-terminal 
pseudogene) is a pseudogene associated with diabetic retinopathies.272 Diabetic retinopathy is 
blood vessel damage in the retina, and it shares risk factors with CSVD such as high blood 
pressure and cholesterol levels. The coiled-coil protein, vimentin, assembles into filaments 
potentially involved in integrin-mediated cell adhesion and angiogenesis.273 In the backward 
MR analysis, we could find WMH burden influences the methylation level at cg03116124. 
Absence of genetic influence on the probe but association with WMH burden might be 
explained by this backward association. The DNAm level at cg03116124 can be the 
secondary outcome of WMH burden; and might have a potential as a serum biomarker. The 
cg03116124 probe was found to be associated with expression of TRIM67, a member of the 
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tripartite motif containing family; previous large-scale GWASs identified other members of 
the gene family - TRIM47 and TRIM65 - in the association with WMH burden or 
volume.125,150,152,274  
 
Only five of our target probes showed significant genetic components (Table 7), lack 
of genetic components may implicate environmental influences. Also, polygenic control was 
inferred by that we could not identify the genetic control in cis for heritable probes. 
Cg17577122 was mapped to CLDN5, implicated in the CSVD etiology via endothelial cell-
related mechanisms. The heritability estimate for cg17577122 was 14.3%; however, no 
mQTLs in cis were identified. Recently, a region-based EWAS reported a DMR mapped to 
CLDN5 in the association with cognitive trajectory.275 In the study, genetic variations within 
CLDN5 were associated with DNAm, but not with cognitive trajectory. Considering the 
correlation between WMH and cognitive function, the result supports our conclusion that 
WMH-associated DNAm at CLDN5 is not under in cis genetic control. In our study, genetic 
controls over this probe appears to be scattered throughout the genome, especially in AA 
subjects multiple mQTL loci were shown (Figure S6). Generally, trans-effects of genetics 
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explain only a small portion of genetic control over DNA methylation;225,226 however, it is 
still possible that some DNAm is controlled by multiple genetic loci in a polygenic manner.  
We studied DNAm levels in whole blood samples and the utility of DNAm probes as 
preventive biomarkers can be secured by checking the correlation with the levels in brain 
tissues. For 450,000 probes on the Illumina Human450 Methylation BeadChip, correlations 
between DNAm level in whole blood and the levels in four brain tissues (i.e. prefrontal 
cortex, entorhinal cortex, superior temporal gyrus and cerebellum) were reported on the 
Blood Brain DNA Methylation Comparison Tool website 
(https://epigenetics.essex.ac.uk/bloodbrain/).276 We searched 11 target probes in the tool, and 
marginal to high correlations of DNAm levels in blood and brain tissues were observed at 
several target probes (Table S11). The correlation coefficients at cg06809326 were similarly 
significant in four tissues from 0.566 to 0.711. At cg04245766, DNAm levels in blood and 
the brain were highly correlated (r=0.923 to 0.954). Marginal correlation was confirmed at 
cg24202936 in prefrontal and entorhinal cortex and superior temporal gyrus (r=0.324 to 
0.398). At some probes, tissue-specific correlation was found - r=0.0494 in entorhinal cortex 
(cg02741985), r=0.242 in cerebellum (cg03116124), r= -0.312 in cerebellum (cg10051414), 
and r=0.255 in superior temporal gyrus (cg18950108). Probes with high correlated blood and 
brain methylation levels are more likely to be eligible as an epigenetic biomarker for WMH 
burden. 
 Integrative genetic analyses provided us novel and additional information about the 
CSVD etiology. Using multi-level associations (GWAS, EWAS and TWAS), we meta-
analyzed gene-based associations and identified biological functions associated with WMH 
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burden. A significant association was identified in the alphaV-beta3 integrin-IGF-1-IGF1R 
complex (FDR adjusted P value=0.022) ontology. IGFBP-2, which binds IGF-1 to the 
integrin complex, was recently suggested as a biomarker for dementia and Alzheimer’s 
disease.277 By co-localizing QTL, mQTL, and eQTL associations at WMH loci, our analysis 
linked several GWAS loci with DNAm and gene expression possibly involved in the 
pathology. Especially, the well-established WMH locus, 17q25.1, showed co-localization 
evidence for multiple genes including GALK1; ITGB4. Co-localization at the integrin subunit 
beta 4 gene integrin-related gene (ITGB4) again suggests integrin-mediated cell adhesion and 
angiogenesis as a possible etiological mechanism.  
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CONCLUSIONS 
This dissertation study was designed to investigate the role of DNA methylation, a 
kind of epigenetic variations, in WMH burden, a shared pathology among critical public 
health burdens including stroke and dementia. As the first step, we have identified DNAm 
levels at 11 novel loci in association with WMH burden and implicated biological functions 
related to the genes mapped to those loci. In the next step, we characterized the relationship 
between DNAm at the identified probes and the genetics or gene expression. We confirmed 
significant genetic components in six DNAm probes and identified genetic variants (mQTLs) 
associated with four of them. Based on mQTLs, we tested a causal direction between DNAm 
and WMH burden in either way. DNAm at cg06809326 was found to influence WMH 
burden, while WMH burden influences DNAm at cg03116124. Additionally, expression 
levels of the closest genes to these two probes were confirmed to be associated with the 
DNAm at the probes (i.e. CCDC144NL for cg06809326, and TRIM67 for cg03116124). The 
causal association from the genetics through DNAm and then gene expression towards WMH 
burden was also confirmed at cg06809326. We also investigated the WMH etiology utilizing 
multi-dimensional data available. We integrated genome-, transcriptome-, and our 
epigenome-wide associations and identified a novel ontology related to integrin complex 
associated with WMH burden. Had tested co-localization of genetic associations at multi-
dimensions at the reported WMH burden loci, we found significant co-occurrences of mQTL, 
eQTL, and QTLs at four GWAS reported loci including ITGB4 (integrin subunit beta 4). This 
indicates that some genetic influences lead to WMH burden through related epigenetics and 
gene expressions. In conclusion, we found novel loci associated with WMH burden and 
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functionally annotated these loci in relation to the etiology, suggesting involvement of the 
integrin-mediated pathway. 
This is the first epigenome-wide association study of WMH in a large-scale. Aging 
influences DNA methylation,278 and WMH burden is known to be associated with older 
ages32,35,46–50. Thus, epigenetics might unravel the unknown etiology of WMH burden. In this 
study, we identified novel epigenetic loci associated with WMH burden, and these loci might 
provide a novel explanation to the aging-related WMH pathology. The main finding of this 
study was the integrin-associated pathway. Integrins play a crucial role in cell-to-cell and 
cell-to-extra-cellular matrix interactions, and these interactions are essential for effective T-
cell-mediated immune response.279 The ageing process often leads to reduced efficiency of 
adaptive immunity, while B-cell functions and innate immune system tend to maintain.280 
Integrin-mediated functions might be able to explain the shared pathology of ageing and 
WMH burden. This study exhibits several limitations as well; however, those can be 
overcome with future studies. MetaUSAT multivariate analysis computes a joint statistic 
using two sets of summary statistics. In a multi-trait analysis of GWASs, the joint association 
becomes stronger when correcting for the correlation structure of SNPs. Likewise, the joint 
analysis can improve with a future study in the correlation structure among methylation 
probes. Heritability estimates showed that only five of our EWAS probes have genetic 
compositions. The target probes with small or non-significant genetic components need to be 
studied for their association with environmental factors including blood pressure. We 
observed that mQTLs showed underpowered significance in UKBB GWAS, this might 
improve with greater sample size. We used the summary statistics from a previous GWAS to 
establish directional associations for target probes. Mendelian randomization analysis 
81 
 
requires the effect size and its standard error for exposure and outcome associations to 
compute the statistics for directional association. The largest CHARGE GWAS including 
17,936 EA subjects provides Z-scores only, so it was not applicable for MR analyses. We 
used the summary statistics from the UKBB GWAS; however, it covers fewer SNPs. Many 
mQTLs and eQTLs are not included in the UKBB dataset, and the CHARGE GWAS does 
not provide effect size. One of the target probes, cg04245766 mapped to BMP4, was not 
included in the causal association analyses since it did not pass QC criteria in EA subjects of 
ARIC, FHS, and RS. The EWAS association for cg04245766 was driven by ADNI, ARIC 
AA subjects, CARDIA, and SHIP-TREND. When mQTL associations for cg04245766 are 
available, we can test the directional association toward WMH burden with or without 
mediation of gene expression. In the functional analysis, the BMP4 gene was enriched in 
endothelial cell differentiation and regulation; thus, confirming the causal pathway related to 
cg04245766 might be a valuable addition to the understanding of the WMH burden-
associated epigenetics. Lastly, the Bayesian method-based co-localization test simply 
confirms the co-occurrence of independent associations, not providing the evidence on the 
causal pathway. Based on the co-localization results, the etiology of WMH burden involving 
genetics, DNAm and gene expression can be further investigated. 
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APPENDICES 
Appendix A. Supplemental Material 
IRB approval from the UTHSC committee 
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Alzheimer's Disease Neuroimaging Initiative (ADNI) 
Study Description 
ADNI is a longitudinal, multi-site observational study including Alzheimer’s disease 
(AD), mild cognitive impairment (MCI), and elderly individuals with normal cognition 
assessing clinical and cognitive measures, MRI and PET scans (FDG and 11C PIB) and 
blood and CNS biomarkers.281,282 In 2004, the initial phase, ADNI-1, recruited 400 subjects 
with MCI, 200 subjects with early AD and 200 cognitively normal elderly from multiple site 
in North America. The study was extended with ADNI-GO in 2009 including 500 ADNI-1 
subjects (normal controls and MCI cases) and 200 new early MCI cases. In 2011, one more 
extension, ADNI-2, started to study approximately 450-500 ADNI-1 subjects, 200 ADNI-GO 
subjects and 650 new cases (150 controls, 150 early MCI cases, 150 late MCI cases and 200 
mild AD cases). In this study, 387 normal or early MCI subjects who provided brain MRI 
and methylation data were included. Brain MRI for WMH burden assessment was taken at 
ADNI-1 in 73 subjects and at ADNI-2 in 314 subjects. Samples for DNA methylation were 
drawn in ADNI-GO and ADNI-2 studies. Days between blood sampling and brain MRI were 
within 365 days in 85% of subjects (n=329), between a year and two years in 8% (n=31), 
between two and three years in 16 subjects and more than 3 years in 11 subjects. 
Ethic Statement 
The study protocols for the ADNI studies were approved by the Institutional Review 
Boards of all the participating institutions. 
Acknowledgements 
Data collection and sharing for this project was funded by the Alzheimer's Disease 
Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and 
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DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded 
by the National Institute on Aging, the National Institute of Biomedical Imaging and 
Bioengineering, and through generous contributions from the following: AbbVie, 
Alzheimer’s Association; Alzheimer’s Drug Discovery Foundation; Araclon Biotech; 
BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai 
Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La 
Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO 
Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & 
Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & 
Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; 
Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda 
Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health 
Research is providing funds to support ADNI clinical sites in Canada. Private sector 
contributions are facilitated by the Foundation for the National Institutes of Health 
(www.fnih.org). The grantee organization is the Northern California Institute for Research 
and Education, and the study is coordinated by the Alzheimer’s Therapeutic Research 
Institute at the University of Southern California. ADNI data are disseminated by the 
Laboratory for Neuro Imaging at the University of Southern California. 
 
Atherosclerosis Risk in Communities (ARIC) 
Study Description 
The ARIC Study is a prospective longitudinal investigation of the development of 
atherosclerosis and its clinical sequelae in which 15,792 individuals aged 45 to 64 years were 
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enrolled at baseline. A detailed description of the ARIC study has been reported 
previously.283 At the inception of the study in 1987-1989, participants were selected by 
probability sampling from four communities in the United States: Forsyth County, North 
Carolina; Jackson, Mississippi (African-Americans only); the suburbs of Minneapolis, 
Minnesota; and Washington County, Maryland. Four examinations were carried out at three-
year intervals (exam 1, 1987-1989; exam 2, 1990-1992; exam 3, 1993-1995; exam 4, 1996-
1998). A fifth clinical examination was completed in 2011-2013. Subjects were contacted 
annually to update their medical histories between examinations. After QC, 906 European-
American and 639 African-American subjects with methylation data and brain MRI were 
included in this study. 
Ethic Statement 
Written informed consent was provided by all study participants, and the study design 
and methods were approved by institutional review boards at the collaborating medical 
institutions: University of Mississippi Medical Center Institutional Review Board (Jackson 
Field Center); Wake Forest University Health Sciences Institutional Review Board (Forsyth 
County Field Center); University of Minnesota Institutional Review Board (Minnesota Field 
Center); and the Johns Hopkins School of Public Health Institutional Review Board 
(Washington County Field Center). 
Acknowledgments 
The Atherosclerosis Risk in Communities study has been funded in whole or in part 
with Federal funds from the National Heart, Lung, and Blood Institute, National Institutes of 
Health, Department of Health and Human Services (contract numbers HHSN268201700001I, 
HHSN268201700002I, HHSN268201700003I, HHSN268201700004I and 
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HHSN268201700005I). The authors thank the staff and participants of the ARIC study for 
their important contributions. Funding was also supported by RC2HL102419 and 
R01NS087541. This study was funded by the NIH contract (5R01NS087541-04) granted to 
Myriam Fornage and Eric Boerwinkle. 
 
Coronary Artery Risk Development in Young Adults (CARDIA) 
Study Description 
 Coronary Artery Disease Risk Development in Young Adults (CARDIA) is a 
longitudinal study designed to trace the development of risk factors for coronary heart 
disease in 5,115 relatively young individuals aged 18-30 (52% African American and 55% 
women). The study collected information on anthropometric, lifestyle factors as well as 
biomarkers including brain MRI, genetic and DNA methylation data. Baseline measurements 
were repeated, and additional measurements performed, at Years 2, 5, 7, 10, 15, 20, and 
25.284 DNA methylation level was measured in 1,089 subjects at the examination year 15 and 
1,092 subjects at the year 20. In this study, 126 subjects of European and 68 subjects of 
African-ancestry with the brain MRI image were contributed from CARDIA. 
Ethic Statement 
The CARDIA study is multicenter with recruitment in Birmingham, AL; Chicago, IL; 
Minneapolis, MN; and Oakland, CA. The study protocol was approved by the institutional 
review boards of the coordinating center and the 4 participating field centers, and written 
informed consent was obtained from participants at all examinations. 
Acknowledgments 
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 The Coronary Artery Risk Development in Young Adults Study (CARDIA) is 
conducted and supported by the National Heart, Lung, and Blood Institute (NHLBI) in 
collaboration with the University of Alabama at Birmingham (HHSN268201300025C & 
HHSN268201300026C), Northwestern University (HHSN268201300027C), University of 
Minnesota (HHSN268201300028C), Kaiser Foundation Research Institute 
(HHSN268201300029C), and Johns Hopkins University School of Medicine 
(HHSN268200900041C). CARDIA is also partially supported by the Intramural Research 
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Cardiovascular Health Study (CHS) 
Study Description 
 The CHS is a population-based cohort study of risk factors for coronary heart disease 
and stroke in adults ≥65 years conducted across four field centers in the United States: 
Sacramento County, California; Washington County, Maryland; Forsyth County, North 
Carolina; and Pittsburgh, Allegheny County, Pennsylvania. The original cohort of 5,201 
persons, predominantly of European ancestry, was recruited in 1989-1990 from random 
samples of the Medicare eligibility lists. Later, 687 African-Americans were added to the 
cohort, making the total cohort of 5,888.285 DNA methylation was measured on a randomly 
selected subjects without presence of coronary heart disease, congestive heart failure, 
peripheral vascular disease, valvular heart disease, stroke or transient ischemic attack at the 
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exam year 5. Post QC, 378 European ancestry and African-American participants with 
methylation data and brain MRI were included in this study. 
Ethic Statement 
 Written informed consent to genetic research has been obtained on all individuals 
included in this study. CHS was approved by institutional review committees at each field 
center and individuals in the present analysis had available DNA and gave informed consent 
including consent to use of genetic information for the study of cardiovascular disease. The 
DNA methylation dataset from CHS can be requested at https://chs-nhlbi.org/node/6222. 
Acknowledgements 
 Infrastructure for the CHARGE Consortium is supported in part by the National 
Heart, Lung, and Blood Institute grant R01HL105756. The CHS research was supported by 
NHLBI contracts HHSN268201200036C, HHSN268200800007C, N01HC55222, 
N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083, N01HC85086, 
N01HC15103; and NHLBI grants U01HL080295, R01HL087652, R01HL092111, 
R01HL105756, R01HL103612, R01HL111089, R01HL116747 and R01HL120393 with 
additional contribution from the National Institute of Neurological Disorders and Stroke 
(NINDS). Additional support was provided through R01AG023629 and R01AG033193 from 
the National Institute on Aging (NIA) as well as Laughlin Family, Alpha Phi Foundation, and 
Locke Charitable Foundation. A full list of principal CHS investigators and institutions can 
be found at CHS-NHLBI.org. The provision of genotyping data was supported in part by the 
National Center for Advancing Translational Sciences, CTSI grant UL1TR000124, and the 
National Institute of Diabetes and Digestive and Kidney Disease Diabetes Research Center 
(DRC) grant DK063491 to the Southern California Diabetes Endocrinology Research Center. 
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The content is solely the responsibility of the authors and does not necessarily represent the 
official views of the National Institutes of Health. 
 
Framingham Heart Study (FHS) offspring cohort 
Study Description 
 The FHS is a single-site, community-based, ongoing cohort study that was initiated in 
1948 to investigate prospectively the risk factors for CVD.286–288 The original cohort 
(n=5,209) was randomly recruited in the town of Framingham, MA, USA, and examined 
every 2 year since 1948; their children and spouses of the children (n=5,124), the offspring 
cohort, was enrolled in 1971 and examined approximately every 4 year since 1971. DNA 
methylation was measured on 2,846 offspring participants around 8th examination cycle 
(2005-2008). This study includes 403 and 1,323 offspring subjects with dse and flair MRI 
scans, respectively, as well as DNA methylation data. 
Ethic Statement 
Written informed consent to genetic research has been obtained on all individuals 
included in this study. Ethics permission for FHS and genetic research in FHS was obtained 
from the Institutional Review Board of Boston University Medical Campus (IRB number H-
32132, H-26671) 
Acknowledgements 
This work was supported by the National Heart, Lung and Blood Institute’s 
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by grants from the National Institute of Aging (R01s AG033193, AG008122, AG054076, 
AG033040, AG049607, AG05U01-AG049505), and the National Heart, Lung and Blood 
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Institute (R01 HL093029, HL096917). The laboratory work for this investigation was funded 
by the Division of Intramural Research, National Heart, Lung, and Blood Institute, National 
Institutes of Health, and by NIH contract N01-HC-25195. The analytical component of this 
project was funded by the Division of Intramural Research, National Heart, Lung, and Blood 
Institute, and the Center for Information Technology, National Institutes of Health. 
 
Genetic Epidemiology Network of Arteriopathy (GENOA) 
Study Description 
The Genetic Epidemiology Network of Arteriopathy (GENOA) study was designed to 
investigate the genetics of hypertension and target organ damage in hypertensive sibships.20 
The GENOA study is a community-based study including African Americans from Jackson, 
Mississippi and non-Hispanic whites from Rochester, Minnesota.289 The initial GENOA 
study, from 1996 to 2001, recruited any members in sibships having more than two 
individuals with clinically diagnosed hypertension before age 60. Exclusion criteria of the 
GENOA study were secondary hypertension, alcoholism or drug abuse, pregnancy, insulin-
dependent diabetes mellitus, or active malignancy. Eighty percent of African Americans 
(1,482 subjects) and 75% of non-Hispanic whites (1,213 subjects) from the initial study 
population returned for the second examination (Phase II: 2001-2005). Study visits were 
made in the morning after an overnight fast of at least eight hours. Demographic information, 
medical history, clinical characteristics, lifestyle factors, and blood samples were collected in 
each phase. DNA methylation levels were measured only in African Americans participants. 
After quality control, DNA methylation and brain MRI data were available for 356 African 
Americans. 
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Ethic Statement 
Written informed consent was obtained from all subjects, and approval was granted 
by participating institutional review boards at the University of Mississippi Medical Center, 
the Mayo Clinic, and the University of Michigan. 
Acknowledgements 
 Support for the Genetic Epidemiology Network of Arteriopathy (GENOA) was 
provided by the NHLBI (HL054457, HL100185, HL119443, and HL133221) and the NINDS 
(NS041558) of the NIH. 
 
Lothian Birth Cohort 1936 (LBC1936)  
Study Description 
The Lothian Birth Cohorts of 1936 (LBC1936) is a longitudinal study of ageing. 
Participants were born in 1936 and mostly live in the Lothain region of Scotland.290,291 The 
study was derived of the Scottish Mental Surveys of 1947 that conducted a general cognitive 
ability test on nearly all 11 year old children in Scotland. Residents in the Lothian area of 
Scotland (n=1,091) were recruited in late-life at mean age 70 and followed-up at their ages 
70, 73, and 76. In this study, 230 subjects who provided epigenetic information and brain 
imaging, blood biomarkers and anthropomorphic and lifestyle measures were included. 
Ethic Statement 
Following written informed consent, venesected whole blood was collected for DNA 
extraction. Ethics permission for the LBC1936 was obtained from the Multi-Centre Research 
Ethics Committee for Scotland (Wave 1: MREC/01/0/56), the Lothian Research Ethics 
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Committee (Wave 1: LREC/2003/2/29), and the Scotland A Research Ethics Committee 
(Waves 2 and 3: 07/MRE00/58). 
Acknowledgements 
 We thank the cohort participants and team members who contributed to these studies. 
Phenotype collection in the Lothian Birth Cohort 1936 was supported by Age UK (The 
Disconnected Mind project). Methylation typing was supported by the Centre for Cognitive 
Ageing and Cognitive Epidemiology (Pilot Fund award), Age UK, The Wellcome Trust 
Institutional Strategic Support Fund, The University of Edinburgh, and The University of 
Queensland. Analysis of these data were carried out within the University of Edinburgh 
Centre for Cognitive Ageing and Cognitive Epidemiology (CCACE). CCACE is supported 
by funding from the BBSRC, the Medical Research Council (MRC), and the University of 
Edinburgh as part of the cross-council Lifelong Health and Wellbeing initiative 
(MR/K026992/1). Funding from the Australian NHMRC (613608) supported quality control 
analysis of the methylation data. 
 
Rotterdam Study III (RS3)  
Study Description 
 The Rotterdam Study is a prospective, population-based cohort study that includes 
inhabitants of the well-defined district Ommoord, located in the city of Rotterdam in the 
Netherlands.292 The cohort was initiated in 1990 among approximately 7,900 persons aged 55 
years and older, who underwent a home interview and extensive physical examination at the 
baseline and during the follow-up rounds every 3-4 years (RS-I). The cohort was extended in 
2000-2001 (RS-II, 3,011 individuals, aged 55 years and older) and 2006-2008 (RS-III, 3,932 
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individuals aged 45 and older). Collected data include genetic information, epigenetic 
information, imaging (of heart, blood vessels, eyes, skeleton and brain) and numerous blood 
biomarkers, anthropomorphic and lifestyle measures.293,294 Post QC, DNA methylation and 
brain MRI used for the analyses were available in 547 subjects from the first visit of RS-III 
and 442 subjects from the fifth visit of RS-I, the third visit of RS-II and the second visit of 
RS-III. The latter dataset is part of the Biobanking and Biomolecular Resources Research 
Infrastructure for The Netherlands (BBMRI-NL), BIOS (Biobank-based Integrative Omics 
Studies) project [http://www.bbmri.nl/?p=259]. Whole blood DNA methylation was 
quantified in a random subset of 750 individuals with genotyping and RNA expression data 
available in the first cohort of RS-III. 
Ethic Statement 
 The Rotterdam Study has been approved by the Medical Ethics Committee of the 
Erasmus MC (registration number MEC 02.1015) and by the Dutch Ministry of Health, 
Welfare and Sport (Population Screening Act WBO, license number 1071272-159521-PG). 
The Rotterdam Study has been entered into the Netherlands National Trial Register (NTR; 
www.trialregister.nl) and into the WHO International Clinical Trials Registry Platform 
(ICTRP; www.who.int/ictrp/network/primary/en/) under shared catalogue number NTR6831. 
All participants provided written informed consent to participate in the study and to have 
their information obtained from treating physicians. 
Acknowledgements 
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The EWAS data was funded by the Genetic Laboratory of the Department of Internal 
Medicine, Erasmus MC, and by the Netherlands Organization for Scientific Research (NWO; 
project number 184021007) and made available as a Rainbow Project (RP3; BIOS) of the 
Biobanking and Biomolecular Research Infrastructure Netherlands (BBMRI-NL). We thank 
Mr. Michael Verbiest, Ms. Mila Jhamai, Ms. Sarah Higgins, Mr. Marijn Verkerk, and Lisette 
Stolk PhD for their help in creating the methylation database.  
The Rotterdam Study is funded by Erasmus Medical Center and Erasmus University, 
Rotterdam, Netherlands Organization for the Health Research and Development (ZonMw), 
the Research Institute for Diseases in the Elderly (RIDE), the Ministry of Education, Culture 
and Science, the Ministry for Health, Welfare and Sports, the European Commission (DG 
XII), and the Municipality of Rotterdam. The authors are grateful to the study participants, 
the staff from the Rotterdam Study and the participating general practitioners and 
pharmacists. HHHA is supported by ZonMW grant number 916.19.151. 
 
The Study of Health in Pomerania TREND (SHIP-TREND) 
Study Description 
 The Study of Health in Pomerania (SHIP-Trend) is a longitudinal population-based 
cohort study in West Pomerania, a region in the northeast of Germany, assessing the 
prevalence and incidence of common population-relevant diseases and their risk factors. 
Baseline examinations for SHIP-Trend were carried out between 2008 and 2012, comprising 
4,420 participants aged 20 to 81 years. Study design and sampling methods were previously 
described.295 The medical ethics committee of the University of Greifswald approved the 
study protocol, and oral and written informed consents were obtained from each of the study 
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participants. DNA was extracted from blood samples of n=256 SHIP-Trend participants to 
assess DNA methylation using the Illumina HumanMethylationEPIC BeadChip array. 
Samples were randomly selected based on availability of multiple OMICS data, excluding 
type II diabetes, and enriched for prevalent MI. The samples were taken between 07:00 AM 
and 04:00 PM, and serum aliquots were prepared for immediate analysis and for storage at -
80 °C in the Integrated Research Biobank (Liconic, Liechtenstein). Processing of the DNA 
samples was performed at the Helmholtz Zentrum München. After exclusion of subjects who 
refused participation or who fulfilled exclusion criteria for MRI (e.g. cardiac pacemaker), 
2189 subjects from SHIP-Trend-0 underwent the MRI scanning. After exclusion of scans 
with technical artifacts, major structural abnormalities and stroke, full data sets with EWAS 
data and MRI scans were available in 214 subjects in SHIP-TREND. 
Ethic Statement 
 SHIP and SHIP TREND were approved by the local ethics committee. After 
complete description of the study to the subjects, written informed consent was obtained. The 
medical ethics committee of the University of Greifswald approved the study protocol. 
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the Social Ministry of the Federal State of Mecklenburg-West Pomerania, and the network 
‘Greifswald Approach to Individualized Medicine (GANI_MED)’ funded by the Federal 
Ministry of Education and Research (grant 03IS2061A). DNA methylation data have been 
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WMH measurements in each cohort 
Study MRI technology Scanning Protocol Image Processing  WMH quantification 
ADNI296–299 
1.5T (ADNI-1) 
and 3T (ADNI-2) 
MRI scanners 
from General 
Electric Medical 
Systems, Philips 
Medical Systems, 
or Siemens 
Medical 
Solutions 
A series of sagittal T1-weighted 
scans and axial proton-density/ 
T2- weighted fast spin echo 
scans. 
T1-, T2- and PD-weighted MRI 
scans were co-registered, and 
skull stripped, then corrected for 
bias field.  
ADNI-1: Brain images were reviewed by 
a neuroradiologist to exclude infarcts and 
other abnormalities and graded by a 
trained individual. ADNI-2: the 
FreeSurfer software package version 4.3 
and 5.1 (http://surfer.nmr. 
mgh.harvard.edu/) by the Schuff and 
Tosun laboratory at the University of 
California-San Francisco 
ADNI-1: WMH was quantified based on T1-, T2- and PD- 
intensities, the prior probability of WMH, and the probability 
of WMH conditioned on the presence of WMH at neighboring 
voxels. 
ADNI-2: WMH was measured with a Bayesian approach 
using segmentation of high resolution 3D T1 and FLAIR 
sequences. 
ARIC300 
1.5-Tesla 
scanners (General 
Electric Medical 
Systems or Picker 
Medical Systems) 
A series of sagittal T1-weighted 
scans and axial proton-density, 
T2- weighted and T1-weighted 
scans with 5 mm thickness and 
no interslice gaps.  
Images were interpreted directly from a 
PDS-4 digital workstation consisting of 
four 1024 X 1024-pixel monitors capable 
of displaying all 96 images 
simultaneously.  
WMHs were estimated as the relative total volume of 
periventricular and subcortical WM signal abnormality on 
proton density– weighted axial images by visual comparison 
with eight templates that successively increased from barely 
detectable WM changes (Grade 1) to extensive, confluent 
changes (Grade 8). Individuals with no WM changes received 
Grade 0, and those with changes worse than Grade 8 received 
Grade 9.  
CARDIA301 
3T scanners 
(Siemens Medical 
Solutions and 
Philips Medical 
Systems) 
A sequence of sagittal 3DT2 
with slice thickness 1 mm; 
sagittal 3D FLAIR with slice 
thickness 1 mm; and sagittal 3D 
MPRAGE with slice thickness 
1mm. 
Structural MR images were processed 
using previously described methods that 
were based on an automated multispectral 
computer algorithm.  
We classified all supratentorial brain tissue into GM, WM, and 
CSF. GM and WM were characterized as normal and 
abnormal (ischemic). 
CHS300 
General Electric 
or Picker 1.5-
Tesla scanners 
and Toshiba 0.35-
Tesla scanner 
A series of sagittal T1-weighted 
scans and axial PD, T2- weighted 
and T1-weighted scans with 5 
mm thickness and no interslice 
gaps.  
Images were interpreted directly from a 
PDS-4 digital workstation consisting of 
four 1024 X 1024-pixel monitors capable 
of displaying all 96 images 
simultaneously.  
WMHs were estimated as the relative total volume of 
periventricular and subcortical WM signal abnormality on 
proton density– weighted axial images by visual comparison 
with eight templates that successively increased from barely 
detectable WM changes (Grade 1) to extensive, confluent 
changes (Grade 8). Individuals with no WM changes received 
Grade 0, and those with changes worse than Grade 8 received 
Grade 9.  
FHS 
1 or 1.5 T 
Siemens 
Magnetom 
scanner 
Offspring cohort: 3D T1 and 
double echo proton density (PD) 
and T2 DSE coronal images 
were acquired in 4-mm 
contiguous slices  
3rd Generation cohort: FLAIR  
Analyzed with QUANTA 6.2 at the 
University of California–Davis Medical 
Center. Images were analyzed and 
interpreted blind to subject data and in 
random order. Semi-automated analysis 
of pixel distributions, based on 
For segmentation of WMH from other brain tissues the first 
and second echo images from T2 sequences were summed and 
a lognormal distribution was fitted to the summed data (after 
removal of CSF and correction of image intensity non-
uniformities). A segmentation threshold for WMH was 
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mathematical modeling of MRI pixel 
intensity histograms for CSF, WM, and 
GM, were used to determine the optimal 
threshold of pixel intensity to best 
distinguish CSF from brain matter based 
on previously published methods. The 
intracranial vault above the tentorium was 
outlined manually to determine the TIV.  
determined as 3.5 standard deviations in pixel intensity above 
the mean of the fitted distribution of brain parenchyma.  
GENOA302 
1.5 T MRI 
scanner from 
General Electric 
Medical Systems 
FLAIR images consisting of 48 
contiguous 3-mm interleaved 
slices with no interslice gap. 
Total intracranial volume (head 
size) was measured from T1-
weighted spin echo sagittal 
images, each set consisting of 32 
contiguous 5 mm thick slices 
with no interslice gap. 
A fully automated algorithm was used to 
segment each slice of the edited multi-
slice FLAIR sequence into voxels 
assigned to one of three categories: brain, 
CSF, or leukoaraiosis. 
Interactive imaging processing steps were performed by a 
research associate who had no knowledge of the subjects’ 
personal or medical histories or biological relationships. Total 
leukoaraiosis volumes were determined from axial FLAIR 
images. 
LBC1936288 
1.5 T HDx MRI 
scanner from 
General Electric 
Medical Systems 
T1-w coronal and T2-W, FLAIR, 
and T2*-weighted axial whole 
brain images  
A semi-automatic computational program 
written specifically for the project, 
MCMxxxVI, a multispectral color fusion 
method that combines different pairs of 
sequences in red-green color space and 
performs minimum variance quantization 
to highlight different tissues.  
WMH were measured in the cerebral hemispheres, cerebellum 
and brainstem. Intracranial volume, brain and WMH volume 
were extracted and manually corrected as necessary to remove 
false positive lesions in the insular cortex, cingulate gyrus, 
anterior temporal cortex and around the floor of the third 
ventricle, and correct false negatives 
(http://www.bric.ed.ac.uk/research/imageanalysis.html). All 
focal stroke lesions were manually removed. 
RSIII and  
RSI-III 
(BBMRI)293,303 
1.5 T scanner 
(GE Signa 
Excite) using an 
8-channel head 
coil 
Structural imaging is performed 
with T1-weighted (T1w), proton 
density-weighted (PDw) and 
fluid-attenuated inversion 
recovery (FLAIR) sequences. 
The combination of different MR 
contrasts provided by acquired sequences 
can be used for automated brain tissue 
and white matter lesion segmentation. For 
this purpose, the T1w scan is acquired in 
3D at high in-plane resolution and with 
thin slices (voxel size <1 mm3). 
WMH volume was quantified using two fully automated 
methods, which was described previously in more detail. 
Either the HASTE, PD and T2 sequences were used, or the 
FLAIR, T1 and PD sequences. Briefly, cerebrospinal fluid 
(CSF), gray matter (GM) and white matter (WM) are 
segmented by an atlas-based k-nearest neighbor classifier on 
multi-modal magnetic resonance imaging data. This classifier 
is trained by registering brain atlases to the subject. The 
resulting GM segmentation is used to automatically find a 
WMH threshold in a fluid-attenuated inversion recovery scan. 
SHIP-
TREND304 
1.5-T MR imager 
from Siemens 
Medical systems 
A series of T1, MP-RAGE/ axial 
plane with the resolution of 1.0 x 
1.0 x 1.0mm3 and T2 FLAIR / 
axial plane with the resolution of 
0.9 x 0.9 x 3.0mm3. 
The FreeSurfer 5.1.0 software 
WMH quantification was based on the following sequences: 
T1, MP-RAGE/ axial plane, TR=1900 ms, TE=3.4 ms, Flip 
angle=15°, resolution of 1.0 x 1.0 x 1.0mm^3 and T2 FLAIR / 
axial plane, TR= 5000, TE= 325, voxel= 0,9 x 0,9 x 3,0. 
Abbreviations: Double spin echo (DSE). Fluid-attenuated inversion recovery (FLAIR). Proton-density (PD). Cerebrospinal fluid (CSF). White matter (WM). Grey matter 
(GM). Total (intra)cranial volume (TIV/TCV) 
99 
 
DNA methylation data collection and association study in each cohort 
  Technology 
Tissue 
source 
Normaliz-
ation 
QC methods  
Experimental/ 
Biological covariates  
Covariate Assessment 
Technical 
Covariate
s 
Methods of 
Adjustment for 
Covariates 
ADNI 
Illumina 
850K 
Whole 
blood 
BMIQ 
removed probes with  
- a low detection rate (P>0.01 for 
>5% of samples)  
removed samples with  
- low call rate (P<0.01 for <95% 
of probes) 
Model 1: ICV, age, sex, 
WBC, study site, visit, 
time between MRI and 
DNAm visits, early 
MCI status, population 
structure (surrogates); 
Model 2: + Smoking, 
BMI SBP, DBP  
- Smoking status was coded as 
“Yes” or “No”.  
- Systolic and diastolic blood 
pressure was measured at the 
MRI visit. 
chip ID, 
chip 
Position 
Linear mixed 
models of 
DNAm~WMH 
burden adjusted for 
biological and 
technical covariates. 
Technical covariates 
as random effects. 
ARIC305 
Illumina 
450K 
Blood 
leukocytes 
BMIQ 
removed probes with  
- a low detection rate (P>0.01 for 
>5% of samples)  
removed samples with  
- low call rate (P<0.01 for <99% 
of probes) 
In each ancestry, 
Model 1: age, sex, 
WBC, technical 
covariates, population 
structure (surrogates); 
Model 2: + Smoking, 
BMI, SBP, DBP 
- Smoking was obtained at either 
exam 2 or 3 using an interviewer-
administered questionnaire and 
was classified as current, former, 
or never.  
- Blood pressure was assessed at 
exam 2 and 3, the average value 
of two visit was used in this 
study. 
Chip ID, 
Chip Row, 
plate  
Linear mixed 
models of 
DNAm~WMH 
burden adjusted for 
biological and 
technical covariates. 
Technical covariates 
as random effects. 
CARDIA 
Illumina 
850K 
Whole 
blood 
RCP 
- excluded 6,209 CpGs with a 
detection rate <95%  
- excluded 87 samples with the 
percentage of low-quality 
methylation measurements >5%  
- extremely low intensity of 
bisulfite conversion probes (less 
than mean intensity – 3 × 
standard deviation of the 
intensity across samples). 
Model 1: age, sex, race, 
WBC, technical 
covariates, population 
structure (surrogates); 
Model 2: + Smoking, 
BMI, SBP, DBP 
- Smoking status was coded as 
“never”, “ex-smoker”, and 
“current smoker” based on a self-
administered questionnaire.  
- Systolic and diastolic blood 
pressure in mmHg measured at 
the same examination as the 
DNA sampling.  
chip ID, 
chip 
position 
Linear mixed 
models of 
DNAm~WMH 
burden adjusted for 
biological and 
technical covariates. 
Technical covariates 
as random effects. 
CHS 
Illumina 
450K 
Blood 
leukocytes 
SWAN 
excluded samples with 
- a proportion of probes falling 
detection of greater than 0.5% 
- low median intensities of below 
10.5 (log2) across the methylated 
and unmethylated channels 
- QC probes falling greater than 
3 standard deviation from the 
Model 1:age, sex, 4 
genetic PCs, batch, 
WBC estimates, race, 
technical covariates 
Model 2:Model 1 + 
Smoking, BMI , SBP, 
DBP 
- Smoking was assessed with a 
standard questionnaire during in-
person interview at the time of 
blood assessment for methylation. 
Smoking status was categorized 
into never, former or current 
smoker.  
- Systolic and diastolic blood 
chip ID, 
chip 
position 
Linear mixed 
models of 
DNAm~WMH 
burden adjusted for 
biological and 
technical covariates. 
Technical covariates 
as random effects. 
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mean 
- with sex-check mismatches 
- failed concordance with prior 
genotyping or > 0.5% of probes 
with a detection p-value > 0.01  
pressure in mmHg measured at 
the same examination as the 
DNA sampling.  
FHS 
Illumina 
450K 
Whole 
blood 
DASEN  
(wateRmel
on) 
Samples were excluded if  
- outliers in multidimensional 
scaling (MDS) analysis, high 
missing rate (>1%), poor 
matching to SNP genotype 
Probes were excluded if 
- high missing rate (>20%), 
mapped to multiple locations, 
had SNP (MAF>5% in EUR 
1000G) at CpG site or ≤10 bp of 
Single Base Extension. 
Model 1: age, sex, 
WBC, technical 
covariates, population 
structure (surrogates); 
Model 2: + Smoking, 
BMI 
- Current smoking is defined as 
regularly smoking in the past year 
which was self-reported at each 
examination. Using examination 
8 and previous examination data, 
participants were classified as 
current smoker, ex-smoker, never 
smoker. 
chip ID, 
chip 
position 
Linear mixed 
models of 
DNAm~WMH 
burden adjusted for 
biological and 
technical covariates. 
Family structure is 
also adjusted. 
GENOA Illumina 27K 
Blood 
leukocytes 
SWAN 
- Remove probe if >5% of 
samples have a detection p-value 
of >0.01; 
- Remove sample if >5% of 
probes have a detection p-value 
of >0.01; 
Model 1: age, sex, total 
intracranial volume, 4 
genetic PCs, WBC, 
technical covariates, 
familial relationship; 
Model 2: + smoking, 
BMI, SBP, DBP 
- Smoking status: current smoker 
(smokes currently or quit 
smoking within the past year), ex-
smoker (formerly smoked, but 
quit more than 1 year ago), and 
never-smoker (smoked less than 
100 cigarettes in his/her entire 
life).  
- Blood Pressure: sitting systolic 
and diastolic blood pressure in 
mmHg were measured three 
times with a random zero 
sphygmomanometer. The average 
of the last two measurement was 
used. 
plate, row, 
column 
Linear mixed 
models of 
DNAm~WMH 
burden adjusted for 
biological and 
technical covariates. 
Technical covariates 
and familial 
relationship were 
treated as random 
effects. 
LBC193
6306 
Illumina 
450K 
Whole 
blood 
minfi 
Remove probes with  
- a low detection rate (P>0.01 for 
>5% of samples) - low quality 
(manual inspection) 
Remove samples with  
- low call rate (P<0.01 for <95% 
of probes) 
- a poor match between 
genotypes and SNP control 
probes 
- incorrect predicted sex. 
Model 1: age + Sex + 
ICV+ 4 genetic PCs + 
WBC + technical 
covariates, Model 2: 
BMI + current smoking 
+ dbp3sit + sbp3sit + 
age + Sex + ICV+ 4 
genetic PCs + WBC + 
technical covariates 
- Smoking status was self-
reported in three categories: 
current smoker, ex-smoker, never 
smoker.  
- Blood Pressure: dbp3sit + 
sbp3sit (3rd reading)  
Chip, 
position, 
sample 
plate, 
hybridizati
on date 
Linear mixed 
models of 
DNAm~WMH 
burden adjusted for 
biological and 
technical covariates. 
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RSIII 
and 
RSI-III 
(BBMRI)
Illumina 
450K 
Whole 
blood 
DASEN  
(wateRmel
on) 
- Excluded samples with 
incomplete bisulfite treatment, a 
low detection rate (<99%), or 
gender mismatches. 
- Excluded probes with a 
detection p-value>0.01 in >1% 
samples 
Model 1: ICV, age, sex, 
array number, array 
position, WBC counts. 
Model 2: model 1 + 
smoking, BMI, SBP, 
DBP 
- Smoking status: Smoking status 
was coded as self-reported “never 
smoker”, “ever smoker”, and 
“current smoker” based on a 
home interview. 
- Blood Pressure: Blood pressure 
was measured twice at the center 
visit, and the average of the two 
measurements was used. 
Array 
number, 
array 
position. 
Linear mixed 
models of 
DNAm~WMH 
burden adjusted for 
biological and 
technical covariates. 
Technical covariates 
as random effects. 
SHIP-
TREND 
Illumina 
850K 
Whole 
blood 
CPACOR 
- probes with detection p-
value≥1E-16 were set to missing 
- arrays with call rates ≤0.95 
were excluded 
- arrays with observed technical 
problems during steps like 
bisulfite conversion, 
hybridization or extension, as 
well as arrays with mismatch 
between sex of the proband and 
sex determined by the chr X and 
Y probe intensities were 
excluded. 
Model 1: ICV, age, sex, 
WBC subtypes, 6 
genetic PCs, technical 
covariates; 
Model 2: + smoking, 
BMI, SBP, DBP  
- Smoking status: current smoker 
determined by questionnaire 
- Blood Pressure: measured 
(mean of 2nd and 3rd 
measurement) 
control 
probe  
linear regression 
adjusted for all 
covariates listed 
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Gene expression data description 
Study Technology Tissue source Normalization 
GEO accession 
ID 
FHS307 
Affymetrix Human Exon 
Array ST 1.0 
Whole blood  
The raw data were quantile-normalized and log2 
transformed, followed by summarization using Robust 
Multi-array Average. The percentages of each imputed 
cell type were then normalized, where the negative 
predicted values were set to 0 and the sum of the 
percentages for all cell types were set 100%.    
RS308,309 
Illumina HumanHT12v4 
Expression Beadchip 
Whole blood  
Quantile-normalized to the median distribution and 
subsequently log2-transformed. The probe and sample 
means were centered to zero and Z-transformed. 
GSE33828 
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Appendix B. Supplemental Figures 
 
Figure S 1 Manhattan Plots of genome-wide WMH burden associations at each 
DNA methylation (DNAm) site in the trans-ethnic meta-analyses. The DNAm 
locations are plotted against the –log10(p value). The red line indicates the Bonferroni 
threshold (1 x 10-7) for epigenome-wide significance. The blue line marks the putative 
threshold (1 x 10-6).
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Figure S 2 QQ plots for observed vs expected –log10 (P value) at each DNAm site in 
the trans-ethnic meta-analyses.
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Figure S 3 Spearman correlation among DNA methylation probes associated with 
WMH burden in ARIC subjects of European ancestry (ARIC-EA) and of African 
ancestry (ARIC-AA). The color scale corresponds to strength of correlation, where 
inverse correlations are blue and direct correlations are red. 
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To be continued 
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Figure S 4 DNase I hypersensitivity signal around EWAS probes 
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Figure S 5 Regional Plot of cg06809326 
 
109 
 
AA EA 
cg02741985 
 
cg03116124 
 
cg04245766 
 
 
 
To be continued 
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To be continued 
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To be continued 
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Figure S 6 Manhattan plots of mQTLs for 11 target probes
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Appendix C. Supplemental Tables 
Table S 1 Descriptive statistics of participating cohorts 
Study #Markers Ancestry No. GI (λ) Female Age BMI  HT Smoking 
WMH 
burden  
ADNI 864,460 EA 387 
0.98/ 
0.99 
187 (48.3%) 74.1±7.0 27.2±4.7 274 (70.8%) 158 (40.8%) 
1.29 
[0.58,2.01] 
ARIC 483,526 
EA 906 
1.00/ 
1.00 
519 (57.3%) 63.1±4.4 26.4±4.6 306 (33.8%) 162 (17.9%) 
0.69 
[0.69,1.10] 
AA 639 
0.97/ 
0.99 
413 (64.8%) 61.8±4.5 29.6±5.4 412 (64.5%) 127 (19.9%) 
0.69 
[0.69,1.10] 
BBMRI 419,938 EA 
442/ 
404 
1.04/ 
1.06 
255 (57.7%) 64.7±5.8 27.4±3.9 
279 (63.1%)/ 
269 (66.6%) 
63 (14.2%) 
1.40 
[1.03,1.92] 
CARDIA 860,628 Pooled 194 
0.71/ 
0.73 
88 (45.4%) 50.2±3.5 28.8±5.3 42 (21.6%) 27 (13.9%) 
0.18 
[0.10,0.41] 
CHS 483,624 Pooled 378 
1.33/ 
1.30 
153 (40.5%) 74.6±5.4 27.5±5.0 240 (63.5%) 49 (13.0%) 
1.10 [0.69-
1.38] 
FHS 
Offspring 
FLAIR 
443,314 EA 
1,323/ 
1,320 
0.96/ 
0.99 
711 (53.7%) 66.9±8.7 28.0±5.0 
764 (57.7%)/ 
761 (57.7%) 
101 (7.6%) 
1.18 
[0.79,1.69] 
DSE 
403/ 
399 
0.98/ 
1.01 
230 (57.1%) 60.6±9.6 28.1±5.7 
186 (46.2%)/ 
185 (46.4%) 
61 (15.1%) 
0.46 
[0.28,0.79] 
GENOA 26,449 AA 
356/ 
355 
0.85/ 
0.83 
259 (72.8%) 66.3±7.19 31.0±5.98 
291 (81.7%)/ 
290 (85.4%) 
50 (14.0%) 
2.10 [1.81, 
2.56] 
LBC1936 450,727 EA 230 
1.23/ 
1.23 
107 (46.5%) 72.1±.52 27.7±4.51 190 (82.6%) 13 (5.6%) 
2.04 [1.33, 
2.76] 
RS3 474,529 EA 
547/ 
163 
1.31/ 
1.19 
291 (53.2%) 62.6±7.3 27.2±4.1 
229 (41.9%)/ 
95 (58.3%) 
113 (20.7%) 
1.34 
[0.97,1.77] 
SHIP-TREND 865,860 EA 214 
1.23/ 
1.20 
117 (54.7%) 49.7±13.3 27.2±4.1 84 (39.3%) 42 (19.6%) 
0.74 
[0.59,0.93] 
#Markers: number of markers. No.: Number of subjects in model1 (reduced) /model2 (full). GI: genomic inflation factor in model1 (reduced) /model2 (full). 
Female: number of female subjects, %. Age: mean± standard deviation (s.d.) in years. BMI: mean and s.d. of body mass index, kg/m2. HT: hypertensive 
subjects, number (%) in model1 (reduced) /model2 (full). Smoking: current smoker, number (%). WMH burden: median and the IQR (interquartile range; 
Q1-Q3) of log(WMH+1). 
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Table S 2 Coefficient point estimates and P values for 11 target probes in the meta-
analyses among hypertensive and normotensive individuals 
 HT NT 
 Z score (S.E.) N Z score (S.E.) N 
Reduced model 
cg03116124 -2.83(0.005) 2,816 -3.009(0.003) 2,599 
cg24202936 3.18(0.001) 3,006 2.866(0.004) 2,599 
cg17577122 3.46(0.0005) 3,006 3.319(0.0009) 2,599 
cg06809326 3.34(0.0009) 3,006 3.289(0.001) 2,599 
cg04245766 1.09(0.276) 798 -2.21(0.027) 587 
cg06450373 0.61(0.543) 2,727 -5.102(3.36E-07) 2,437 
cg18950108 -1.66(0.097) 3,006 -5.059(4.22E-07) 2,599 
cg07675682 -0.49(0.627) 3,296 -3.664(0.0002) 2,664 
cg10051414 -0.27(0.789) 2,606 3.648(0.0003) 2,204 
cg25317585 5.20(2.05E-07) 3,006 1.061(0.289) 2,599 
cg02741985 2.09(0.037) 3,006 0.019(0.985) 2,599 
Full model 
cg03116124 -2.71(0.007) 2,668 -3.141(0.002) 2,321 
cg24202936 2.96(0.003) 2,858 1.971(0.049) 2,321 
cg17577122 3.64(0.0003) 2,858 3.967(7.28E-05) 2,321 
cg06809326 3.31(0.0009) 2,858 2.615(0.009) 2,321 
cg04245766 0.82(0.410) 798 -2.319(0.020) 587 
cg06450373 0.53(0.598) 2,589 -4.623(3.78E-06) 2,186 
cg18950108 -2.11(0.035) 2,858 -4.421(9.81E-06) 2,321 
cg07675682 -0.49(0.624) 3,147 -4.095(4.22E-05) 2,386 
cg10051414 -0.56(0.574) 2,458 3.853(0.0001) 1,926 
cg25317585 5.14(2.76E-07) 2,858 0.185(0.853) 2,321 
cg02741985 2.13(0.034) 2,858 -0.186(0.852) 2,321 
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Table S 3 Top DMRs identified from race-specific analysis 
Chr start end Pmin Size PComb-p PSidak Gene 
EA 
Model 1 
19 50191341 50191882 2.68E-08 6 9.46E-14 8.29E-11 PRMT1 
17 20799407 20799769 7.60E-08 10 1.68E-12 2.19E-09 CCDC144NL-AS1 
12 122018896 122019117 4.47E-05 7 3.12E-09 6.68E-06 KDM2B 
3 
193272560 193272869 2.11E-03 4 2.95E-07 4.53E-04 
ATP13A4 
;ATP13A4-AS1 
5 140515674 140515961 0.006 3 3.99E-07 6.59E-04 PCDHB5 
16 89894097 89894329 0.003 3 5.54E-07 0.001 SPIRE2 
10 105428384 105428818 0.008 5 1.94E-06 0.002 SH3PXD2A 
13 46757317 46757415 0.008 3 2.14E-06 0.010 LCP1 
8 144451642 144451924 0.013 3 6.14E-06 0.010 RHPN1 
11 130185383 130185670 0.019 3 6.34E-06 0.010 ZBTB44 
1 209921095 209921370 1.26E-02 4 7.48E-06 1.28E-02 LOC101930114 
9 116861287 116861532 3.15E-02 4 1.20E-05 0.023 KIF12 
17 78800573 78800806 0.032 4 1.25E-05 0.025 RPTOR 
Model 2 
6 30039129 30039600 3.03E-07 21 1.39E-11 1.40E-08 RNF39 
19 50191341 50191882 1.44E-06 6 5.42E-11 4.75E-08 PRMT1 
2 3704500 3704793 3.25E-06 6 1.65E-10 2.66E-07 ALLC 
12 122018896 122019117 4.10E-05 7 6.45E-09 1.38E-05 KDM2B 
6 28973317 28973497 4.23E-05 9 1.09E-07 0.0003 ZNF311 
18 23713728 23714084 0.001 6 7.31E-07 0.001 PSMA8 
10 105428384 105428818 3.61E-03 5 1.04E-06 0.001 SH3PXD2A 
16 89894097 89894329 6.69E-03 3 2.08E-06 0.004 SPIRE2 
1 209921030 209921370 6.69E-03 5 2.16E-06 3.01E-03 LOC101930114 
13 46757317 46757415 0.010 3 3.22E-06 0.015 LCP1 
5 140305946 140306458 0.014 10 7.57E-06 6.98E-03 
PCDHA6;PCDHA12;
PCDHA9;PCDHA1; 
PCDHA2;PCDHA3; 
PCDHA4;PCDHA5; 
PCDHA10;PCDHA7;
PCDHA8;PCDHA11;
PCDHAC1;PCDHA13 
3 193272560 193272869 1.28E-02 4 9.52E-06 1.45E-02 
ATP13A4;ATP13A4-
AS1 
14 88621423 88621721 2.66E-02 5 1.42E-05 2.24E-02 KCNK10 
15 101093777 101093900 2.95E-02 3 1.67E-05 6.24E-02 PRKXP1 
8 144451642 144451924 1.01E-02 3 2.00E-05 3.31E-02 RHPN1 
AA 
Model 1 
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8 1765065 1765820 1.71E-07 13 4.11E-13 2.57E-10 MIR596 
6 32847197 32847845 1.71E-07 24 7.24E-11 5.27E-08 LOC100294145 
3 49170495 49171185 1.39E-06 9 9.19E-11 6.29E-08 LAMB2 
3 126911726 126911953 6.74E-05 4 7.56E-09 1.57E-05 C3orf56 
11 58869662 58870494 0.0002 6 3.49E-08 1.98E-05 FAM111B 
16 89118837 89119709 5.96E-04 7 1.14E-07 6.19E-05 ACSF3 
6 170732119 170732353 8.19E-04 3 1.54E-07 3.12E-04 FAM120B 
15 102501639 102501654 2.25E-03 3 6.09E-07 1.90E-02 WASH3P 
1 236557181 236557758 2.35E-03 5 6.75E-07 0.001 EDARADD 
10 131669405 131669630 0.003 3 8.08E-07 0.002 EBF3 
4 20985622 20985984 0.006 4 2.59E-06 0.003 KCNIP4 
13 100217961 100218552 3.63E-03 4 5.79E-06 4.62E-03 TM9SF2 
7 42533000 42533414 0.013 5 6.30E-06 0.007 LINC01448 
21 15352607 15352983 1.80E-03 7 7.39E-06 0.009 ANKRD20A11P 
19 49699495 49700427 0.029 2 9.05E-05 0.045 TRPM4 
Model 2 
6 32847209 32847845 3.50E-07 23 8.30E-12 6.16E-09 LOC100294145 
3 49170495 49171185 4.44E-07 9 1.32E-11 9.01E-09 LAMB2 
3 126911726 126911953 4.49E-06 4 3.23E-10 6.73E-07 C3orf56 
10 29697904 29698685 9.44E-07 10 8.62E-10 5.21E-07 SVIL-AS1 
8 1765295 1765477 7.26E-06 8 3.51E-09 9.11E-06 MIR596 
13 100217961 100218552 1.68E-06 4 4.85E-09 3.87E-06 TM9SF2 
6 170732119 170732353 1.75E-03 3 4.60E-07 9.28E-04 FAM120B 
10 131669405 131669630 0.003 3 9.25E-07 0.002 EBF3 
15 102501639 102501654 0.005 3 1.45E-06 0.045 WASH3P 
1 236557181 236557758 1.02E-02 5 3.65E-06 2.99E-03 EDARADD 
8 145008109 145008397 0.002 3 8.38E-06 0.01365 PLEC 
19 49223833 49224454 0.002 5 1.15E-05 0.009 RASIP1 
7 116786596 116786870 2.76E-02 3 1.57E-05 0.027 ST7 
5 150678161 150678334 2.77E-02 2 1.67E-05 4.45E-02 SLC36A3 
13 113633378 113634042 0.014 8 2.00E-05 0.014 MCF2L 
2 114341630 114342108 1.23E-02 3 2.31E-05 2.25E-02 WASH2P 
17 37893802 37894636 0.028 6 5.74E-05 0.032 GRB7 
Pmin: the minimum P value in the DMR. Size: Number of methylation probes in the DMR. 
PComb-p: combined Z-score based on Comb_P. PSidak: Sidak multiple-testing corrected P value 
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Table S 4 Top DMRs from gene-based analysis in hypertensive subjects 
Chr start end Pmin Size PComb-p PSidak Gene 
Model 1 
8 99984349 99985049 6.11E-3 5 1.16E-06 7.85E-04 OSR2 
3 193272560 193273057 1.23E-2 5 2.57E-06 2.45E-03 
ATP13A4;ATP13A4-
AS1 
22 45680497 45681036 1.86E-2 12 6.30E-06 0.00552 UPK3A 
2 210074019 210074359 3.67E-2 3 1.70E-05 2.34E-02 MAP2 
12 125225315 125225808 0.048 3 2.74E-05 0.02598 SCARB1 
Model 2 
18 13611369 13611824 2.94E-5 7 5.57E-10 5.81E-07 LDLRAD4 
19 50191341 50191882 1.03E-3 6 1.25E-09 1.09E-06 PRMT1 
9 96623031 96623674 0.00136 4 7.50E-08 5.53E-05 MIR4291 
8 99984349 99985049 1.12E-2 5 4.64E-06 3.14E-03 OSR2 
12 4918390 4918848 1.71E-5 2 9.46E-06 9.74E-03 KCNA6 
3 193272560 193273057 3.29E-2 5 1.15E-05 1.09E-02 
ATP13A4;ATP13A4-
AS1 
20 13200684 13201551 1.80E-2 13 4.97E-05 2.68E-02 ISM1 
Pmin: the minimum P value in the DMR. Size: Number of methylation probes in the DMR. 
PComb-p: combined Z-score based on Comb_P. PSidak: Sidak multiple-testing corrected P value 
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Table S 5 Top DMRs from race-specific analysis in hypertensive subjects 
Chr start end Pmin Size PComb-p PSidak Gene 
EA 
 Model 1 
 6 31691226 31692375 3.55E-8 29 1.04E-10 4.28E-8 MPIG6B 
 7 95025406 95026248 2.44E-4 21 1.50E-8 8.42E-6 PON3 
 19 843540 843995 2.13E-5 4 5.24E-8 5.45E-5 PRTN3 
 3 193272560 193273057 2.47E-3 5 2.89E-7 2.76E-4 ATP13A4;ATP13A4-AS1 
 15 93580021 93580327 0.002 5 3.65E-7 5.64E-4 RGMA 
 18 23713594 23714084 1.38E-2 9 4.15E-6 4.01E-3 PSMA8 
 1 209979282 209979779 2.94E-2 12 1.38E-5 1.31E-2  
 5 176755198 176755805 0.040 5 2.26E-5 1.75E-2 LMAN2 
 9 96623031 96623480 0.014 3 2.91E-5 3.03E-2 MIR4291 
 17 41924042 41924577 3.59E-2 11 2.97E-5 2.60E-2 CD300LG 
 Model 2 
 1 42384389 42384564 1.28E-5 3 3.39E-8 9.17E-5 HIVEP3 
 20 36148619 36149271 0.001 29 9.79E-8 7.11E-5 BLCAP 
 7 95025735 95026211 8.18E-4 18 2.48E-7 2.47E-4 PON3 
 16 979487 979662 0.002 3 3.60E-7 9.75E-4 LMF1;LMF1-AS1 
 18 77545027 77545223 0.005 3 5.97E-7 1.44E-3 CTDP1 
 15 93580021 93580327 5.09E-3 5 7.73E-7 1.20E-3 RGMA 
 3 193272560 193272869 9.77E-3 4 1.69E-6 2.59E-3 ATP13A4;ATP13A4-AS1 
 10 104196242 104196541 0.015 3 3.29E-6 5.20E-3 MIR146B 
 2 210074019 210074276 3.76E-3 2 4.08E-6 7.50E-3 MAP2 
 1 209979469 209979779 1.38E-2 9 5.70E-6 8.67E-3 IRF6 
 6 168491617 168491686 2.30E-2 3 5.91E-6 3.98E-2 FRMD1 
 5 147699717 147699892 0.031 3 9.37E-6 2.50E-2 LOC102546294 
AA 
 Model 1 
 6 32118203 32119041 1.53E-6 17 7.51E-11 4.23E-8 PRRT1 
 17 80059407 80059540 0.0003 2 1.22E-8 4.33E-5 CCDC57 
 7 27183368 27184853 7.11E-4 43 1.93E-8 6.15E-6 HOXA-AS3 
 18 13611369 13611824 0.001 7 9.85E-8 1.02E-4 LDLRAD4 
 9 139715700 139716599 0.002 4 3.57E-7 1.88E-4 RABL6 
 5 150678161 150678334 0.004 2 9.82E-7 2.68E-3 SLC36A3 
 12 110156244 110156459 1.04E-2 5 3.21E-6 7.03E-3 FAM222A 
 19 49223833 49224454 1.62E-3 5 4.86E-6 3.69E-3 RASIP1 
 3 195489707 195490309 0.010 8 6.19E-6 4.84E-3 MUC4 
 8 145730817 145731409 7.40E-3 3 1.39E-5 1.11E-2 GPT 
 Model 2 
 5 23507029 23507752 8.01E-7 12 1.61E-11 1.05E-8 PRDM9 
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 7 1609340 1609908 1.76E-6 11 5.10E-10 4.24E-7 PSMG3;PSMG3-AS1 
 3 195489305 195490309 2.42E-5 9 1.79E-9 8.40E-7 MUC4 
 19 49223813 49224454 8.04E-5 6 6.19E-9 4.56E-6 RASIP1 
 18 13611369 13611824 8.04E- 7 7.48E-9 7.76E-6 LDLRAD4 
 5 150678161 150678334 0.002 2 3.37E-7 9.19E-4 SLC36A3 
 14 100203941 100204528 0.005 7 8.87E-7 7.14E-4 CYP46A1 
 11 123430574 123431162 2.03E-2 5 6.69E-6 5.36E-3 GRAMD1B 
 12 110156244 110156459 0.030 5 1.23E-5 2.67E-2 FAM222A 
 9 139716025 139716599 0.016 3 1.40E-5 1.14E-2 RABL6 
 16 87736669 87737091 0.015 4 3.43E-5 3.76E-2 KLHDC4 
 
Pmin: the minimum P value in the DMR. Size: Number of methylation probes in the DMR. 
PComb-p: combined Z-score based on Comb_P. PSidak: Sidak multiple-testing corrected P value 
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Table S 6 Top DMRs from gene-based analysis in normotensive subjects 
 
 
 
 
Chr start end Pmin Size PComb-p PSidak Gene 
Model 1 
20 62693942 62694005 1.39E-08 6 4.93E-13 3.71E-09 TCEA2 
2 27665016 27665306 3.04E-09 7 4.73E-12 7.73E-09 NRBP1;KRTCAP3 
17 37123637 37123949 2.10E-05 9 9.75E-10 1.48E-06 FBXO47 
3 195576389 195578280 9.28E-03 8 1.06E-09 2.66E-07 LINC01983 
12 122018896 122019117 0.000243 7 1.44E-08 3.08E-05 KDM2B 
1 84326461 84326856 2.80E-04 8 5.04E-08 6.04E-05 LINC01725 
22 42828124 42828418 0.006238 5 1.61E-06 0.002586 NFAM1 
11 89956516 89956777 9.21E-04 7 1.97E-06 3.57E-03 CHORDC1 
16 57728631 57728700 0.008 2 2.33E-06 0.01584 DRC7 
2 198650008 198651076 9.65E-04 2 2.59E-06 1.15E-03 BOLL 
10 133946673 133946881 0.031 3 1.35E-05 0.0303 JAKMIP3 
7 150498593 150498843 0.002 2 1.40E-05 2.62E-02 TMEM176A 
19 57742216 57742444 0.014 8 1.43E-05 0.02918 AURKC 
Model 2 
20 62693656 62694005 4.63E-13 7 2.82E-18 3.83E-15 TCEA2 
3 195576389 195578280 3.92E-03 8 9.27E-11 2.32E-08 LINC01983 
15 39871807 39872071 1.13E-06 6 3.34E-10 6.00E-07 THBS1 
6 74072241 74072447 1.43E-05 7 6.03E-10 1.39E-06 KHDC3L 
17 37123637 37123949 2.15E-05 9 1.40E-09 2.13E-06 FBXO47 
16 8806530 8807043 8.69E-05 12 1.11E-08 1.02E-05 ABAT 
8 142233381 142233705 1.94E-03 5 5.82E-07 8.51E-04 SLC45A4 
22 42828124 42828516 6.57E-05 7 6.17E-07 0.000746 NFAM1 
19 10736005 10736355 0.005097 7 9.67E-07 0.001308 SLC44A2 
10 4230412 4230752 0.006747 6 1.40E-06 0.001948 LINC00702 
11 89956572 89956777 4.49E-03 6 2.32E-06 5.34E-03 CHORDC1 
4 165877874 165878317 2.26E-03 8 3.13E-06 3.34E-03 FAM218A;TRIM61 
7 158280409 158280480 0.0143 2 4.23E-06 0.02781 PTPRN2 
1 206785999 206786222 1.77E-02 6 5.58E-06 1.18E-02 EIF2D 
13 44716512 44716778 0.01952 2 6.36E-06 1.13E-02 
LINC00390;SMIM2-
AS1; 
SMIM2-AS1 
12 108168823 108169020 0.01409 3 9.70E-06 0.02305 ASCL4 
Pmin: the minimum P value in the DMR. Size: Number of methylation probes in the DMR. 
PComb-p: combined Z-score based on Comb_P. PSidak: Sidak multiple-testing corrected P value 
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Table S 7 Top DMRs from race-specific gene-based analysis in normotensive 
subjects 
Chr start end Pmin Size PComb-p PSidak Gene 
EA 
 Model 1 
 
17 20799407 20799769 1.24E-09 10 3.01E-14 3.94E-11 
CCDC144NL-AS1; 
CCDC144NL 
 2 27665016 27665306 1.28E-09 7 4.31E-12 7.05E-09 NRBP1; KRTCAP3 
 17 37123637 37123949 1.53E-06 9 8.41E-11 1.28E-07 FBXO47 
 20 62693942 62694005 2.49E-06 6 2.19E-09 1.65E-05 TCEA2 
 12 122018769 122019117 2.31E-05 8 2.25E-09 3.06E-06 KDM2B 
 6 74072241 74072447 4.99E-05 7 5.47E-09 1.26E-05 KHDC3L 
 16 57728631 57728700 3.59E-04 2 4.77E-08 3.27E-04 DRC7 
 7 24323674 24323840 2.09E-05 6 3.68E-07 1.05E-03 NPY 
 11 66085249 66085299 5.39E-03 2 1.07E-06 1.01E-02 CD248 
 10 104535791 104536052 0.02529 8 1.04E-05 1.87E-02 WBP1L 
 Model 2 
 20 62693942 62694005 4.26E-09 6 4.13E-13 3.11E-09 TCEA2 
 17 37123637 37123949 1.04E-06 9 4.40E-11 6.69E-08 FBXO47 
 15 39871807 39872071 1.04E-06 6 2.15E-10 3.86E-07 THBS1 
 6 74072241 74072447 4.39E-06 7 2.87E-10 6.61E-07 KHDC3L 
 17 17110119 17110353 2.35E-06 5 1.64E-09 3.31E-06 PLD6 
 8 144120334 144120706 5.88E-04 7 6.10E-07 7.77E-04 C8orf31 
 2 241497411 241497663 5.32E-03 7 1.10E-06 2.07E-03 ANKMY1 
 22 42828124 42828418 0.007968 5 2.12E-06 0.00341 NFAM1 
 7 158280409 158280480 9.85E-03 2 2.83E-06 1.87E-02 PTPRN2 
 11 66085249 66085299 1.10E-02 2 3.23E-06 3.02E-02 CD248 
 16 57728631 57728700 0.01098 2 3.45E-06 2.34E-02 DRC7 
 10 4230481 4230752 4.00E-02 5 2.84E-05 4.84E-02 LINC00702 
AA 
 Model 1 
 5 135414857 135416613 4.67E-25 20 1.15E-34 3.10E-32 VTRNA2-1 
 5 6755025 6755843 9.57E-21 8 4.39E-25 2.54E-22 PAPD7 
 11 6518107 6518907 1.03E-11 11 7.47E-16 4.59E-13 DNHD1 
 19 37825008 37825679 5.20E-08 8 8.18E-11 5.76E-08 HKR1 
 3 49170495 49171185 1.36E-06 9 3.00E-10 2.05E-07 LAMB2 
 16 56995200 56995856 7.71E-06 6 4.87E-09 3.51E-06 CETP 
 3 195576389 195578280 2.47E-02 8 7.79E-09 1.95E-06 LINC01983 
 7 24323260 24323799 3.27E-06 7 6.64E-08 5.82E-05 NPY 
 2 239139910 239140733 2.00E-04 15 9.66E-08 5.54E-05 LOC151174; LOC643387 
 19 58595667 58596261 0.001005 3 2.49E-07 0.000198 ZSCAN18 
 4 81118793 81119473 1.27E-03 7 7.53E-07 5.23E-04 PRDM8 
 17 79225572 79225974 0.00173 4 2.03E-06 0.002379 SLC38A10 
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 11 65315029 65315466 7.45E-06 4 2.13E-06 2.30E-03 LTBP3 
 13 113776872 113777160 2.52E-02 9 1.39E-05 2.25E-02 F10 
 12 132859440 132859951 0.04213 5 2.77E-05 2.53E-02 GALNT9 
 Model 2 
 5 135415128 135416613 2.54E-12 19 1.25E-18 3.98E-16 VTRNA2-1 
 6 32063393 32064212 5.43E-10 24 1.79E-14 1.04E-11 TNXB 
 5 6755025 6755439 4.95E-12 6 1.22E-13 1.39E-10 PAPD7 
 11 6518107 6518907 1.00E-08 11 9.34E-13 5.52E-10 DNHD1 
 1 45965448 45966115 9.51E-08 11 1.02E-11 7.22E-09 MMACHC; CCDC163 
 13 113776872 113777160 1.78E-07 9 2.34E-11 3.84E-08 F10 
 
2 
48844727 48845068 6.80E-07 8 1.07E-10 1.48E-07 
STON1-GTF2A1L; 
GTF2A1L 
 3 49170495 49171343 1.50E-04 10 4.17E-08 2.32E-05 LAMB2 
 2 239139517 239140733 3.21E-08 16 6.01E-08 2.33E-05 LOC151174; LOC643387 
 21 47717405 47718080 0.000997 5 3.69E-07 0.000258 YBEY 
 20 259897 259925 0.005748 2 2.85E-06 0.04691 C20orf96 
 4 74718977 74719597 6.25E-03 6 3.28E-06 2.50E-03 PF4V1 
 10 135341869 135342936 0.01292 6 1.03E-05 0.004552 CYP2E1 
 6 149777805 149778058 0.01522 3 1.09E-05 0.02007 ZC3H12D 
 11 116699588 116700049 1.25E-02 3 1.87E-05 1.90E-02 APOC3 
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Table S 8 DNA features and regulatory elements at target DNAm loci 
ProbeID Chr Pos Score BP Relevant Tissue* 
cg03116124 1 231293208 5   
cg24202936 11 50257256 5   
cg17577122 22 19511967 2b POLR2A umbilical vein endothelial cells 
cg06809326 17 20799526 2b CTCF 
umbilical vein endothelial cells, 
brain microvascular endothelial 
cells, glioblastoma cells  
cg04245766 14 54421051 4 POLR2A umbilical vein endothelial cells 
cg06450373 5 19766434 6   
cg18950108 6 30920171 5   
cg07675682 17 78195515 5   
cg10051414 22 38598733 2b 
POLR2A umbilical vein endothelial cells 
MAX umbilical vein endothelial cells 
CTCF 
umbilical vein endothelial cells, 
brain microvascular endothelial 
cells 
REST glioblastoma/ astrocytoma 
cg25317585 13 102568886 4 
EZH2 astrocytes 
CTCF 
umbilical vein endothelial cells, 
brain microvascular endothelial 
cells, glioblastoma cells, 
neuroblastoma cells 
RAD21 neuroblastoma cells 
REST glioblastoma/ astrocytoma cells 
YY1 neuroblastoma cells 
cg02741985 17 80059408 4 REST neuroblastoma cells 
Chr: Chromosome. Pos: Position. BP: Binding Protein. *Endothelial cells and brain 
tissues were reviewed. 
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Table S 9 Transcription factors enriched in the fetal brain tissue - eFORGE 
ProbeID Motif Name Binding Site Database P value Q value 
cg06450373 ONECUT1_CUT_1 5:19766428-19766442:- Taipale/SELEX 1.75E-07 4.65E-06 
ONECUT1_CUT_2 5:19766428-19766442:- Taipale/SELEX 2.05E-07 4.65E-06 
ONECUT2_CUT_1 5:19766428-19766442:- Taipale/SELEX 2.05E-07 4.65E-06 
ONECUT3_CUT_1 5:19766428-19766442:- Taipale/SELEX 1.65E-07 4.65E-06 
cg24202936 V_MTERF_01 11:50257253-50257267:- TRANSFAC 3.61E-06 6.55E-05 
Rara_secondary 11:50257251-50257267:- UniProbe 1.92E-04 2.18E-03 
Klf7_primary 11:50257254-50257270:+ UniProbe 7.55E-03 3.42E-02 
Ascl2_secondary 11:50257254-50257270:+ UniProbe 9.50E-03 3.91E-02 
cg25317585 V_NRSF_Q4 13:102568875-
102568894:+ 
TRANSFAC 1.17E-03 8.16E-03 
cg06809326 PAX2_PAX_1 17:20799510-20799528:+ Taipale/SELEX 5.46E-05 8.25E-04 
PAX5_PAX_1 17:20799510-20799528:+ Taipale/SELEX 6.69E-05 8.67E-04 
NRF1_NRF_1 17:20799523-20799535:-
/+ 
Taipale/SELEX 4.64E-04 4.21E-03 
V_NRF1_Q6 17:20799525-20799535:+ 
17:20799523-20799533:- 
TRANSFAC 4.63E-04 4.21E-03 
V_ZFP206_01 17:20799524-20799535:-
17:20799523-20799534:+ 
TRANSFAC 1.04E-03 7.85E-03 
MA0014.1-Pax5 17:20799509-20799529:- JASPAR 1.66E-03 9.50E-03 
V_PAX5_01 17:20799505-20799533:- TRANSFAC 3.61E-03 1.72E-02 
cg17577122 Egr3.mouse_C2H2_
1 
22:19511961-19511976:- Taipale/SELEX 8.72E-04 7.18E-03 
Egr1.mouse_C2H2_
1 
22:19511961-19511977:- Taipale/SELEX 1.40E-03 9.08E-03 
EGR1_C2H2_1 22:19511962-19511976:- Taipale/SELEX 1.68E-03 9.50E-03 
EGR3_C2H2_1 22:19511962-19511977:- Taipale/SELEX 2.49E-03 1.33E-02 
Egr1_primary 22:19511962-19511976:- UniProbe 3.31E-03 1.67E-02 
Sp4_primary 22:19511962-19511979:- UniProbe 8.92E-03 3.85E-02 
V_KROX_Q6 22:19511962-19511976:- TRANSFAC 1.18E-02 4.67E-02 
V_SP1_Q6 22:19511966-19511979:+ TRANSFAC 1.72E-02 6.50E-02 
 TF binding site: Transcription factor binding site. P value: p-value calculated for sequence 
overlaps with each of the motifs. Q-value: Multiple-testing corrected p-value with the 
Benjamini-Yekutieli method (FDR 0.1%)  
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Table S 10 Shared epigenetic associations between white matter hyperintensities (WMH) 
burden and cognitive abilities (CA) 
CpG Gene ZWMH PWMH ZCA PCA Pjoint Qjoint 
Reduced model 
Digital Symbol 
cg05575921 AHRR -2.79 5.30E-03 6.62 3.59E-11 3.19E-11 1.35E-05
cg18181703 SOCS3 -1.59 1.13E-01 6.62 3.53E-11 2.11E-10 4.29E-05
cg21566642  -2.81 4.99E-03 6.24 4.49E-10 3.06E-10 4.29E-05
cg05951221  -3.61 3.12E-04 5.75 9.12E-09 4.55E-10 4.79E-05
cg12593793  -1.99 4.70E-02 6.20 5.82E-10 1.86E-09 1.57E-04
cg03366574  1.83 6.68E-02 -6.15 8.00E-10 3.09E-09 2.17E-04
cg03636183 F2RL3 -2.92 3.54E-03 5.67 1.47E-08 5.24E-09 3.16E-04
cg06126421  -2.82 4.87E-03 5.60 2.17E-08 9.61E-09 5.06E-04
cg26470501 BCL3 -2.98 2.90E-03 5.34 9.49E-08 2.29E-08 1.07E-03
cg06946797  -1.82 6.95E-02 5.73 1.02E-08 3.43E-08 1.22E-03
cg17417856 PRMT1;C19orf76 -4.72 2.40E-06 3.74 1.82E-04 3.77E-08 1.22E-03
cg17759224  0.79 4.28E-01 5.67 1.47E-08 3.26E-08 1.22E-03
cg22953759 ANKRD33B -0.73 4.63E-01 5.85 4.88E-09 3.71E-08 1.22E-03
cg00134210 FAM107B -1.63 1.04E-01 5.65 1.58E-08 6.53E-08 1.73E-03
cg13092901 TYMP;SCO2 -2.90 3.72E-03 5.16 2.50E-07 6.57E-08 1.73E-03
cg17386185 GLYCTK -2.21 2.71E-02 5.49 4.00E-08 6.31E-08 1.73E-03
cg14943908 BAT2 -1.66 9.70E-02 5.51 3.59E-08 1.35E-07 3.33E-03
cg19405484  -1.26 2.10E-01 5.57 2.57E-08 1.47E-07 3.41E-03
cg19859270 GPR15 -3.87 1.09E-04 4.26 2.00E-05 1.54E-07 3.41E-03
cg01940273  -1.94 5.30E-02 5.39 6.92E-08 1.67E-07 3.47E-03
cg03183540  -1.43 1.54E-01 5.49 4.12E-08 1.97E-07 3.47E-03
cg04987734 CDC42BPB 3.24 1.21E-03 -4.68 2.87E-06 2.19E-07 3.47E-03
cg07195224 AIM2 -1.67 9.57E-02 5.41 6.20E-08 2.21E-07 3.47E-03
cg16594502  -2.64 8.29E-03 5.07 4.08E-07 1.95E-07 3.47E-03
cg21108085 CD82;CD82 -1.61 1.08E-01 5.46 4.90E-08 1.91E-07 3.47E-03
cg22331294 LIMD1 0.99 3.25E-01 5.27 1.35E-07 2.21E-07 3.47E-03
cg25376310 ZDHHC14 -2.36 1.83E-02 5.17 2.29E-07 2.22E-07 3.47E-03
cg01657995 
C6orf48;SNORD5
2 -1.05 2.95E-01 5.50 3.92E-08 2.49E-07 3.75E-03
cg07660627 ACACA -0.56 5.74E-01 -5.36 8.55E-08 2.66E-07 3.86E-03
cg00252813 GAPDH -1.61 1.08E-01 5.38 7.41E-08 2.82E-07 3.96E-03
cg12142865 ALDH2 -0.82 4.14E-01 5.46 4.80E-08 3.32E-07 4.51E-03
cg01406381 SLC1A5 -1.25 2.12E-01 5.37 7.79E-08 4.21E-07 5.49E-03
cg05673882 POLK -2.64 8.35E-03 4.89 1.03E-06 4.42E-07 5.49E-03
cg12473916 SHC1 -2.09 3.67E-02 5.14 2.71E-07 4.43E-07 5.49E-03
cg02003183 CDC42BPB 2.41 1.58E-02 -4.99 6.03E-07 4.64E-07 5.58E-03
cg14602222 RAD52 2.59 9.73E-03 -4.89 1.02E-06 4.97E-07 5.82E-03
cg00780520 PVT1 -1.40 1.61E-01 5.30 1.14E-07 5.26E-07 5.99E-03
cg03881294  -0.50 6.18E-01 5.33 1.00E-07 6.95E-07 7.71E-03
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cg02657160 CPOX -2.59 9.65E-03 4.79 1.68E-06 7.64E-07 7.86E-03
cg10475172 CCR9 0.91 3.63E-01 -5.30 1.17E-07 7.57E-07 7.86E-03
cg21171320 TRPM3 -0.35 7.24E-01 5.30 1.13E-07 7.57E-07 7.86E-03
cg01955153  0.89 3.74E-01 5.06 4.26E-07 8.25E-07 8.28E-03
cg27050612 NFE2L1 -2.28 2.27E-02 4.92 8.67E-07 8.52E-07 8.35E-03
cg04885881  -3.34 8.48E-04 4.25 2.17E-05 9.43E-07 9.02E-03
cg15095917 CD68 -0.38 7.05E-01 5.26 1.44E-07 9.63E-07 9.02E-03
cg11231349 NOS1AP -2.02 4.31E-02 4.99 6.00E-07 1.01E-06 9.10E-03
cg23842572 MPRIP 0.66 5.06E-01 -5.25 1.49E-07 1.02E-06 9.10E-03
cg00310412 SEMA7A -1.65 9.91E-02 5.11 3.30E-07 1.06E-06 9.30E-03
cg16736826 EDN2 -2.54 1.11E-02 4.68 2.90E-06 1.38E-06 1.19E-02
cg04158018 NFE2 -1.20 2.32E-01 5.14 2.80E-07 1.46E-06 1.21E-02
cg06809326 CCDC144NL 4.99 6.14E-07 0.75 4.52E-01 1.47E-06 1.21E-02
cg04973995  0.82 4.13E-01 4.96 7.16E-07 1.55E-06 1.26E-02
cg10721220  -0.91 3.64E-01 5.15 2.56E-07 1.60E-06 1.27E-02
cg24202936 LOC441601 5.08 3.78E-07 0.19 8.47E-01 1.74E-06 1.36E-02
cg26140475  0.54 5.91E-01 5.00 5.66E-07 1.80E-06 1.38E-02
cg02068690 DTNB 0.72 4.75E-01 -5.12 2.99E-07 1.97E-06 1.39E-02
cg02507296 C10orf95 -0.23 8.16E-01 5.11 3.20E-07 1.98E-06 1.39E-02
cg02519286 GAPDH -0.43 6.65E-01 5.13 2.85E-07 1.89E-06 1.39E-02
cg04424621 HIST1H2BJ -1.80 7.16E-02 4.92 8.67E-07 2.04E-06 1.39E-02
cg11146034 ELK3 -2.10 3.56E-02 4.80 1.57E-06 2.05E-06 1.39E-02
cg21139312 MSI2 0.84 4.03E-01 -5.12 3.02E-07 1.92E-06 1.39E-02
cg26856257  0.41 6.79E-01 5.01 5.35E-07 1.98E-06 1.39E-02
cg01127300  -3.97 7.21E-05 3.42 6.33E-04 2.09E-06 1.40E-02
cg07960624 SAMD12 -1.18 2.38E-01 5.06 4.23E-07 2.18E-06 1.44E-02
cg09586583 SSBP3 -1.66 9.72E-02 -4.56 5.18E-06 2.30E-06 1.49E-02
cg00611192 ZNF692 -2.41 1.58E-02 4.60 4.26E-06 2.57E-06 1.53E-02
cg02010481 JAZF1 -1.80 7.19E-02 4.89 1.04E-06 2.40E-06 1.53E-02
cg09182189 NADK -2.19 2.89E-02 4.71 2.45E-06 2.57E-06 1.53E-02
cg09676630 FBRSL1 -4.49 7.16E-06 2.63 8.54E-03 2.47E-06 1.53E-02
cg14277403 ANP32B -2.95 3.14E-03 4.28 1.83E-05 2.46E-06 1.53E-02
cg18006990 GTPBP2 -2.22 2.65E-02 4.70 2.61E-06 2.55E-06 1.53E-02
cg14753356  -1.40 1.61E-01 4.97 6.73E-07 2.74E-06 1.59E-02
cg19572487 RARA -1.91 5.66E-02 4.82 1.47E-06 2.75E-06 1.59E-02
cg16878214 PLEKHF2 -1.79 7.36E-02 -4.45 8.54E-06 2.82E-06 1.60E-02
cg02767093 STK24 -3.19 1.40E-03 4.04 5.34E-05 3.17E-06 1.77E-02
cg03707168 PPP1R15A -0.12 9.08E-01 5.01 5.56E-07 3.20E-06 1.77E-02
cg05438378 SMAD3 -2.43 1.53E-02 4.53 5.97E-06 3.38E-06 1.83E-02
cg26729380 TNF 0.70 4.87E-01 4.84 1.31E-06 3.40E-06 1.83E-02
cg16618104 CHST11 0.85 3.96E-01 4.79 1.68E-06 3.47E-06 1.85E-02
cg24296397 BSN 1.31 1.91E-01 -4.93 8.08E-07 3.57E-06 1.88E-02
cg26695387 MAP2K3 -1.14 2.54E-01 4.95 7.28E-07 3.73E-06 1.94E-02
cg11344352 ERCC1 -1.59 1.12E-01 4.85 1.22E-06 3.78E-06 1.94E-02
cg04949225  -0.95 3.41E-01 4.97 6.76E-07 3.93E-06 2.00E-02
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cg00415665 ZHX2 0.55 5.85E-01 -4.98 6.43E-07 4.18E-06 2.03E-02
cg17577122 CLDN5 4.89 1.02E-06 -1.37 1.70E-01 4.14E-06 2.03E-02
cg19940644  -2.80 5.13E-03 4.26 2.05E-05 4.06E-06 2.03E-02
cg21241410  0.89 3.71E-01 4.74 2.16E-06 4.17E-06 2.03E-02
cg03116124  -4.91 9.32E-07 1.22 2.22E-01 4.39E-06 2.03E-02
cg05168229  -0.41 6.84E-01 4.96 6.91E-07 4.44E-06 2.03E-02
cg06285727 ATG16L2 0.46 6.47E-01 4.85 1.23E-06 4.28E-06 2.03E-02
cg15705273 NCLN 2.53 1.16E-02 -4.41 1.01E-05 4.30E-06 2.03E-02
cg16346032  -0.02 9.88E-01 4.93 8.22E-07 4.41E-06 2.03E-02
cg08620426  -0.31 7.61E-01 -4.87 1.12E-06 4.58E-06 2.07E-02
cg10717214 TNF 0.83 4.05E-01 4.73 2.20E-06 5.04E-06 2.25E-02
cg25375916 SLC33A1 0.51 6.08E-01 4.82 1.47E-06 5.08E-06 2.25E-02
cg13854219  1.28 2.02E-01 4.53 5.86E-06 5.40E-06 2.35E-02
cg27115863  -1.41 1.59E-01 4.82 1.42E-06 5.40E-06 2.35E-02
cg07092212 DGKZZ -0.61 5.44E-01 4.92 8.89E-07 5.49E-06 2.36E-02
cg12966875 SLPI 0.71 4.78E-01 4.74 2.12E-06 5.76E-06 2.45E-02
cg00144180 HDAC4 0.60 5.47E-01 -4.90 9.42E-07 6.04E-06 2.54E-02
cg13709639 TUBA1B -1.80 7.16E-02 4.67 2.99E-06 6.15E-06 2.57E-02
cg24837149 
CCNL2;LOC1484
13 -2.41 1.58E-02 4.38 1.21E-05 6.49E-06 2.65E-02
cg26079320 POGK -0.52 6.03E-01 4.89 1.02E-06 6.48E-06 2.65E-02
cg15030712 CHN2 0.06 9.55E-01 4.84 1.28E-06 6.66E-06 2.70E-02
cg02610723 FAM38A 0.98 3.27E-01 4.62 3.80E-06 6.98E-06 2.78E-02
cg05492306 ERCC1 -1.43 1.52E-01 4.76 1.93E-06 6.94E-06 2.78E-02
cg25648203 AHRR -0.64 5.20E-01 4.87 1.15E-06 7.24E-06 2.85E-02
cg10021364 MYADM -2.49 1.29E-02 4.28 1.84E-05 7.89E-06 3.07E-02
cg25607249 SLC1A5 -0.46 6.43E-01 4.85 1.21E-06 7.95E-06 3.07E-02
cg03535253 BTBD7 0.01 9.96E-01 -4.83 1.38E-06 8.28E-06 3.17E-02
cg16253157 CYB561D1 -0.22 8.25E-01 -4.80 1.58E-06 8.50E-06 3.23E-02
cg27067618 CYP4F3 -0.09 9.30E-01 4.83 1.39E-06 8.65E-06 3.25E-02
cg04994217 C9orf170 -3.32 9.12E-04 3.64 2.69E-04 9.07E-06 3.38E-02
cg02656560  -2.39 1.69E-02 4.30 1.68E-05 9.65E-06 3.57E-02
cg00711496 C19orf76;PRMT1 -4.12 3.86E-05 2.69 7.11E-03 9.98E-06 3.66E-02
MMSE 
cg01127300  -3.97 7.21E-05 3.74 1.86E-04 3.93E-07 2.37E-02
cg03636183 F2RL3 -2.92 3.54E-03 4.97 6.78E-07 7.13E-08 7.35E-03
cg05575921 AHRR -2.79 5.30E-03 5.14 2.77E-07 4.38E-08 7.35E-03
cg05704155 PGD;PGD 4.55 5.26E-06 -3.33 8.65E-04 1.39E-07 9.75E-03
cg05951221  -3.61 3.12E-04 4.84 1.29E-06 1.45E-08 6.10E-03
cg06126421  -2.82 4.87E-03 4.60 4.31E-06 5.47E-07 2.88E-02
cg19859270 GPR15 -3.87 1.09E-04 3.60 3.18E-04 9.48E-07 4.44E-02
cg21450381  -0.13 8.98E-01 -5.72 1.04E-08 7.45E-08 7.35E-03
cg22529900 PARK7 -4.47 7.87E-06 -2.53 1.15E-02 1.12E-06 4.74E-02
cg25923609  3.59 3.32E-04 -4.46 8.17E-06 8.71E-08 7.35E-03
Verbal Fluency 
 
128 
 
cg04987734 CDC42BPB 3.24 1.21E-03 -4.47 7.89E-06 4.75E-07 2.86E-02
cg07102705 HTR4 3.08 2.07E-03 -4.48 7.56E-06 7.23E-07 3.54E-02
cg10313673 CILP2 1.75 7.99E-02 -5.07 3.90E-07 9.85E-07 3.78E-02
cg10922280 DPEP2 1.23 2.20E-01 -5.59 2.33E-08 1.31E-07 1.38E-02
cg12025310 TMPRSS6 3.43 6.00E-04 -4.05 5.16E-05 1.36E-06 4.77E-02
cg12507869 INPP5A -0.04 9.69E-01 -5.81 6.44E-09 3.78E-08 9.83E-03
cg12582616 JARID2 -3.54 3.96E-04 -4.15 3.38E-05 4.66E-08 9.83E-03
cg13696609 FOXE1 -1.21 2.27E-01 -4.97 6.66E-07 8.40E-07 3.54E-02
cg14945937 PLEKHF1 -1.95 5.16E-02 -4.79 1.68E-06 4.19E-07 2.86E-02
cg15909981 TMPRSS6 -1.49 1.36E-01 -4.88 1.06E-06 7.64E-07 3.54E-02
cg16201957 MAML3 1.17 2.44E-01 -5.67 1.41E-08 8.45E-08 1.19E-02
cg23722790 SLC35D1 0.47 6.39E-01 -5.56 2.71E-08 1.97E-07 1.66E-02
Vocabulary 
cg04513006 ESRP2 0.41 6.85E-01 -5.65 1.60E-08 1.18E-07 4.96E-02
Full model  
MMSE  
cg05704155 PGD 4.88 1.07E-06 -3.53 4.11E-04 1.42E-08 6.00E-03
cg21450381  -0.05 9.57E-01 -5.66-1.55E-08 1.15E-07 2.43E-02
Verbal Fluency 
cg12507869 INPP5A -0.82 4.11E-01 -5.96 2.47E-09 8.79E-09 3.71E-03
cg16201957 MAML3 1.35 1.78E-01 -5.46 4.71E-08 1.80E-07 3.79E-02
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Table S 11 Correlation between Methylation Levels in Blood and Brain 
Brain tissues cg02741985 cg03116124 cg04245766 cg06450373 cg06809326 cg07675682 
PFC (n=74) -0.053, 0.652 0.292, 1.16E-02 0.923, 1.38E-31 0.227, 0.052 0.566,1.49E-07 -0.114, 0.333 
EC (n=71) 0.248, 3.68E-02 0.177, 0.141 0.954, 6.89E-38 -0.037, 0.763 0.711, 3.83R-12 -0.078, 0.518 
STG (n=75) 0.049, 0.674 0.218, 6.00E-02 0.924, 4.17E-32 -0.036, 0.763 0.601, 1.15E-08 -0.048, 0.686 
CER (n=71) 0.202, 9.17E-02 0.242, 4.2-E-02 0.939, 1.16E-33 0.003,0.982 0.582, 1.02E-07 -0.070, 0.562 
Brain tissues cg10051414 cg17577122 cg18950108 cg24202936 cg25317585  
PFC (n=74) -0.102, 0.388 -0.158, 0.178 0.122, 0.302 0.327,0.005 0.102, 0.389  
EC (n=71) -0.158, 0.189 0.122, 0.311 -0.010, 0.937 0.398, 5.81E-04 0.043, 0.724  
STG (n=75) 0.066, 0.575 0.051, 0.666 0.255, 2.73E-02 0.324, 4.60E-03 -0.123, 0.295  
CER (n=71) -0.312, 8.18E-03 0.122, 0.311 0.106, 0.380 0.158, 0.189 0.020, 0.871  
Correlation r and P value. PFC: prefrontal cortex, EC: entorhinal cortex, STG: superior temporal gyrus and CER: cerebellum 
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